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"The road goes ever on and on
Down from the path where it began. 
Now far ahead the road has gone,
And I must follow, if I can,
Pursuing it with eager feet,
Until it joins some larger way 
Where many paths and errands meet
And whither then? I cannot say."
J. R. R. Tolkien
ii
Summary
Tumour necrosis factor-a (TNF) may contribute to the depression in cardiac function 
often observed during septic shock, however potential mechanisms responsible for this 
remain unresolved. Increased circulating levels of TNF have also been associated with a 
variety of cardiac diseased states including chronic heart failure and myocardial ischaemia, 
and TNF may play a pathogenic role during these conditions. For these reasons the actions 
of TNF in the rat isolated perfused heart have been investigated. The major findings of this 
investigation are summarised below.
TNF was shown to attenuate insulin-stimulated glycogen synthesis, without altering 
insulin-stimulated glucose uptake. This effect could be mimicked by the cell permeable 
ceramide analogue, C2-ceramide. Okadaic acid blocked the disruptions in insulin- 
stimulated glycogen synthesis seen with ceramide, however okadaic acid could not 
completely inhibit the actions of TNF on insulin-stimulated responses. TNF was also 
shown to have an early negative inotropic effect, which was accompanied by a coronary 
constriction. An attempt to characterise these responses with pharmacological probes was 
made. In this regard it was shown that the negative inotropic effect was probably the result 
of activation of the sphingomyelinase pathway. The coronary constriction was also 
appeared to be due to activation of the sphingomyelinase pathway, however, the 
phospholipase A2 pathway, and in particular thromboxane A2, were also involved in this 
action. Under certain conditions the direct negative inotropic effect and the coronary 
constrictor actions of TNF could synergise to cause a further depression in cardiac 
function.
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Tumour necrosis factor-a is a molecule which belongs to a large family of proteins 
termed cytokines. Cytokines are produced in response to a wide variety stimuli and are 
secreted by their producer cells, acting to alter the behaviour of target cells. Cytokines 
differ from the classical hormones, such as insulin, as they can be produced by a variety 
of different cell types and therefore tissues, where as hormones are produced by 
specific endocrine organs. Cytokines must normally bind to specific membrane 
receptors on the surfaces of target cells, and produce their effects by signal 
transduction across a plasma membrane. The actions of cytokines can be mediated in a 
number of different ways. Cytokines can act in an autocrine manner, whereby, if the 
producer cell expresses the required functional receptors, then the actions of the 
producer cell can be modified by the released cytokine. They can also act in a paracrine 
fashion, where the target cell is adjacent or close to the producer cell. Cytokines may 
also be released into the bloodstream and interact with distant target cells, thereby 
having an endocrine action.
1.1.1 Tumour necrosis factor
There are two types of tumour necrosis factor: tumour necrosis factor-a and tumour 
necrosis factor-p or lymphotoxin. Each share a number of related biological activities 
(Pennica et al., 1984), bind to similar receptors and are approximately 30 % 
homologous to each other (Nedwin et al., 1985). Tumour necrosis factor-P is 
lymphocyte-derived and is very important in various aspects of immune
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responsiveness. However this project has focused on tumour necrosis factor-a (TNF), 
which is classically thought of as being macrophage-derived, although it is now 
recognised that TNF production is not exclusively synonymous with the macrophage 
and many other cells have been shown to produce TNF including cardiac myocytes 
(Kapadia et al,. 1995; Benigni et al., 1996; Meldrum et al,. 1998; Wagner et al., 
1998). Many organs, including the heart, also have the potential to produce TNF due 
to the ubiquitous resident mast cell (Frangogiannis et al., 1998)
1.1.2 Structure and release of TNF
TNF is secreted from producer cells as a protein with a molecular mass of 17 kDa 
(Beutler et al., 1985a), consisting of 157 amino acids (in the human form). In 
macrophages, after TNF gene transcription, TNF mRNA is translated into a 26 kDa 
precursor to TNF in the cytoplasm. This 26 kDa precursor undergoes membrane 
insertation, where finally it is cleaved by TNF-a converting enzyme, releasing the 
mature 17 kDa TNF into the extracellular space (Moss et al., 1997). Metalloproteinase 
inhibitors can suppress the TNF-a converting enzyme and inhibit TNF release (Mohler 
et al., 1994). Biologically active TNF is composed of three 17 kDa TNF molecules in a 
noncovalently bound compact trimer (Jones et al., 1989).
1.1.3 TNF receptors
Most, if not all, of the actions of TNF are secondary to TNF binding to specific cell 
surface receptors that are present on almost all cell types, with between 100 to 10,000 
receptors per cell. Studies have identified two distinct TNF receptors, both of which
have been cloned and have molecular masses of 55 kDa and 75 kDa (Tartaglia & 
Goeddel, 1992), and have a lower and higher affinity for TNF, respectively. 
Crosslinking studies have demonstrated that the TNF trimer must bind with two or 
three receptor molecules to generate an intracellular signal (Tartaglia & Goeddel, 
1992). The extracellular domains of the 55 kDa and the 75 kDa receptor share a 28 % 
sequence identity, however intracellular domains of each receptor show very little 
homology, suggesting activation of different signalling pathways. Polyclonal antibodies 
to both murine TNF receptors have been developed, and been shown to behave as 
receptor specific agonists. Studies with these antibodies have demonstrated that 
activation of each receptor signals two distinct TNF activities. The 55 kDa receptor is 
responsible for signalling cytotoxicity, and induction of several genes, whereas the 75 
kDa receptor was shown to be responsible for the proliferation of primary thymocytes 
and a cytotoxic T-cell line (Tartaglia et al., 1991). As mentioned earlier the 75 kDa 
receptor has a higher affinity for TNF than the 55 kDa receptor, and a ligand passing 
model between the two receptors has been suggested by Tartaglia et al (1993). In this 
model the 75 kDa receptor could augment the 55 kDa receptor mediated killing of 
murine L929 cells without itself generating a signal. The authors postulated that the 75 
kDa receptor could increase the local concentration of TNF at the cell surface by rapid 
TNF association and disassociation, thereby producing an artificially high 
concentration of TNF at the 55 kDa receptor.
An interesting phenomenon concerning TNF receptor biology is the ability of these 
receptors to be shed in response to various stimuli, resulting in soluble TNF receptor 
type I (-55 kDa), and type II (-75 kDa) in the circulation of healthy humans, which are 
increased in a number of disease states, including sepsis (Girardin et al., 1992; Van der
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Poll et a l , 1993; Latini et a l , 1994). These shed receptors retain their ability to bind 
TNF and therefore can compete with cell surface TNF receptors for TNF binding 
(Kapadia et a l, 1995) and hence they can modulate TNF activity. The precise 
biological role for these shed receptors is uncertain, but it is thought to depend on the 
ratio of TNF soluble receptors and TNF protein, whereby low concentrations of 
soluble receptors could augment the biological effects of TNF by slowing degradation. 
Conversely, higher concentrations could act as TNF buffers, neutralising circulating 
levels of TNF (Tracey & Cerami., 1993).
1.1.4 TNF as a proinflammatory cytokine
TNF falls into a subset family of cytokines, known as proinflammatory cytokines, a 
group which also includes cytokines such as interleukin-1 (IL-1) and interferon-y. 
Proinflammatory cytokines are key mediators in the hosts response to injury, 
inflammation and infection.
One of most important pro-inflammatory actions of TNF is activation of endothelial 
cells, leading to the active participation of these cells in an inflammatory response. 
TNF causes the induction and expression of various cell adhesion molecules on the 
surface of the endothelial cells, allowing binding of both neutrophils and mononuclear 
cells. Neutrophils can then be activated by TNF to increase superoxide generation 
(Laudanna et a l, 1993), thus increasing neutrophil mediated damage of cells. TNF can 
also stimulate endothelial cells to produce IL-1, prostacyclin, platelet activating factor 
and factors which exhibit pro-coagulant activities, all of which play important roles 
during inflammation (for review see Kunkel et al, 1989). Activation of macrophages
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by TNF inhibits intracellular replication of viral and parasitic organisms (Mestan et al., 
1986). Activated macrophages show increased cytotoxicity towards viral infected cells 
(Wong & Goeddal, 1986). Indeed, 55-kDa receptor knockout mice have been shown 
to have increased susceptibility to intracellular bacteria such as Listeria monocytogenes 
(Pfeffer et al., 1993).
1.1.5 Signalling mechanisms of TNF
The multiple actions of TNF are mediated by a number of second messengers, and 
considerable effort has been devoted to clarifying the precise biological role for all of 
these. Available data are difficult to interpret since they have been obtained in a variety 
of different cells which respond in different ways to TNF. Many of the actions of TNF 
can be attributed to the degradation of membrane phospholipids, and subsequent 
generation of lipid second messengers. This section will describe the importance of the 
enzymes phospholipase C (PLC), phospholipase A2 (PLA2), and sphingomyelinase 
(SMase) in signal transduction by TNF.
1.1.5.1 TNF and phospholipase A2 (PLA2)
One of the most important signalling pathways utilised by TNF is the stimulation of 
phospholipase A2 (PLA2), which leads to the breakdown of membrane phospholipids 
to arachidonic acid (AA) and lysophospholipids. This action accounts for the 
proinflammatory actions of TNF. Once released by TNF, AA can be metabolised by 
cyclo-oxygenase enzymes to prostaglandins (Elias et al., 1987) and thromboxane 
(Godfrey et al., 1987), which are essential for the inflammatory process. In addition to
6
mediating the inflammatory responses to TNF, PLA2 activation is thought to play an 
essential role in the cytotoxicity often seen with TNF (Suffys et al., 1987; Hayakawa et 
al., 1993).
An interesting study by Jayadev et al. (1994) linked the PLA2 pathway to the 
metabolism of sphingomyelin and activation of SMase, where release of AA by PLA2 
could subsequently activate SMase. This is interesting as the SMase pathway is rapidly 
becoming recognised as another very important signalling mechanism utilised by TNF 
(see section 1.1.5.3).
1.1.5.2 TNF and phospholipase C (PLC)
Soon after the binding of TNF to the 55 kDa TNF receptor, TNF stimulates the 
production of diacylglycerol (DAG) from membrane phospholipids by the activation of 
PLC (Schutze et al., 1992). Here generation of DAG was associated with a decline in 
phosphatidylcholine (PC) and increases in phosphorylcholine content, without changes 
in intracellular Ca2+. These authors went on to show activation of a PC-specific PLC, 
where this PLC causes the production of DAG without accumulation of the Ca2+ 
mobilising inositol trisphosphate (IP3) normally associated with PLC activation. Due to 
the lack of changes in intracellular calcium (Ca2+) it is likely that the DAG produced 
activates a Ca2+-insensitive isoform of protein kinase C (PKC). Also shown in this 
study was that the DAG produced could activate an acidic isoform of the SMase 
enzyme, and hence, initiate the SMase pathway (see section 1.1.5.3). Activation of 
PKC has also been observed by other groups, and is thought to mediate the actions of
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TNF on the induction of JUN and FOS proteins, which are components of the AP-1 
transcription factor (Brenner et a l, 1989).
1.1.5.3 The sphingomyelinase (SMase) pathway: relevance to TNF
As the SMase pathway is not as recognised as the pathways of PLA2  and PLC, and 
because the SMase pathway is implicated in many of the actions of TNF described in 
this report, the following is an overview of the SMase signalling pathway. 
Comprehensive reviews of the degradation of sphingomyelin and subsequent second 
messenger functions of its metabolites have previously been published (Kolesnick, 
1991; Merrill et al.t 1997).
Sphingomyelin is a phospholipid which is concentrated in the outer leaflet of the 
plasma membrane of most mammalian cells. The structure of sphingomyelin is shown 
in figure 1.1. When hydrolysed by SMase an immediate metabolite of sphingomyelin is 
ceramide. Ceramide can subsequently be converted, via the actions of ceramidase into 
sphingosine (structures of ceramide and sphingosine are also shown in figure 1.1). 
Both ceramide and sphingosine have potential functions as second messengers. 
Sphingosine can be converted to sphingosine 1-phosphate which also has biological 
activity. Interest in sphingolipids, of which sphingosine is one, arose when it was 
demonstrated that they could inhibit PKC (Hannun & Bell, 1987), and thus compounds 
which were initially thought to be inert were shown to alter the activity of a very 
important signalling molecule. An interesting observation at about the same time 
showed that DAG, the endogenous activator of PKC, could also activate SMase 













Figure 1.1. Molecular structures of sphingomyelin, ceramide and sphingosine. Also 
shown are the enzymes required for the breakdown of sphingomyelin to ceramide, and 
the breakdown of ceramide to sphingosine.
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DAG stimulation of PKC, where DAG activation of SMase leads to the production of 
sphingosine, and inhibition of PKC. Therefore a negative feedback mechanism 
controlling overactivation of PKC by DAG may exist (Kolesnick, 1991). Many 
biological actions of ceramide, sphingosine and sphingosine 1-phosphate are now 
known, and some of these are discussed in later sections.
Identification of the SMase pathway as an important mediator of some of the biological 
actions of TNF came in 1991 (Kim et al., 1991). It is now widely established that TNF 
can activate the SMase pathway. Indeed, TNF can activate the SMase pathway in a 
cell free system (Dressier et al., 1992), suggesting tight coupling of the SMase 
enzymes to the TNF receptor, although as mentioned above prior release of AA may 
be required as an intermediary step in SMase activation (Jayadev et a l , 1994). The 55 
kDa TNF receptor is thought to be responsible for activation of SMase (Weigmann et 
a l , 1992).
In a study by Candela et al, (1991) a situation was described where TNF-stimulated 
PLA2 and cyclooxygenase enzymes were enhanced in the presence of low 
concentrations of sphingosine. This is especially interesting when taken in context of 
the study by Jayadev et a l (1994) and suggests that a self potentiating mechanism 
exists for TNF activation of the PLA2 pathway through TNF-mediated generation of 
sphingosine. Also of interest was a recent study where exogenous sphingosine, or 
SMase caused a constriction in pig coronary artery which was blocked by the 
cyclooxygenase inhibitor, indomethacin (Murohara et a l , 1996). Thus, there appears 
to be intriguing interactions between the PLA2 and SMase pathways.
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1.2 TNF and insulin resistance
Increased plasma TNF levels, such as those which can occur during septic shock, 
cancer and various cardiac disease states (see below), have been associated with a 
general increase in the catabolic state of the body. A state of cachexia can develop, 
characterised by gross host wasting and a dramatic loss of body weight. Indeed, TNF 
was originally termed cachectin for its ability to induce cachexia. During cachexia 
decreased insulin sensitivity is common, a phenomenon which is also observed upon 
exogenous TNF administration (Lang et al, 1992). In addition to this, TNF has been 
strongly implicated in the insulin resistance observed during obesity-induced diabetes 
and non-insulin dependant diabetes mellitus (NIDDM). In obesity-linked insulin 
resistance models or NIDDM models adipocytes appear to overproduce TNF, which if 
neutralised can increase peripheral uptake of glucose in response to insulin 
(Hotamisligil et al., 1993). Also TNF deficient mice are protected from obesity 
induced insulin resistance (Uysal et al., 1997).
The heart is an organ which requires a great deal of energy to fulfil its job of constantly 
pumping blood around the body. Although the preferred “fuels” for the heart under 
physiological conditions are circulating free fatty acids (normally providing 60 - 70 % 
of energy needs), the heart still has a large capacity to utilise glucose as a substrate. In 
this regard the heart is an organ which is very sensitive to insulin. Two of the major 
actions of insulin, on carbohydrate metabolism, in hearts are to increase glucose uptake 
by cardiac myocytes and to increase glycogen synthesis within these cells. Glycogen is 
an important endogenous energy store for the heart, which acts as a reserve of energy
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to support sudden increases in heart work and may also contribute to survival and 
recovery of hearts after a periods of substrate deprivation, such as ischaemia (Cross et 
al., 1996). Thus, any disruption in the actions of insulin could have important 
consequences for the heart.
In order to appreciate the potential mechanisms behind TNF-induced insulin resistance 
it is first necessary to understand glucose uptake and metabolism within cells. It is also 
important to understand the signal transduction pathways utilised by insulin.
1.2.1 Glucose uptake and metabolism
It has long been known that the plasma membranes of virtually all mammalian cells 
possess a transport system for glucose (GLUT transporters), which allow the 
movement of glucose down its concentration gradient either into or out of cells. The 
glucose concentration in the extracellular space is so much greater than in the cytosol 
that facilitated diffusion under physiological conditions is always into the cell. GLUT 
transporters are stereospecific for the D-enantiomer of glucose and require no 
additional energy input, such as ATP, for their actions (Baldwin & Lienhard, 1981). It 
has long been established that perfused rat hearts are sensitive to insulin, increasing 
glucose uptake upon insulin administration (Neely & Morgan, 1974). Although there is 
a large family of glucose transporters, only two are expressed in cardiac tissue, GLUT1 
and GLUT4. GLUT transporter proteins exist within cells in tubulo-vesicular 
structures and undergo a cycle of exocytosis to the plasma membrane, and endocytosis 








Tubulo-vesknilar pool Early endereome pool
Figure 1.2. The cycling of the GLUT4 glucose transporter within insulin sensitive cells.
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Holman, 1993). This cycle is thought to be constantly active, and changes in the cell 
surface GLUT concentration occur by increasing or decreasing endocytosis or 
exocytosis. GLUT1 is the transporter responsible for basal glucose uptake, and is 
constitutively expressed at high levels at the plasma membrane. GLUT1 is only weakly 
sensitive to insulin (Yang & Holman, 1993) and it is generally regarded as insulin- 
independent. GLUT4 has very low basal plasma membrane expression and resides 
mainly within the tubulo-vesicular pool. Insulin stimulation leads to an increase in the 
exocytosis of GLUT4 to the plasma membrane and, therefore, increased glucose 
uptake (figure 1.2; Satoh et al., 1993). Therefore, GLUT4 is classically recognised as 
the insulin-sensitive glucose transporter.
Once glucose enters the cell, it is rapidly phosphorylated to glucose 6-phosphate (G-6- 
P) via the action of hexokinase. Phosphorylation of glucose serves three major 
purposes; firstly, phosphorylation turns the glucose molecule into a negatively charged 
ion, which cannot leave the cell; secondly, it serves to “prime” the glucose molecule 
for metabolism via glycolysis; and thirdly, phosphorylation of glucose maintains the 
concentration gradient for glucose entry into the cell. G-6-P can then enter into the 
glycolytic pathway or it can be converted to the endogenous glucose store, glycogen. 
During glycolysis, glucose is transformed by a host of reactions to two molecules of 
pyruvate, producing a net of two molecules of ATP and two molecules of NADH. The 
fate of pyruvate is then decided by the oxygen (O2) levels within the heart. If O2 is 
sufficient then pyruvate enters into the citric acid cycle, where the energy stored within 
the molecule is fully realised. If the heart is operating under anaerobic conditions then
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pyruvate is converted to lactate via the lactate dehydrogenase reaction, and lost 
through the cell wall (Katz, 1992a).
As mentioned above G-6-P can also be converted to glycogen. In this process, G-6-P 
is first converted to glucose 1-phosphate (G-l-P) by the enzyme phosphoglucomutase. 
G-l-P is the initial substrate required for glycogen synthesis as well as being the 
product of glycogen breakdown. Glycogen synthesis and breakdown are separate 
processes which are both tightly controlled and mediated by two highly regulated 
enzymes. Glycogen synthase (GS) is responsible for glycogen formation and 
phosphorylase mediates glycogen breakdown. Both of these enzymes exist in active 
and inactive forms. The initial reaction in the synthesis of glycogen involves the 
conversion of G-l-P to UDP-glucose, utilising the high energy phosphate bond of 
UTP, this reaction is not rate limiting. The glucose moiety is then transferred to 
glycogen via the action of GS, a reaction which is rate limiting, and depends on the 
activation state of the GS enzyme. GS exists in two activation states, which are 
controlled by phosphorylation reactions, the dephosphorylated form being more active 
that the phosphorylated one (Roach et al., 1976). Phosphorylation of GS by PKA is 
thought to be one of the mechanisms by which p-adrenergic agonists stimulate 
glycogen breakdown (Dent et al., 1990). G-6-P levels are also very important to 
glycogen synthesis, as G-6-P is an endogenous allosteric activator of GS, and with a 
high concentration of G-6-P nearly full GS activity can be observed even when GS is in 
its less active state (Roach & Lamer, 1976).
Phosphorylase, the enzyme responsible for the degradation of glycogen, is also 
controlled by its phosphorylation state, but in this case the phosphorylated form is the
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more active one (Madsen, 1986). Again PKA can phosphorylate this enzyme, causing 
activation and hence stimulate glycogen breakdown. Activity of phosphorylase is 
controlled by yet another enzyme, phosphorylase kinase. Phosphorylase kinase itself is 
activated by phosphorylation and deactivated by dephosphorylation (Pickett-Gies & 
Walsh, 1986). The process of glycogen synthesis and breakdown is shown in figure 
1.3.
The glycogen associated form of protein phosphatase-1 (PP-1g) is an enzyme which is 
very important in the regulation of both GS and phosphorylase kinase activities, when 
activated by phosphorylation, it causes the dephosphorylation of both GS (activating 
it), and phosphorylase kinase (deactivating it), with the effect of stimulating glycogen 
synthesis and inhibiting glycogen breakdown respectively (figure 1.3; Dent et al., 
1990). Interestingly PP-1g has been shown to be phosphorylated and therefore 
activated by p90rek (MAPKAP kinase I), thereby linking glycogen metabolism to the 
MAP kinase pathways (Sutherland et al., 1993). Glycogen synthase kinase-3 (GSK3), 
is another important regulatory enzyme, which causes the phosphorylation and 
therefore inactivation of GS (Hughes et al., 1993). Moreover, it appears that GSK-3 is 
constituatively active, resulting in basal phosphorylation and therefore basal inhibition 
of GS (Hughes et al., 1993). Most of these studies have been conducted in either 
adipocytes or in skeletal muscle, therefore, interpretation of these results need to be 
extrapolated into the heart, however almost certainly differences exist between the 
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Figure 1.3. A diagrammatical representation of the enzymes controlling glycogen 
synthesis and breakdown. Abbreviations: Glycogen synthase, GS; protein kinase A, 
PKA; glucose 6-phosphate, G-6-P; glucose 1-phosphate. G-l-P.
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1.2.2 Insulin signal transduction and effects on glucose metabolism
Binding of insulin to its receptor causes the receptor to undergo autophosphorylation 
which significantly increases catalytic activity of the receptor leading to tyrosine 
phosphorylation of cellular substrates (Wilden et al., 1992). In this manner, insulin 
stimulates a variety of different signal transduction pathways leading to protein 
synthesis, gene expression, cell growth and changes in glucose transport and 
metabolism. However, this section will concentrate on the pathways thought to be 
involved in glucose transport and metabolism.
Insulin receptor substrate-1 (IRS-1) is probably the most important, and certainly most 
extensively studied substrate of the insulin receptor, although IRS-2 and IRS-3 also 
exist (Tsuji et al., 1998). IRS-1 has been widely implicated in the actions of insulin on 
glucose transport (Kanai et al., 1993; Holman & Cushman, 1994; White & Kahn, 
1994). When phosphorylated, IRS-1 can bind other cytoplasmic signalling molecules 
that contain Src homology 2 (SIC) domains. This enables IRS-1 to associate with the 
p85 regulatory subunit of phosphatidylinositol 3’-kinase (PI-3K), activation of PI-3K 
thus ensues (Myers et al., 1992). The specific PI-3K inhibitor, wortmannin, has been 
shown to inhibit insulin stimulated glucose uptake (Kanai et al., 1993). IRS-1 may act 
to localise PI-3K to low density membrane fractions, which is thought to represent the 
GLUT4 containing tubulo-vesicular pool (Yang, et al., 1996). The formation of 
phosphatadylinositol 3,4,5-trisphosphate, which is a product of PI-3K activation, could 
alter the nature of the lipids in the intracellular vesicles or the plasma membrane 
increasing the probability of fusion and docking.
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Another major action of insulin, and one which has not been very well characterised, is 
its ability to stimulate the synthesis of glycogen. As mentioned earlier, two very 
important enzymes in glycogen metabolism are PP-1g and GSK-3. Insulin acts to 
inhibit GSK-3 and to stimulate PP-1g, thus causing glycogen synthesis (Dent et al., 
1990; Sutherland et al., 1993). Although there is much controversy concerning the 
precise mechanism responsible for insulin stimulated glycogen synthesis, two main 
pathways have been outlined, these are summarised in figure 1.4.
In 1990, Dent et al, proposed a theory that upon insulin stimulation, a protein kinase 
was activated, which they termed insulin stimulated protein kinase-1 (ISPK-1). ISPK-1 
was shown to have the ability to cause phosphorylation of PP-1g, thereby inactivating 
phosphorylase kinase and therefore decreasing glycogen breakdown. As expected, PP- 
1g activation also caused activation of GS, stimulating glycogen synthesis. ISPK-1 was 
subsequently shown to be p90Tsk (Sutherland et al., 1993; figure 1.4).
Thus, the first model for insulin-stimulated glycogen synthesis was proposed to 
account for these effects on glycogen synthesis, whereby insulin causes tyrosine 
phosphorylation of She protooncogene which induces its association with growth 
factor receptor-bound protein 2 (Grb2). Grb2 can then target the nucleotide exchange 
factor, Son of sevenless (Sos), leading to the binding of GTP to p21ras and, thus, 
stimulation of the mitogen activated protein kinase (MAP kinase) cascade, and 
subsequent stimulation of p90rak (this potential pathway is outlined in a recent review 
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(1995) showed that similar activation of the MAP kinase cascade by epidermal growth 
factor, was not associated with any major changes in glycogen synthesis. Also the
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Figure 1.4. Potential mechanisms of insulin-induced glycogen synthesis. Abbreviations: 
Insulin receptor substrate-1, IRS-1; phosphatidyl inositol 3-kinase, PI-3K; protein 
kinase B, PKB; glycogen synthase kinase 3, GSK3; growth factor receptor-bound 
protein 2, Grb2 i son of sevenless, Sos.
MAP kinase inhibitor PD 098059, could not block insulin stimulated activation of GS 
(Azpiazu et al, 1996).
The other potential mechanism for insulin-induced glycogen synthesis, like insulin- 
induced glucose uptake, involves activation of IRS-1 and PI-3K. Here the target 
molecule for the insulin signal is GSK-3. In this proposed model insulin inhibits the 
high basal activity of GSK-3 causing activation of GS and, therefore, increased 
glycogen synthesis. Phosphorylation and inhibition of GSK-3 by insulin is mediated by 
a relatively newly discovered kinase, protein kinase B (PKB), which is activated by PI- 
3K (figure 1.4; Cross et al., 1995; Cross et al., 1997). This pathway is also reviewed 
by Lawrence & Roach (1997).
1.2.3 Potential mechanisms responsible for TNF mediated insulin resistance
Since the realisation that TNF is an essential mediator of the insulin-resistance 
observed during obesity-induced diabetes (Hotamisligil et al., 1993), and therefore 
could play an important role in NIDDM, research into the mechanisms behind TNF- 
induced insulin resistance has almost grown into a field of its own. Studies have taken 
place almost exclusively in cultured or isolated cell lines. Several, often contradictory, 
mechanisms have been suggested and these will be reviewed in the following section.
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Prior to the suggestion that TNF may mediate obesity-induced diabetes a study by 
Stephens & Pekala (1991) showed that in 3T3-L1 adipocytes chronic (20 hr) treatment 
lead to an 85 - 90 % decrease in mRNA for the insulin-sensitive GLUT4 transporter, 
and the authors postulated that the actions of TNF were at least in part at the level of 
transcription. This observation was subsequently confirmed in the initial study 
implicating TNF in obesity-induced diabetes (Hotamisligil et a l , 1993), where 10 days 
treatment of adipocytes with TNF resulted in a marked decrease in the expression of 
GLUT4. Increased TNF mRNA was observed in adipose tissue from obese, insulin 
resistant animals (Hotamisligil et a l , 1993). In addition to this, administration of anti- 
TNF antibodies increased glucose uptake.
The first evidence for TNF induced alterations in insulin signalling was also presented 
in 1993 (Feinstein et a l , 1993), where in hepatoma Fao cells 60 min exposure to TNF 
suppressed insulin-induced tyrosine autophosphorylation of the insulin receptor, this 
was accompanied by decreased tyrosine phosphorylation of IRS-1. These changes 
were not due to alterations in insulin binding to its receptor. Evidence implicating 
changes in the tyrosine kinase activity of the insulin receptor, and so furthering the 
observations by Feinstein et al, came a year after (Hotamisligil et a l , 1994a; 
Hotamisligil et al, 1994b). In the first of these studies, decreased tyrosine kinase 
activity of the insulin receptor was seen during obesity-induced diabetes in both muscle 
and fat cells, and was accompanied by decreased phosphorylation of IRS-1. 
Neutralising antibodies to TNF caused a marked increase in insulin-stimulated 
autophosphorylation, and subsequent phosphroylation of the IRS-1 (Hotamisligil et a l , 
1994a). The second of these studies showed that in adipocytes, 5 days treatment with
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TNF caused a decrease in insulin-stimulated glucose uptake, which was accompanied 
again by decreased insulin receptor autophosphorylation and decreased 
phosphorylation of IRS-1 (Hotamisligil et al., 1994b).
Kanety et al (1995), showed that only 60 min treatment of Fao cells with TNF resulted 
in a decrease in insulin-stimulated tyrosine phosphorylation of IRS-1, however this was 
not associated with a reduction in insulin-receptor tyrosine kinase activity. Decreased 
phosphorylation of IRS-1 resulted in impaired association of IRS-1 with PI-3K. 
Interestingly, TNF caused increased serine phosphorylation of IRS-1 which lead to a 
decrease in the electrophoretic mobility of IRS-1, and could have further impaired 
association with PI-3K. This increase in serine phosphorylation was mimicked by 
inclusion of okadaic acid or calyculin A. As these compounds have been shown to 
inhibit phosphatase enzymes (Bialojan, & Takai, 1988; Ishihara et al., 1989), it was 
suggested that the actions of TNF on IRS-1 were due to inhibition of a 
serine/threonine phosphatase. Thus, increased serine phosphorylation of IRS-1 
impaired its activation by the insulin receptor (Kanety et al., 1995). Serine 
phosphorylation of IRS-1 induced by TNF was observed again in 1996 (Hotamisligil et 
al., 1996). In cultured adipocytes the serine phosphorylated form of IRS-1 was shown 
to actually act as an inhibitor of the insulin receptor tyrosine kinase activity. A similar 
inhibitory form of IRS-1 was also observed in fat and muscle tissue from obese, insulin 
resistant animals (Hotamisligil et al., 1996), and a soluble TNF receptor fusion protein 
could ameliorate this.
Another study, this time using antibody agonists specific for each TNF receptor, 
implicated the 55 kDa TNF receptor in TNF mediated insulin resistance (Peraldi et al.,
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1996). An important finding in this investigation was that serine phosphorylation of 
IRS-1 could be mimicked by exogenous addition of either sphingomyelinase (SMase) 
or the cell permeable analogues of ceramide, C2-ceramide and C6-ceramide (Peraldi et 
al., 1996). Again this resulted in an inhibitory form of the IRS-1 molecule with respect 
to the insulin receptor. The 55 kDa receptor for TNF is known to be coupled to the 
SMase pathway (section 1.1.5.3), implying that the actions of TNF on IRS-1 are 
mediated by ceramide. Indeed, ceramide has been shown to activate a kinase termed 
ceramide-activated protein kinase (CAPK), capable of serine/threonine 
phosphorylation (Mathias e ta l, 1991).
Evidence for implicating the SMase pathway in TNF-induced insulin resistance has 
been presented by another group, however in this study, a completely different 
mechanism of action was suggested (Begum & Ragolia, 1996). Here, 60 min exposure 
of a cultured skeletal muscle cell line to TNF resulted in a decrease in insulin- 
stimulated glucose uptake as well as a decline in glycogen synthase activity. TNF 
blocked insulin activation of PP-1g, and it appeared that the action of TNF on 
glycogen synthesis was more potent than its effect on insulin-stimulated glucose 
uptake. Again this could be mimicked by SMase and cell permeable ceramide 
analogues. Ceramide is capable of activating a phosphatase termed ceramide-activated 
protein phosphatase (CAPP), a member of the PP-2A family of phosphatase and, 
therefore, potently inhibited by okadaic acid (Dobrowsky & Hannun, 1992), PP-2A 
can dephosphorylate PP-1g, therefore it could interfere with insulin stimulation of PP- 
1G (Dent et al., 1990). PP-2A can also dephosphorylate GSK3, thereby reversing 
insulin induced GSK3 inactivation (Murai et al., 1996), both of these actions would 
inhibit insulin-stimulated glycogen synthesis.
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Yet another suggested mechanism of TNF-induced insulin resistance involves the 
activation of a tyrosine phosphatase, which would directly deactivate the insulin 
receptor and inhibit IRS-1 activation (Kroder et al., 1996). Conversely, it has been 
shown that 15 min exposure of 3T3-L1 adipocytes to TNF lead to increased tyrosine 
phosphorylation of IRS-1, and thus increased the association of IRS-1 to PI-3K in 
response to insulin (Guo & Donner, 1996), suggesting a pro-insulin effect of TNF. 
However, insulin-stimulated glucose uptake was not measured in this study. Chronic 
treatment with TNF for 5 days, did lead to a disruption in the insulin receptor signal. 
Also, another study failed to observe any effect of TNF on insulin-stimulated glucose 
uptake or glycogen synthesis in isolated rat soleus muscle strips regardless of exposure 
time (Fumsinn et al., 1997).
Therefore, it is clear that although there has been extensive work investigating the 
interactions between TNF and insulin the story is still quite confused. Current theories 
suggest inhibitory actions of TNF on the insulin receptor, its direct substrates (IRS-1) 
or even at more distal targets of the insulin signal. Specific actions of TNF are 
probably dependant on the tissue or cell studied, however to my knowledge there has 




Septic shock is a state which is characterised by fever, profound hypotension, 
decreased cardiac function and increased systemic vascular resistance, resulting in 
renal, hepatic and cerebral injury, finally death can ensue due to multi-organ systems 
failure or respiratory arrest. Many of the deleterious consequences of septic shock can 
be mimicked by injecting endotoxin, which is a lipopolysaccharide (LPS) component of 
the cell wall in certain bacteria.
1.3.1 Septic shock, and the role of TNF
It is widely accepted that TNF plays a central role in the pathophysiology of septic 
shock, and its experimental counterpart, endotoxin shock. Indeed, it has long been 
known that endotoxin is one of the most potent inducers of TNF release from 
macrophages (Beutler et al., 1985a), and it is now apparent that other cell types, 
including cardiac myocytes and resident cardiac mast cells, are capable of producing 
significant amounts of TNF in response to endotoxin (Giroir et a l, 1992; Kapadia et 
a l, 1995; Saghizadeh et a l, 1996; Frangogiannis etal., 1998).
Early release of TNF into the circulation in response to a Gram-negative bacterial 
lipopolysaccharide challenge was first described by Beutler et al in 1985 (Beutler et 
a l, 1985b). Subsequent studies have shown that immunisation of animals against TNF 
can produce marked protection from many of the pathophysiological consequences of 
an endotoxic challenge or direct E. coli administration (Beutler et a l, 1985c; Tracey et
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al., 1987; Mathison et al.y 1988). These protective effects resulted in increased survival 
of experimental animals. The study by Tracey et al. (1987) showed that anti-TNF 
antibodies protected against some of the profound cardiovascular consequences of 
endotoxin administration, such as decreased cardiac output and severe hypotension. In 
1986, Tracey et al. showed that infusion of recombinant TNF into mammals could 
mimic the effects of endotoxin, inducing hypotension and shock. Histological 
examination after death showed ischaemic lesions of the gastrointestinal tract, and 
acute renal tubular necrosis, suggesting increased systemic vascular resistance and 
inadequate vital organ perfusion. In addition to this, administration of antibodies to 
TNF attenuates the appearance of other cytokines involved in septic shock syndrome, 
i.e. interleukin-1 and interleukin-6 (Fong etal.y 1989).
Thus, three major lines of evidence suggest that TNF is a causal factor in septic shock 
syndrome: firstly, it is one of the earliest mediators secreted by the host in response to 
bacterial or endotoxic challenge; secondly, administration of recombinant TNF causes 
a shock-like state; and finally, neutralisation of TNF with anti-TNF antibodies can 
attenuate the release of other mediators of septic shock, and effect marked protection 
from a lethal endotoxic challenge.
1.3.2 Depressed cardiac function during septic shock
As mentioned earlier, one of the major characteristics of septic shock is profound 
hypotension with depressed cardiac function. This depressed cardiac function could 
potentially contribute to the hypotension observed, and hence to under-perfusion of 
vital organs, and eventually multiple-organ systems failure.
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Abnormal cardiac function during shocked states has been observed on numerous 
occasions, and has been recognised for many years (Solis & Downing, 1966; Starzecki 
& Spink, 1968). Although it is generally appreciated that there is depressed cardiac 
function, the precise time course for this is not so certain. Some investigators have 
observed myocardial depression within 30 - 60 min (Solis & Downing, 1966; 
Guntheroth et al., 1982), while other investigators have described late (> 4 hr) 
myocardial dysfunction (Hinshaw et al., 1974; Starzecki & Spink, 1968). Depressed 
cardiac function in patients is thought to be reversible, whereby patients surviving 
septic shock show a return to normal cardiac contractility by about 10 days after the 
onset of shock (Parker et al., 1984).
Various studies have been performed with the aim of characterising changes in cardiac 
function after endotoxin administration. It does not appear likely that endotoxin itself 
can abnormally alter cardiac contractility, as addition of 1000 pg.ml'1 did not alter 
tension developed by a guinea-pig atrial muscle preparation after 90 min incubation 
(Parker & Adams, 1979). However, depression was seen when hearts were removed 
from animals treated with endotoxin, suggesting the release of a myocardial depressant 
substance (Parker & Adams, 1979). Further evidence for a circulating myocardial 
depressant substance during shock came from studies by Parrillo et al. (1985), where 
sera from septic patients could depress in vitro cardiac myocyte performance. The 
depression in cardiac myocyte performance was obvious within minutes of perfusion 
with sera from septic patients, but not evident at all during perfusion with sera from 
healthy volunteers or post-shock patients. Cardiac myocytes, isolated 4 hr after E. coli 
LPS administration to guinea pigs, were shown to have depressed contractile activity,
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which was not due to altered myofilament Ca2+ responsiveness, but probably a 
consequence of a decrease in the Ca2+-transient during systole (Rigby et a l , 1998). 
Earlier the same group had demonstrated reduced L-type calcium currents in 
ventricular cardiac myocytes isolated 4 hrs after LPS administration to guinea pigs 
(Zhong et a l , 1997). Herbertson et a l  (1996) showed that decreased left ventricular 
contractility 4 hr after endotoxin could be partially attenuated by nitric oxide (NO) 
synthase inhibition in the pig. Although a role for NO in the depressed contractility 
seen in isolated perfused hearts ex vivo after LPS treatment was not found (Decking et 
a l , 1995).
One of the potential mechanisms for depressed myocardial performance during sepsis 
involves decreased sensitivity, or surface expression, of P-adrenergic receptors 
(Eisinger et a l , 1988; Yasuda & Lew, 1997). Although it is unlikely that this 
mechanism would be important during the in vitro depressed cardiac myocyte 
performance with sera from septic patients (Parrillo et a l , 1985) or the decreased 
inotropy of ex vivo heart muscle preparations (Parker & Adams, 1979) mentioned 
earlier, in whole animals it could be important. Decreased p-adrenoceptor 
responsiveness, whether through decreased sensitivity or P-adrenergic receptor down- 
regulation, in the whole animal would lead to altered inotropic responses to circulating 
catecholamines, and, hence, would be expected to be observed as a depression in 
cardiac function.
An interesting study by Hohlfeld et a l  (1995) showed that 3 hr after LPS 
administration to rats, ex vivo perfusion of hearts from these animals lead a marked 
increase in coronary tone when compared to control hearts. The authors showed that
this coronary vasoconstriction was due to endothelin-1 (ET-1). Although ET-1 would 
be unlikely to have a direct negative inotropic action (Kramer et al., 1991), coronary 
constriction would decrease substrate supply to the heart, and, hence, compromise 
cardiac function in an indirect manner. In this study it was also shown that this 
increased coronary resistance could be blocked by anti-TNF antibodies when 
administered 30 min prior to LPS.
1.3.3 TNF as a myocardial depressant in septic shock
Tracey et al. (1986) showed that many of the cardiovascular alterations observed 
during septic shock could be mimicked by TNF. In a later study Tracey et al. (1987) 
showed that antibodies against TNF could protect against the decreased cardiac output 
seen after endotoxin. In addition, TNF has been shown to cause a decrease in cardiac 
function in vivo in dogs (Pagani et al., 1992; Mitaka et al., 1994; Murray & Freeman, 
1996). Also, various in vitro investigations have shown a direct negative inotropic 
action of TNF (Finkel et al., 1992; Foulkes & Shaw, 1992; Yokoyama et al., 1993; 
Weisensee et al., 1993; Goldhaber et al., 1996; Oral et al., 1997). In addition to this, 
media from activated macrophages, containing cytokines, as well as mixtures of 
cytokines themselves have been shown to disrupt p-adrenergic function (Gulick et al., 
1988; Chung et al., 1990; Balligand et al., 1993b). All of these will be discussed in 
detail in section 1.5. So due to the increased circulating levels of TNF during shock, 
and the fact that TNF is a cardiodepressant in its own right, TNF has become a prime 
candidate as a mediator of the cardiac abnormalities observed during septic shock.
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1.4 Heart disease and TNF
Chronic heart failure is a syndrome that has symptoms of fatigue and dyspnea and 
where impaired left ventricular function leads to many secondary changes in other 
organs. During the development of chronic heart failure the heart can undergo 
structural changes characterised by enlargement of the left-ventricular cavity, which is 
often accompanied by gross histological cardiac changes manifested by hypertrophy or 
even thinning of the ventricular wall, processes known as “remodelling”. In addition to 
this, there are structural changes at the microscopic level which include increased 
collagen content of the extracellular matrix, which can cause a general “stiffening” of 
the ventricular wall and, therefore, impair relaxation. These changes in structure are 
accompanied by left ventricular dysfunction, and impaired ability to respond to the 
increased demands of exercise. The sensation of dyspnea, suggests alterations in 
pulmonary physiology, and indeed, pulmonary oedema is often observed (for review 
see Coats, 1997).
As heart failure progresses patients can develop a syndrome known as cardiac 
cachexia, characterised by profound weight loss and anorexia, which is generally 
accompanied by inflammation (Anker & Coats, 1997). The initial study implicating 
increased TNF levels in chronic heart failure (Levine et al., 1990), showed that TNF 
levels were increased in patients with chronic heart failure, but this was limited to a 
subset of patients with cachexia. The ability of TNF to induce cachexia was described 
in section 1.2. Increased serum TNF in cachexic patients with heart failure has 
subsequently been shown on many other occasions (McMurry et al., 1991; Dutka et
31
al., 1993; Katz et al., 1994), and recently increased levels of TNF and its binding 
proteins have now been shown in heart failure without cachexia (Ferrari et al., 1995).
Raised circulating TNF levels in chronic heart failure is reason enough to investigate 
the cardiac actions of TNF, however a review of the literature shows that many of the 
clinical hallmarks of heart failure can be mimicked by TNF, namely cardiac remodelling 
(Bozkurt et al., 1998) and cardiomyopathy (Hegewisch et al, 1990), left ventricular 
dysfunction (Pagani et al., 1992) and pulmonary oedema (Millar et al., 1989). 
Therefore the characterisation of the exact cardiac effects of TNF is important and 
could lead to novel therapeutic strategies in the treatment of chronic heart failure.
Two recent studies have investigated the effects of overexpression of TNF in the hearts 
of transgenic mice (Bryant et a l, 1997; Kubota et al., 1997). The first of these showed 
biventricular dilation with a decreased ejection fraction, supporting a role for TNF in 
the pathogenesis of heart disease (Bryant et al., 1997). In the second study, very 
similar results were obtained, where TNF overexpression lead to an increase in the 
heart:body weight ratio, with ventricular dilation and decreased ejection fraction 
(Kubota et al., 1997). In addition to this it was shown that there was a decreased 
responsiveness to isoprenaline (Kubota et al., 1997). P-adrenergic dynsfunction is 
common in heart failure (Bristow, 1984).
Raised serum TNF concentrations have also been observed during ischaemic heart 
disease (Vaddi et a l, 1994), and a number of investigations have implicated TNF in the 
pathogenesis of experimental ischaemia. Squadrito et al. (1993) showed that in an 
anaesthetized rat model of coronary artery ligation, serum TNF levels were markedly
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increased upon release of the coronary artery ligature. Immunisation with a 
hyperimmune serum containing antibodies against TNF showed a significantly 
increased survival rate for experimental animals (Squadrito et al., 1993). During a 
study of hepatic ischaemia reperfusion, increased TNF was again observed upon 
reperfiision (Colletti et al., 1993). Pulmonary injury was also observed during 
reperfiision, secondary to hepatic injury. Pre-treatment with anti-TNF antibodies 
effected complete protection from both the pulmonary oedema observed, and from 
hepatic injury seen. Very recently Meldrum et al. (1997) have shown that TNF is 
released from an in vitro perfused heart preparation after an ischaemic episode 
followed by reperfiision. Prior treatment with adenosine improved recovery of these 
hearts, as well as decreasing TNF release. Another interesting, very recent, study by 
the same group showed that TNF is expressed in the human myocardium following the 
obligatory global ischaemia during cardiopulmonary bypass (Meldrum et al., 1998)
1.4.1 Cardiac acidosis
During cardiac ischaemia, cardiac acidosis can often be observed, indeed pH values of 
below 6.0 have been reported (Kolocassides et al., 1996). This acidosis is the result of 
a build up of lactic acid from anaeobic glycolysis, as well as the release of protons from 
ATP hydrolysis. Interestingly, it has been reported that at low pH values, in the 
presence of TNF, ion channels can form in artificial membranes (Kagan et al., 1992). 
Further investigation provided evidence that during low pH conditions, the compact 
trimer configuration of biologically active TNF was relaxed, allowing insertion into the 
plasma membrane (Baldwin et al., 1996). This was accompanied by an increase in
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sodium (Na4) flux across the membrane. Elevated intracellular Na+ can cause an 
increase in intracellular Ca2+ via the Na+/Ca2+ exchanger (Tani & Neely, 1989). 
Therefore, during acidosis TNF could contribute to the Ca2+ overload seen during 
ischaemia by forming Na+ permeable channels. Indeed, NMR experiments have shown 
that increased intracellular sodium has been is seen during ischaemia (Pike et at., 
1990).
Increases in serum TNF have also been observed in other cardiac diseased states 
including acute myocardial infarction (Latini et al., 1994), cardiac allograft rejection 
(Arbustini eta l., 1991) and acute viral myocarditis (Smith & Allen, 1992).
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1.5 Actions of TNF in the heart
Due to the aforementioned potential role for TNF as a mediator of the observed 
alterations in cardiac function during septic shock (section 1.3), as well as the marked 
increase in circulating TNF levels seen in various cardiovascular disease states (section 
1.4), the direct cardiac actions of TNF have been a subject of increasing interest. 
Whilst it is generally acknowledged that TNF can disrupt normal heart function, much 
controversy still exists as to the precise nature of this disruption and many potential 
mechanisms have been suggested. There appear to be two phases in the observed 
depression in cardiac function produced by TNF, an early phase (<30 min) and a late 
phase (> 120 min). In addition to this actions of TNF have been observed in the 
coronary circulation, independent of any cardiac depression. The following section will 
discuss the above observations in detail.
1.5.1 TNF induced immediate negative inotropic effects
Various in vitro and in vivo studies have described an early direct and reversible 
negative inotropic action of TNF (Finkel et al., 1992; Foulkes & Shaw, 1992; 
Weisensee et al., 1993; Yokoyama et a l , 1993; Kapadia et a l , 1995; Torre-Amione et 
a l , 1995; Goldhaber et al., 1996; Oral et a l , 1997) however, others have disputed this 
early action of TNF (Mitikata et al., 1994; Schulz et al., 1995; Murray & Freeman, 
1995; Nishikawa et a l , 1996). The studies by both Schulz and Murray & Freeman 
actually showed an initial positive inotropic effect of TNF.
35
In 1992, Finkel et al. were the first to show a direct and early negative inotropic action 
of TNF. This landmark paper describes studies in the electrically stimulated isolated 
ferret papillary muscle, where TNF caused a concentration-dependant decrease in 
contractile function, which was evident after 2 -3  min, and reached a maximum after 5 
min. Moreover these responses were shown to be reversible upon wash-out of TNF. 
This negative inotropic response was sensitive to NO synthase inhibitors, suggesting a 
vital role for NO (NO is briefly review in section 1.5.2). The rapid time-course 
required for this action implicated the constituatively expressed form of CO synthase 
(cNOS) as the enzyme responsible. In contrast to these observations, Yokoyama et al. 
(1993), showed that in the isolated feline heart as well as in isolated adult feline 
ventricular myocytes TNF caused an early, concentration-dependent and fully 
reversible negative inotropic effect which was insensitive to NO synthase and 
cyclooxygenase inhibition. The reversibility of this action and the lack of fragmented 
DNA suggested that responses seen were not secondary to necrotic or apoptotic cell 
death. An important observation of this study was that the negative inotropic effect 
was accompanied by a decline in the systolic peak intracellular calcium [Ca2+]i 
transients. This was not attributable to changes in the voltage-sensitive calcium current 
(L-type Ca2+ current). The discrepancy between these two important investigations is 
not clear, species variability is one possible explanation, but this is not entirely 
satisfying.
In 1993, Weisensee et al. showed that within minutes TNF could cause complete 
cessation of the spontaneously beating rhythmic contractions seen in murine isolated 
neonatal myocytes, which with time progressed to arrhythmic beating, they also
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showed that TNF caused a decrease in the resting membrane potential but the 
mechanisms responsible for these actions were not investigated.
In 1995 the same group which showed decreased [Ca2+]i, also demonstrated, using 
mutants of TNF which selectively bind to each TNF receptor, that the TNF type I 
receptor was responsible for the negative inotropic actions of TNF in adult rat cardiac 
ventricular myocytes (Torre-Amione et al., 1995). Krown et al. (1995) presented data 
which partially supported the observations by Yokoyama et al. (1993) as well as those 
of Torre-Amione et al. (1995) showing that TNF could cause depressed [Ca2+]i 
transients, but unlike Yokoyama et al. (1993), these other studies was concluded that 
inhibition of the L-type Ca2+ channel was likely to be the mechanism responsible. 
Single cell reverse transcription-PCR, [125I]-TNF ligand binding and Western 
immunoblotting experiments again implicated the TNF type I receptor in these actions 
of TNF. However, this study did not include any data concerning the contractile 
activity of the cardiac myocytes involved.
Support for the publication by Finkel et al. (1992) implicating NO in the early negative 
inotropic actions of TNF was presented in a study using isolated adult rabbit 
ventricular myocytes (Goldhaber et al., 1996). It was shown that, within 20 min, TNF 
could decrease cell shortening in response to electrical stimulation, an action which in 
contrast to Yokoyama etal. (1993) was not due to changes in [Ca2+]i transients. Again 
this action was blocked by a NO synthase inhibitor (L-NAME), as well as by 
haemoglobin, a scavenger of NO. This suggests that a possible mechanism for the 
negative inotropic action of TNF involves the release of NO. It was suggested that this
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NO could then cause decreased responsiveness of the cardiac myocyte myofilaments to 
Ca2+ (Goldhaber et al., 1996).
In 1997, Oral et al. outlined a mechanism by which TNF could cause depressed [Ca2+]i 
transients in cardiac myocytes via TNF-stimulated increases in free sphingosine. Both 
TNF and exogenous sphingosine caused an immediate ( 5 -15  min) negative inotropic 
action. The actions of TNF could be blocked by an inhibitor of the enzyme responsible 
for the metabolism of sphingomyelin to sphingosine, N-oleoylethanolamine (NOE). 
This study was again conducted in isolated adult feline ventricular myocytes. A later 
study (Bozkurt et al.f 1998) subsequently showed that NOE could also partially 
attenuate the depression in cardiac function in vivo observed upon slow TNF infusion 
into rats.
As mentioned in section 1.1.5.3, sphingosine is an endogenous inhibitor of PKC, 
however this is not the only biological action of this sphingomyelin metabolite. In a 
study utilising skinned rabbit skeletal muscle fibres it was shown that sphingosine could 
act as a ligand for the ryanodine receptor (Sabbadini et al., 1992). In this regard, 
sphingosine was shown to decrease caffeine-induced calcium release from internal 
stores. In line with this, sphingosine significantly increased the Kd for specific binding 
of [3H]-ryanodine to terminal cistemae. This was in contrast to caffeine which 
increased Kd for ryanodine binding. In cardiac muscle, the ryanodine receptor is of 
great importance as it mediates a phenomenon known as calcium-induced calcium 
release (CICR). In cardiac myocytes depolarisation leads to relatively small amounts of 
Ca2+ entry through L-type calcium channels. This Ca2+ is thought to interact with the 
ryanodine receptor situated on the sarcoplasmic reticulum (SR), causing the release of
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far greater quantities of Ca2+ from the SR into the cytosol, and this Ca2+ then causes a 
contraction (Fabiato, 1983). Soon after the initial report concerning the ryanodine 
receptor in skeletal muscle, it was shown that sphingosine could also disrupt the 
ryanodine receptor function in isolated canine cardiac SR membranes (Dettbam et a l , 
1994). Ca2+ release in response to caffeine, doxorubicin or by Ca2+ itself was also 
inhibited by prior administration of sphingosine. Sphingosine inhibited the extent of 
CICR, and significantly shifted the threshold for CICR, so that a higher level of trigger 
calcium was required. Another report from the same group showed that sphingosine 
could inhibit [Ca2+]i transients in adult and neonatal cardiac myocytes, an effect which 
was dependant on a decrease in the L-type Ca2+ current as well as decreased CICR 
(McDonough et al., 1994). Another report in the same year, by the same group 
showed that the disruptions in Ca2+ homeostasis seen upon sphingosine administration 
translated into depressed cardiac myocyte function (Webster et al, 1994). These 
authors showed that sphingosine had no effect on the contractile machinery of the 
cardiac myocytes.
Thus, it is very plausible that sphingosine could mediate some of the early changes in 
cardiac function seen with TNF. However greater research is required in this area due 
to the reports suggesting a role for NO in this early depression in cardiac function. 
Neither of the two reports implicating NO in the early depression in function (Finkel et 
a l , 1992; Goldhaber et a l, 1996) convincingly demonstrated activation of cNOS 
which would be necessary for the rapid release of NO.
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1.5.2 TNF induced late alterations in cardiac function
TNF induced late cardiac dysfunction has been observed on several occasions in vivo 
(Pagani et al., 1992; Mitaka et al., 1994; Murray & Freeman, 1996), and 
characterisation of this has proven more successful than investigations into the early 
depressant actions. Under in vitro conditions however, disruption in cardiac function 
almost always requires the addition of another cytokines such as IL-1. In the whole 
animal situation, TNF would be expected to cause the release of other cytokines 
including IL-1 (see section 1.1). Cytokine induced late cardiac dysfunction almost 
certainly involves NO synthesis, via an inducible form of NO synthase (iNOS), 
therefore a brief overview of the biology of NO will be given before presentation of the 
evidence supporting a role for NO in late contractile dysfunction seen with cytokines.
NO is a small lipophilic free radical gas which is synthesised from L-arginine and 
molecular oxygen, and has been shown to be identical the endothelium-derived relaxing 
factor (Furchgott & Zawadzki, 1980). The synthesis of NO is dependent on a family of 
enzymes known as NO synthase (NOS) enzymes, all of which require NADPH, FAD, 
FMN, tetrahydrobiopterin and calmodulin as cofactors. The NOS family includes a 
constituatively expressed, Ca2+-dependant (cNOS) as well as an inducible, Ca2+- 
independent NO synthase (iNOS). Traditionally cNOS was thought to be expressed 
exclusively in the vascular endothelium, but it is now known that, amongst other cells, 
cardiac myocytes can also express cNOS (Balligand et al., 1993a). cNOS generally 
produces NO in small “puffs”. iNOS on the other hand is a high output source of NO 
which, with its tightly bound calmodulin, does not depend on increases in Ca2+. iNOS 
can be induced by cytokines (Koide et al., 1993), and this requires protein synthesis
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and, therefore, may take several hours to become fully active (Tsujino et al., 1994). A 
major target for the actions of NO is guanylate cyclase, which when activated increases 
the production of cGMP (Palacios et al., 1989). However, NO can also react with the 
free radical superoxide anion (O2'), to form the highly reactive and potentially 
damaging molecule, peroxynitrite (ONOO') (Radi et al., 1991).
One of the first studies to try to characterise a mechanism for the late cardiac 
dysfunction came from Gulick et al. (1988), who showed that in cardiac myocytes, 
several hours incubation with cell free supernatants from activated macrophages could 
inhibit the expected increase in cAMP, as well as the concomitant positive inotropic 
effects of isoprenaline. Supernatants from activated macrophage would be expected to 
contain many cytokines, especially TNF and IL-1. Another study from the same 
laboratory subsequently showed that supernatants from rat activated splenocyte 
cultures (containing TNF, IL-1 and IL-2), could also cause inhibition of isoprenaline 
induced increases in cAMP in cardiac myocytes after 48-72 hours exposure (Chung et 
al., 1990). This action was not altered by phosphodiesterase inhibitors or cholera 
toxin, but was inhibitable by petussis toxin, thus implicating altered coupling of (3- 
adrenergic receptors to adenylate cyclase at the level of the stimulatory/inhibitory G- 
proteins (Chung etal., 1990).
These studies were supported and extended by Balligand et al. (1993b), who showed 
that supernatant from LPS-activated macrophages, when incubated for 24 hours with 
cardiac myocytes could block the p-adrenergic receptor mediated inotropic response. 
Again this response was sensitive to pertussis toxin. Also shown in this study was the 
generation of NO with concurrent generation of cGMP. L-NMMA an inhibitor of all
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isoforms of NOS could block the inhibitory effects seen on addition of isoprenaline. A 
subsequent study by the same group showed that exogenous cytokines could mimic 
these actions by induction of the iNOS enzyme, and an increased iNOS mRNA was 
observed after 12 hours (Balligand et al., 1994). Cardiac cells other than myocytes 
may also be important in the hearts response to cytokines. In a study by Ungreau- 
Longrois et al. (1995) cardiac microvascular endothelial cells were cultured and 
treated with IL-ip for 24 hours and this induced iNOS in these cells. Following this, 
cardiac myocytes were allowed to settle onto the confluent layer of treated endothelial 
cells. Isoprenaline induced responses were reduced in myocytes when in this 
heterotypic culture. In the presence of L-NMMA, no such decline in isoprenaline 
response was seen. Thus, diffusion of NO from the endothelial cells was able to cause 
the subsequent blockade of responses in adjacent cardiac myocytes (Ungreau-Longrois 
etal., 1995).
Evidence for a direct negative inotropic action involving cytokine induced induction of 
iNOS in the absence of either circulating catacholamines, or exogenously administered 
p-receptor agonists was presented in the isolated perfused rat heart. A combination of 
TNF and IL-ip could depress cardiac function only 2 hours after cytokine application 
(Schulz et al., 1995). This depression in cardiac function did not require isoprenalinee 
to become apparent. No early negative inotropic effect was observed. The action of 
these cytokines could be blocked by the protein synthesis inhibitor cyclohexamide. 
Indeed, iNOS activity was evident, and the depression in cardiac contractility could be 
alleviated by NOS inhibition (Schulz et al., 1995).
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In summary, it is apparent that induction of iNOS over the period of several hours can 
lead to contractile dysfunction either by a direct NO-mediated negative inotropic 
action, or by a reduced responsiveness to p-receptor agonists. The precise mechanism 
behind these actions is not clear at present. Direct negative inotropic actions of NO 
have also been observed in the absence of cytokine stimulated iNOS expression (Smith 
et al., 1991; Brady et al., 1993). The negative inotropic effect of NO could be 
mediated by stimulation of guanylate cyclase (Mery et al., 1993) or by direct inhibitory 
actions of NO on mitochondrial respiratory enzymes (Geng et al., 1992). As 
mentioned in section 1.5.1 Goldhaber et a l (1996) presented evidence that NO could 
decrease Ca2+ responsiveness of myofilaments. The mechanism behind the apparent 
alteration in adenylate cyclase stimulation by p-adrenergic agonists upon cytokine 
incubation is also not clear at this point in time. Increased levels of cGMP, from 
guanylate cyclase stimulation by NO, could activate a cGMP-dependant cAMP 
phosphodiesterase, which in turn could breakdown the product of adenylate cyclase 
activation, cAMP, thereby reducing the effect of adenylate cyclase activation. However 
the studies by Chung et al. (1990), suggest that this is unlikely because the inhibition of 
isoprenaline-induced cAMP accumulation was not altered by a phosphdiesterase 
inhibitor. Instead the mechanism behind this action appears to involve a NO induced 
“uncoupling” of adenylate cylase from the P-adrenergic receptor, and studies with 
pertussis toxin implicate a role of the inhibitory G-protein in this action (Chung et al., 
1990; Balligand etal., 1993b).
NO mediated depression in function is also, at least in part responsible for the 
contractile dysfunction observed during shock, as cardiac myocytes isolated from 
endotoxin treated guinea-pigs show depressed contractile function which is inhibited
by NOS inhibition (Brady et al., 1992). In addition to this, NOS inhibition can partially 
prevent the decrease in left ventricular contractility observed upon in vivo 
administration of endotoxin (Herbertson et al., 1996).
1.5.3 Other cardiac effects of TNF
As mentioned earlier (section 1.3.2) administration of TNF or LPS to whole animals 
results in constriction of the coronary circulation which is observed ex vivo when 
hearts were perfused by the LangendorfF technique (Hohlfeld et al., 1995). It was 
shown that administration of TNF or LPS caused increased circulating levels of ET-1, 
and that the coronary constriction could be blocked by an antagonist of the 
endothelinA (ETA) receptor. In other studies from the same group it was shown that 
antibodies against ET-1 could ameliorate this ex vivo coronary constriction induced by 
TNF, and that exogenous administration of interleukin-2 caused release of TNF, which 
again induced an ET-1 mediated coronary constriction (Klemm et al., 1995a). A 
subsequent investigation showed that during adjuvant-induced arthritis, increased 
circulating cytokine levels were observed (Klemm et al., 1995b). When hearts were 
perfused from this arthritis model, again an increase in coronary tone was observed 
which was blocked by an endothelin receptor antagonist. The source of the ET-1 
responsible for this constriction was not identified. If this coronary constriction 
occurred in the whole animal situation, a decrease in substrate supply to the heart 
could mediate an indirect depression in cardiac function.
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1.6 Aims of this study
1) To investigate the effects of recombinant human TNF on insulin action in the 
isolated perfused rat heart under substrate limiting conditions, i.e. low glucose 
perfusion and low flow ischaemic perfusion. Under such conditions, the actions of 
insulin would be expected to be exacerbated. To attempt to characterise any TNF 
mediated disruptions in insulin action with the use of pharmacological agents.
2) To investigate cardiac depressant actions of TNF in the isolated perfused rat
heart, utilising left ventricular developed pressure, rate of change of both systolic 
contraction and diastolic dilation, heart rate and Starling curves to assess cardiac 
function. To attempt to characterise any depression in function seen with 
pharmacological agents.
3) To see if TNF has any direct actions on the coronary circulation of the rat
heart, and to attempt to characterise any action seen. Also to see if any action of TNF
in the coronary circulation can affect cardiac function.
4) To observe the recovery of hearts after short periods of acidosis, and to see if
TNF adversely affects this recovery.
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Section 2 Materials and Methods
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2.1 Materials
British Drug House (BDH), Poole: D-glucose, ethanol (96%), ethylenediaminetetra- 
acetic acid (EDTA), glycoge (oyster), KC1, NaCl, NaHCC>3 .
Biomol, Affiniti Research Products Ltd., Exeter: Okadaic acid
Fisons Scientific Equipment, Loughborough: CaC1.6H20, Hydrazinium sulphate, 
KH2PO4, MgS04, MgCl2.6H20, NaOH,
Peninsula Laboratories, Merseyside: endothelin-1
R&D systems, Abingdon: recombinant rat TNF-a
Sigma, Poole: adenosine 5’-diphosphate (ADP), adenosine 5’-triphosphate (ATP), P- 
nicotinamide adenine dinucleotide (NAD4), P-nicotinamide adenine dinucleotide 
phosphate (NADP), D-sphingosine, fructose 6-phosphate (F-6-P), fructose 1,6- 
bisphosphate (F-l,6-P), glucose 1-phosphate (G-l-P), glucose 6-phosphate (G-6-P), 
glycine, indomethacin, L-lactate, N-acetly-o-sphingosine (C2-ceramide) Nco-nitro-1- 
arginine, N-oleoylethanolamine, phosphocreatine (PCr), U46619 (9,11-dideoxy- 
9a,l la-epoxy-methanoprostaglandin F2a).
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Enzymes purchased from Sigma, Poole: aldolase (type IV, from rabbit muscle), 
creatine kinase (type I from rabbit muscle), glucose 6 -phosphate dehydrogenase (type 
VII from bakers yeast), glycerol-3-phosphate dehydrogenase (type I from rabbit 
muscle), hexokinase (type C-130 from bakers yeast), lactate dehydrogenase (type I 
from bakers yeast), phosphoglucose isomerase (from bakers yeast), 
phosphoglucomutase (from rabbit muscle), sphingomyelinase (SMase, from Bacillus 
Cereus), triosephosphate isomerase (type I from bakers yeast).
ZD 1542 (4(z)-6-[2S,4S,5R]-2-[ 1 -methyl-1 -(2-nitro-4-tolyloxy)ethyl]-4-(3-pyridyl0-
l,3-dioxan-5-yl]hex-4-enoic acid) was a gift from Dr. M.J. Wayne (Zenica). GR32191 
(([ lR-(a(Z),2p,3 P,5a]]-(+)-7-[5-([ 1,1 ’ -biphenyl]-4-ylmethoxy)-3 -hydroxy-2-( 1 - 
piperidinyl)-cyclopentyl]-4 heptonoic acid) was a gift from Glaxo Pharmaceuticals. 
Bosentan was a kind gift from Dr. A. G. Roach (Rhone-Poulenc Rorer, Dagenham). 
Recombinant human TNFa was a very kind gift from Bayer (Slough).
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Male Wistar rats, University of Bath strain, 280-3 lOg have been used throughout this 
project. In all experiments animals were anaesthetised by an interperitoneal injection of 
sodium pentobarbitone ( 2 0 0  mg.kg'1), and then killed by cervical dislocation.
2.2 The Langendorff isolated perfused heart
The heart of each animal was excised and perfused using a modified Langendorff 
technique via a cannula inserted in the aorta, care was taken not to disrupt the aortic 
valves during this process. Hearts were perfused under conditions of constant flow (10 
ml.min*1 or 2 ml.min'1) or constant pressure conditions (70 mmHg) with prefiltered, 
oxygenated (O2 95%, CO2 5%) Krebs-Henseleit solution, at 37°C (unless otherwise 





MgS04. 7H20 1.2 mM
CaCl2 1.2 mM
D-glucose 11.6 mM
In some experiments glucose levels were altered, and concentrations of both 2 mM and 
25 mM were used. In other experiments NaHC0 3  concentrations were lowered in 
order to alter the pH of the Krebs buffer to either pH 6.1 or pH 5.5. Hearts were
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allowed to beat spontaneously throughout all experimental procedures (Langendorff, 
1895).
A recirculating perfusion method was chosen to examine the cardiac actions of TNF. 
The major advantage of this system is that small volumes of perfusate are required, 
decreasing the amount of any drug used. A disadvantage of this system is that, once 
added, drugs cannot be washed out easily without disrupting the recirculating process. 
A total volume of 50 ml was chosen for recirculation.
2.2.1 Parameters measured
Under constant flow conditions, coronary perfusion pressure (CPP) was measured 
using a Gould P231D pressure transducer, and used as a measure of coronary tone. In 
hearts perfused under a constant head of pressure, coronary inflow was measured 
using a T 206 Transonic Systems Inc. flow meter, attached to the aortic cannula, and 
used as a measure of coronary tone. Contractile function of hearts was measured using 
two different methods, one utilising a hook placed in the apex of the heart, and another 
using intraventricular balloons, these are both described in detail below.
When using the hook method, then developed tension and heart rate were used as a 
measure of cardiac function, and were recorded via a hook in the apex of the heart, 
connected by a pulley system to an isometric force transducer (Dynometer UFI). Each 
heart was initially placed under a resting tension of 2 g. A small gauge needle (0.5 x 16 
mm) was inserted into the left ventricle to allow Thebesian drainage, this is necessary 
in order to drain the left ventricle of its venous return (figure 2 .1 ).
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The other method for measuring heart function utilised an intraventricular balloon. 
Hearts were prepared as before, and a fluid filled Clingfilm balloon was inserted into 
the left ventricle and inflated (great care was taken to ensure the absence of air bubbles 
within the balloon). Pressure changes inside the balloon were measured via a Gould 
P231D pressure transducer and left ventricular developed pressure (LVDP) and heart 
rate were used as in index of cardiac function. In addition to this, the signal generated 
from the balloon was differentiated by a Grass polygraph differentiation, 7P20C, in 
order to measure the rate of change of systolic contraction and rate of change of 
diastolic relaxation. Left ventricular-end diastolic pressure (LVEDP) was set between 
5 and 10 mmHg with the use of a 1 ml syringe connected to a micrometer head, 
allowing fine adjustment of balloon volume. The advantage to using an intraventricular 
balloon is that Starling curves can be performed to asses the Frank-Starling response in 
perfused hearts. In these, studies Starling curves were performed by emptying the 
intraventricular balloon, then slowly filling the balloon, to a total volume of 0.24 ml, in 
0.03 ml aliquots every 30 seconds. LVDP was then measured and plotted against the 
volume added to the balloon. This results in very reproducible volume-response curves 
which represent the hearts ability to respond to changes in diastolic volume. Output 
from all transducers was recorded on either a Grass model 7B polygraph, a Gould 
2400S chart recorder, a Gould RS3400 chart recorder or on a Macintosh Performa 












gassed with 95 % Oj, 5 % COj
Figure 2.1. A diagramatical representation o f  the recirculating perfusion set up used in 
all preliminary experiments.
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2.3 Protocol for assays used
Throughout this study assays have been used to measure glucose uptake from and 
lactate accumulation in the recirculating Krebs buffer. In addition to this, further assays 
have been completed in order to determine the heart tissue levels of glycogen, glucose 
6 -phosphate (G-6 -P), glucose 1-phosphate (G-l-P), adenosine triphosphate (ATP), 
phosphocreatine (PCr), fructose 6 -phosphate (F 6 -P) and fructose 1,6-bisphosphate 
(F-l,6 -P). All of these are described below.
2.3.1 Assay for glucose
The principle behind the assay used to measure glucose levels, in samples from the 
recirculating perfusate, was dependant on the following reaction:
HK
(1) Glucose + ATP -> Glucose-6 -phosphate + ADP
G-6-PDH
(2) Glucose-6 -phosphate + NADP -> 6 -Phosphogluconate + NADPH
HK = Hexokinase
G-6 -PDH = Glucose-6 -phosphate dehydrogenase
(Stein, 1963)
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The reaction mixture for this assay was of the following composition: NADP+ 1.5 mM, 
ATP 1 mM, MgCl 2.1 mM, HK 1000 U.l' 1 and G-6 -PDH 1000 U.l*1, all quantities 
being in excess. To 1 ml of this solution was added 50 pi of the sample to be assayed, 
this was then left to stand for 5 min at room temperature. 50 pi of distilled water was 
used as the control. The absorbance of NADPH in the solution was measured in a 
quartz cuvette at 340 nm and the concentration of glucose calculated using a 
calibration curve constructed from glucose standards (0.1 mM, 0.2 mM, 0.4m M, 0.8 
mM, 1.6 mM and 3.2 mM).
2.3.2 Assay for lactate
The spectrophotometric determination of lactate concentration is dependant on the 
following reaction:
LDH
(3) L-lactate + NAD+ + Hydrazine —> Pyruvate Hydrazone + NADH + H30 +
pH 9.5
LDH = lactate dehydrogenase
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Shown below is the reaction mixture, added to the cuvette, and required for the 
determination of lactate within a given sample:
Hydrazone (0.4 M) - glycine (0.5 M) buffer (pH 9.5), with 20 mM EDTA 0.625 ml 
NAD+ solution, 0.045 M 0.05 ml
Lactate dehydrogenase, 5000U/ml 5 jxl
Sample to be assayed or blank 0.05 ml
After 30 min incubation at 37°C, NADH was measured spectrophotometricaly at 340 
nm, and concentration of lactate calculated using the extinction coefficient of NADH at 
340 nm, whereby a solution containing 1 mM NADH would have an absorbance 
constant of 6.22, when measured at 340 nm. This value is stoichiometrically related to 
the lactate concentration. The method of lactate determination has been described fully 
byHohorst, 1965.
2.3.3 Glycogen determination
Hearts were freeze clamped, between a pair of Wollenberger tongs which had been 
cooled to the temperature of liquid nitrogen (-196°C), the resultant disc of tissue was 
then stored at -80°C until such time as an assay of the levels of glycogen could be 
undertaken.
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Glycogen levels were determined by hydrolysis to glucose and subsequent calculation 
of glucose concentration as described previously (Pfleiderer, 1965). The frozen hearts 
were powdered using an homogeniser, previously cooled in liquid nitrogen. The finely 
powdered tissue, approximately 250 mg, was placed in a pre- weighed test tube 
containing 2 ml KOH (30 % w/v) and 2.8 ml absolute ethanol (95%). The test tube 
was then reweighed to determine tissue weight, then placed in a boiling water bath for 
30 min to allow alkaline digestion of the tissue followed by glycogen extraction with 
ethanol. Tubes were centrifuged for twenty minutes at 1250g, the resulting supernatant 
was discarded and the pellet washed in 5 ml of 70 % v/v ethanol. The tubes were then 
recentrifiiged, the supernatant was again discarded and the pellet dried at 100°C. 1 ml 
of 2M sulphuric acid was added to each tube, the tubes were placed in a boiling water 
bath, stoppered and then left for two hours. The acidic solution was neutralised using 
2M sodium hydroxide and to this was added 5 ml of phosphate buffer (pH 7.5), and 
total volume measured. Concentration of glucose could then be determined using the 
method described previously, 2.3.1. Glycogen levels were expressed as pmoles of 
glucose equivalents per gram of tissue, dry weight.
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2.3.4 Glucose 6-phosphate, glucose 1-phosphate, fructose 6-phosphate, ATP and 
PCr determination
Glucose 6 -phosphate (G-6 -P, glucose 1-phosphate (G-l-P), fructose 6 -phosphate (F- 
6 -P), adenosine triphosphate (ATP) and phosphocreatine (PCr) were all measured 
using the same extraction procedure. The reactions which this depends on are shown in 
figure 2.2. Each was then determined within the same cuvette as described below. 
Freeze clamped hearts were powdered as described above. Approximately 150 mg of 
frozen ventricular tissue was added to a preweighed 1.5 ml centrifuge tube containing 
1 ml ice-cold perchloric acid (6 % w/v). This was then reweighed to determine the 
exact tissue weight. The samples were left on ice to extract for 30 min, with regular 
mixing intervals. 2  min centrifugation, at 1 2 0 0 0 g, resulted in a distinct supernatant, 
500pl of which was removed and neutralised with KOH (40 % w/v) using 5pi of 
universal indicator. This was then allowed to stand on ice for 5 min, whereupon a 
sediment of KCIO4 was formed, after decanting the solution, it was taken immediately 















Figure 2.2. A diagrammatical representation of the reactions involved in the 
determination of G 6 -P, G 1-P, F 6 -P, ATP and PCr. 6 -PG = 6 -phosphogluconate.
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The reaction utilised by this assay follow the same principle as that for glucose 
determination except, stepwise addition of different enzymes allowed determination 
each substrate to be measured. The reaction mixture for this assay is as follows:
Distilled water 550 pi
Phosphate buffer, pH 7.5 350 pi
NADP+, 13 mM 35 pi
Glucose, 100 mM 20 pi
MgCl2, 1 M 35 pi
ADP, 35 mM 8  pi
To 1 ml of this solution was added 40 pi of the sample to be assayed. Absorbance was 
determined, after which 2 pi of G-6 -PDH (1.1U), was added and the following change 
in absorbance measured, after 5 min, and resulted from reaction (2). After this addition 
of 5 pi HK (2.8 U) allowed reaction (3) to take place and determination of ATP via G- 
6 -P can be calculated. After the absorbance reading stabilised, about 5 min, the value 
was recorded. Addition of creatine kinase (CK), 5 pi (2.8 U), allowed reaction (4) to 
take place, and so determination of PCr was possible.
CK
(4) PCr + ADP -» creatine + ATP
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Therefore the generation of more ATP allows reactions 1 and 2 to begin again. After a 
further period to allow the reaction to run to completion, 2  pi of phosphoglucomutase 
(3.13 U) allowed reaction (5) to proceed.
phosphoglucomutase
(5) G-l-P -> G-6 -P
When the absorbance reached a maximum, 2pl of phosphoglucose isomerase (4U) was 
added to the reaction mixture in order to measure F-6 -P via reaction (6 ).
phosphoglucose isomerase 
(6 ) F-6 -P a -  G-6 -P
Therefore, measurement of NADP+ spectrophotometrically allowed estimation of G-6 - 
P, G-l-P, F-l-P, ATP and PCr extracted from hearts using a calibration curves 
constructed from standards. The calibration curves used the following standards, 
prepared from each of the substrates to be measured: 0.1 mM, 0.25 mM, 0.5 mM and 
1 mM. Levels are expressed as pmoles per gram dry weight (Lamprechet & 
Trantschold, 1974, Lamprechet, et al. 1974).
2.3.5 Determination of tissue fructose 1,6-bisphosphate levels
When determining tissue levels of fructose 1,6-bisphosphate (F-l,6 -P), after extraction 
of F-l,6 -P, one must first split the molecule to dihydroxyacetone phosphate (DAP) and 
glyceraldehyde 3-phosphate by reaction (7).
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aldolase
(7) F-l,6 -P2 DAP + GAP
GAP must then be converted to DAP by reaction (8 ).
triosephosphate isomerase 
(8 ) GAP  ----- —  DAP
DAP can then be converted to glycerol-3-phosphate according to reaction (9), and 
then NAD+ levels can be determined spectrophotometrically.
glycerol-3-phosphate dehydrogenase 
(9) DAP + NADH + Y f  ■«...........  glycerol-3-phosphate + NAD+
Freeze clamped hearts were powdered as described above. Approximately 300 mg of 
frozen ventricular tissue was added to a preweighed centrifuge tubes containing 5 ml 
perchloric acid, 0 . 6  M. Tubes were then re-weighed to determine the exact tissue 
weight. After 10 min centrifugation at 3000 rpm, the supernatant was extracted, and 
the sediment mixed with 1 ml perchloric acid and 1 ml distilled water. This was then 
centrifuged again for 10 min at 3000 rpm. After this, the two supernatants were 
combined and the pH adjusted to 3.5 with 5 M potassium carbonate solution. This was 
then brought to a final volume of 8  ml and allowed to stand on ice for 15 min, after 
which the supernatant was pipetted off, and portions of this used in the assay mixture.
61
The following was added to a quartz cuvette:
Buffer (triethanolamine hydrochloride, 0.4 M, pH 7.6; EDTA 40 mM) 0.5 ml 
Supernatant from extraction procedure 0.5 ml
NADH solution (5 mM) 3 pi
Glycerol-3-phosphate dehydrogenase (130 U.l'1) 3 pi
Triosephosphate isomerase (830 U.l'1) 3 pi
This solution was then left in the cuvette until the absorbance reading had stabalised, 
measured at 340 nm. This was to allow the conversion of GAP and DAP extracted 
from the heart tissue to be completely converted to glycerol-3-phosphate. Aldolase, 3 
pi, 45 U.l'1, to the cuvette, and the absorbance change measured. F-l,6 -P2 levels were 
expressed as pmoles per gram of tissue, dry weight. This assay procedure is described 
fully by Slater, 1953.
2.3.6 Determination of wet weight/dry weight ratio
A small piece of ventricular tissue was taken and excess Krebs buffer removed by 
blotting. The tissue was then placed in a 1.5 ml centrifuge tube of known weight, the 
total weight was subsequently determined. This was then placed in a vacuum oven 
overnight at 80°C, before being removed and cooled to room temperature. The dry 
weight of the tissue was then determined and a ratio between dry weight and wet 
weight was calculated.
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2.4 Protocols for isolated heart perfusion
Shown below are diagrammatical representations of the protocols followed in this 






A = initial perfusion, B = recirculation, C = end of perfusion
B)
A B C  D
1 II____________ I
0 25 30 140
min
C)
A = initial perfusion, B = TNF, 20 ng.ml'1, C = recirculation,
D = end of perfusion
A B C D  E
I I  u___________I
0 10 25 30 105
min
A = initial perfusion, and addition of insulin, 10 U.l'1, B = Low glucose, 2mM,
C = TNF, 20 ng.ml'1, or C2-ceramide, 1 jiM, 5 (iM or 10 jiM, D = recirculation, 
E = end of perfusion, freeze clamp TNF treated hearts
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D)
A B C D  E
I I  u I
F
i
0 10 25 30 45 105
min
A = initial perfusion, B = Low glucose, 2mM, C = TNF, 20 ng.m l1,
D = recirculation, E = insulin, 10 U.l'1, F = end of perfusion, freeze clamp hearts
E)
A B C D
l l l l
* * * 





A = initial perfusion, B = zero glucose, C = TNF, 20 ng.ml'1, D = recirculate, 
E = end of perfusion.
* show the various points in the experiment where hearts were freeze clamped
F)
A B C  D E
i n  u _____________ i
0 5 10 25 30 105
min
i) A = initial perfusion, and addition of insulin, 10 U.l'1 B = okadaic acid,
O.lnM or InM, C = Low glucose, 2mM, D = ceramide, lpM, 5|xM or lOpM, 
E = recirculation, F = end of perfusion, freeze clamp hearts.
ii) B = okadaic acid, InM, D = TNF 20 ng.ml'1,
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G)
A B C D  E F
11 u i i
j | C  ) f C
0 10 25 30 50 105
min
A = initial perfusion, B = Low glucose, 2mM, C = TNF, 20 ng.ml'1, D = recirculation, 
E = Low flow ischaemia, 2 ml.min'1, F = end of perfusion.
* show the two points in the experiment where hearts were freeze clamped.
H)
A B C D E
ii ii I
* * * * * *
0 5 25 30 165
min
A = initial perfusion, B = nitro-1-arginine, 100 |LiM, C = TNF, 20 ng.ml'1, 
D = recirculation, E = end of perfusion, hearts freeze clamped.
* show where Starling curves were performed
I)
A B C D E
11 ii i
* * * * * *
0 10 25 30 165
min
A = initial perfusion, B = high glucose perfusion, 25 mM, C = TNF, 20 ng.ml'1, 
D = recirculation, E = end of perfusion, hearts freeze clamped.
* show where Starling curves were performed
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A B C D
1 1  u
E
I
0 5 * 25 30 * * 90
min
A = initial perfusion B = antagonist or inhibitor C = recombinant human TNF 
or recombinant rat TNF, 20 ng.ml'1 or SMase, 0.001 U.l'1, 0.003 U.l'1 or 0.01 U.l'1 
D = recirculation E = end of perfusion
* show where Starling curves were performed.
K)
A B C D
ii ii
* Sft *
0 5 25 30 90
min
A = perfusion under a constant head of pressure, B = NOE, l|iM, C = TNF 20 ng.ml'1, 
D = recirculation, E = end of perfusion.




A B C D  E
ii ii i
*  *  *
0 5 25 30 90
min
A = initial perfusion, B = antagonists, C = sphingosine, 0.5 |iM, 1 |xM, 3pM 
or 10 p,M, D = recirculation, E = end of perfusion.
* show where Starling curves were performed.
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M)
A B C D
i ii i
0 25 30 90
min
A = initial perfusion, B = sphingosine, 0.5 |iM with TNF, 20 ng.ml'1, 
C = recirculation, D = end of perfusion.
* show where Starling curves were performed.
0 15 20 35 40 45 55
min
A = initial perfusion, B = acidosis C = recovery with normal pH, 
D = TNF, 20 ng.ml'1 or no treatment, E = application of acidosis,
F = recovery with normal pH, G = end of perfusion.
N> A B C  D E F G
67
2.5 Statistical analysis of data
All values presented herein are shown as the mean ± standard error of the mean. Un­
paired Student’s t-test was used to compare differences between two grouped means 
from different data sets. Paired Student’s t-test was used to compare differences 
between paired group means. Comparison of a control group mean with multiple test 
group means was conducted with one way ANOVA coupled to Dunnetts’ post-hoc 
test for significance. Multiple comparisons between many group means was 
conducted using one way ANOVA coupled to Tukey’s post-hoc test for significance. 
Comparison of all non-parametric data were conducted using Mann-Whitney test for 
significance. Statistical significance was accepted, and the null hypothesis was 
rejected, when P < 0.05, although when achieved, higher significance levels are also 





3.1.1 Functional studies with TNF
Preliminary experiments were conducted in order to define the conditions under which to 
examine the actions of TNF. Hearts were perfused under constant flow conditions, 10 
ml.min'1. Cardiac contractility was measured using the hook method, where developed 
tension was used as a measure of cardiac function. Experiments were conducted in order 
to asses the viability of the isolated perfused heart under recirculating conditions. This was 
done by a direct comparison between hearts under recirculating and non-recirculating 





A = initial perfusion, B = recirculation, C = end of perfusion
It was concluded from this that the recirculating heart, with a total volume of 50 ml was a 












« —  Recirculating 
o —  Non-recirculating
2
20 40 60 80 100 120 140
Time (mins)
Figure 3.1. Effect o f time on developed tension using recirculating (n = 8) and non­
recirculating (n = 4) modes of perfusion in the isolated rat heart. Recirculation is initiated 
at A. * P < 0.05, for recirculating vs. non-recirculating.
71
Preliminary work was undertaken with TNF. Recombinant human TNF, 20 ng.ml1 and 
100 ng.ml"1, was added to the Krebs buffer after 25 min, 5 min prior to recirculation. 20 
ng.ml"1 TNF has been used in other experiments investigating the cardiac actions of TNF 
(Schultz et al., 1995), and is a concentration which has been observed in sera from 
experimental models of septic shock (Tracey et al., 1996). Perfusion continued for a 
further 110 min as shown below:
A B C  D
i  u _____________________ 1
0 25 30 140
min
A = initial perfusion, B = TNF, 20 ng.ml"1, C = recirculation,
D = end of perfusion
It can be seen from figure 3.2 that addition of TNF, 20 ng.ml"1, caused a decline in 
function which was apparent within 15 min of TNF addition. It can also be seen that TNF, 
100 ng.ml"1, did not cause a greater depression in function. In all subsequent experiments 
TNF at the concentration of 20 ng.ml"1 was used.
3.1.2 Extraction efficiencies of assays used
Experiments were conducted in order to discover the extraction efficiencies of each of the 
assays used. The efficiencies of each assay were as follows: G-6-P, 96 ± 3 %; G-l-P, 93 ± 
1 %; F 1-P, 91 ± 6 %; ATP, 98 ± 6 %; PCr; 72 ± 2 %; F-l,6-P, 95 ± 2 % and glycogen, 
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0 80 100 1 2 020 40 60 140
Time (min)
Figure 3.2. Effect o f TNF, 20 ng.m l'1 (n = 6) and 100 ng.m l'1 (n = 4) on developed tension 
in the isolated heart perfused under recirculating conditions. TN F is added at A, 




As mentioned in the introduction, under certain acidotic conditions, TNF has the ability to 
insert itself into the plasma membrane, where there is potential for it to form ion 
permeable channels (Kagan et al., 1992), For this reason it was decided to investigate 
whether the presence of TNF could alter the recovery of isolated hearts after an acidotic 
challenge following the protocol shown below:
0 15 20 35 40 45 55
min
A = initial perfusion, B = acidosis C = recovery with normal pH, D = TNF, 20 
ng.ml'1, or no treatment, E = application of acidosis, F = recovery with normal 
pH, G = end of perfusion.
Both degrees of acidosis, pH 5.5 and 6.1, produced very reproducible responses in 
developed tension, heart rate and CPP as shown by the experimental trace in figure 3.3. 
Recovery upon restoration of pH to 7.4 was assesed by developed tension, expressed as % 
of the developed tension before acidosis, and was measured 3 min and 7 min after 
acidosis. Prior inclusion of TNF to hearts 5 min before acidosis caused a slight decline in 
the recovery of these hearts from the acidotic challenge of pH 6.1 (figure 3.4) and pH 5.5. 
After a pH 5.5 challenge the recovery of control hearts at 3 min and 7 min was 59 ± 2 % 
and 85 ± 5 %, respectively vs. 56 ± 2 % and 74 ± 4 % with TNF (n = 4 for each).
A BC D E F G
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D e v e lo p e d












pH change 6.1 7.4 6.1 7.4
5 min
Figure 3.3.A typical experimental trace showing the changes in developed tension, 
coronary perfusion pressure and heart rate in the isolated perfused heart during and after 
two acidotic challenges.
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I  Control 
I I TNF, 20 ng.ml 1
End of 3 mins after 1 o mins after
acidosis acidosis acidosis
Figure 3.4. The above graph shows the recovery, in the presence and absence o f TNF, o f 
isolated hearts after a 5 min period o f pH 6.1 acidotic challenge, (n = 4 for each point).
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3.3 Low glucose recirculating heart
As discussed in the introduction, TNF has been shown to cause insulin resistance in whole 
animals (Lang et al., 1992) as well as at the cellular level (Hotamisligil, et al., 1994a; 
Begum & Ragolia, 1996). Therefore, hearts were perfused with low glucose (2 mM) 
containing Krebs buffer in order to observe the actions of insulin, where glucose uptake 
would be expected to show high insulin-dependency.
3.3.1 Insulin and TNF in the low glucose recirculating heart
Hearts were perfused according to the following protocol, then frozen to be assayed for 
glycogen:
A B C D  E
y _ u ____________ i
0 10 25 30 105
min
A = initial perfusion, and addition of insulin, 10 U.l'1, B = Low glucose, 2mM,
C = TNF, 20 ng.ml'1, D = recirculation, E = end of perfusion
When perfused with Krebs buffer containing 2mM glucose and in the absence of TNF, 
developed tension decreased with time at a faster rate than in preliminary experiments 
using normal glucose (11.6 mM) concentration (figure 3.5). This faster decline in 
developed tension dictated a relatively shorter perfusion protocol. Figure 3.6 shows the 
actions of insulin and TNF alone and in combination on developed tension in this model.
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A B
— ■— Normal glucose, 11.6mM 
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CDQ
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Time (mins)
Figure 3.5. Effect o f low glucose perfusion on developed tension in the isolated rat heart 
with time. Normal glucose, n = 6, low glucose, n = 12. Low glucose perfusion 




— ■— Control 
— • — Insulin, 10 U.I'1 
—A— TNF, 20 ng.m l'1 






0 20 40 60 80 1 0 0 1 2 0
Time (min)
Figure 3.6. Actions o f  TN F (n = 10) and insulin (n = 11), alone and in combination (n = 
12), on developed tension in the isolated rat heart perfused under low glucose conditions. 
Control hearts (n = 12). Low glucose (2mM) perfusion commenced at A. W hen present, 
TN F was added at B. Recirculation began at C. Insulin, was present throughout the 
protocol. * P < 0.05, insulin vs. control. #  P < 0.05, ## P < 0.01, TN F and insulin vs. 
insulin alone.
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At early time points after application of low glucose it can be seen that insulin slowed the 
decline in contractility, although this is only significant at one of the time points measured. 
After this developed tension in all groups studied decreased to a similar extent. Addition 
of TNF attenuated the early protection seen with insulin.
As expected perfusion of hearts, under low glucose conditions, with insulin caused a 
marked increase in glucose uptake, measured as decreasing glucose concentrations in the 
recirculating Krebs buffer (figure 3.7). TNF did not affect basal glucose uptake or the 
insulin stimulated glucose uptake (figure 3.7).
End-point glycogen levels in control hearts following low glucose perfusion were low 
(figure 3.8). Insulin caused a marked increase in end-point glycogen levels (figure 3.8). 
Interestingly TNF, when added 25 min after insulin, was able to partially prevent this 
insulin-stimulated glycogen synthesis. It can be seen from this graph that TNF did not 
affect end-point glycogen levels in the absence of insulin.
When insulin was added to hearts 20 min after TNF, very similar results to those described 
above were seen. Below is shown the diagrammatical representation of this protocol:
A B C D  E
i i  u________ I
0 10 25 30 105
min
A = initial perfusion, and addition of insulin, 10 U.l'1, B = Low glucose, 2mM,
C = TNF, 20 ng.ml'1, D = recirculation, E = end of perfusion
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O  -Q
S 5  0 8w ffl 
8  £
<§ 0 .4-
— ■— Control 
— • — Insulin, 10 U.l’1 
— A— TNF, 20 ng.ml -1
-1Insulin, 1 0 U.l' , TNF,2 0 ng.ml -1
0.0
20 40 60 80
Time after recirculation (min)
Figure 3.7. Glucose uptake from the recirculating Krebs buffer under low glucose (2mM) 
conditions, measured after recirculation, in control hearts (n = 6) and in TN F (n = 5), 
insulin (n = 5) and both TN F and insulin (n = 5) treated hearts. * P < 0.05; insulin vs. 
control. # P < 0.05; TN F vs. insulin and TNF.
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Control
-1| I Insulin, 10 U.l
** MU~mF.20na.ml ~1
T  I I Insulin. 10 U.I ~1 . TNF. 20 ng.ml -1
CD jO
Figure 3.8. End-point glycogen levels in hearts perfused under low glucose conditions (n = 
6) in the presence o f insulin (n=6), TN F (n = 6) or both together (n = 6). * P < 0.05, ** P 
< 0.01 when com pared with control. ## P < 0.01; TNF and insulin vs. insulin alone.
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When added at this time point insulin again appeared to cause a slight protection from the 
early loss of function observed with a low glucose perfusion. This was not so in the 
presence of TNF (figure 3.9). However, it can be seen from the graph (figure 3.9), that at 
the point of recirculation, developed tension in hearts which were to have insulin added, 
was already slightly higher than in controls. At this time point, there had been no insulin 
treatment, and so developed tension in these hearts should be similar. Again, insulin 
caused a large increase in glucose uptake, which was not altered by TNF (figure 3.10). 
The insulin stimulated glycogen synthesis, was almost completely blocked by TNF (figure 
3.11).
3.3.2 Ceramide and insulin in the low glucose recirculating rat heart
One of the potential signalling mechanisms utilised by TNF involves the sphingomyelinase
pathway, where ceramide and sphingosine can act as second messengers. Ceramide has
previously been shown to have the ability to disrupt insulin mediated responses (Begum &
Ragolia, 1996), and so it was decided to try to mimic the actions, observed with TNF
treatment, with a cell permeable form of ceramide, C2-ceramide (C2). The following
protocol was used:
A B C D  E
y _ u ____________ i
0 10 25 30 105
min
A = initial perfusion, and addition of insulin, 10 U.l'1, B = Low glucose, 2mM,













4 — ■—  Controls =*=
— o — Insulin 10U.I *1 
—A— Insulin 10U.I '1 , TNF20ng.ml2
0
30 40 50 60 70 80 90 100 110
Time (min)
Figure 3.9. Actions o f  insulin and TN F on developed tension in the low glucose perfused 
heart where insulin was added after TNF. Recirculation began at A, and insulin was added 
at B. TNF, 20 ng.m l'1 was added 5 min prior to recirculation which began at A. * P < 






























Time after insulin (min)
Figure 3.10. This graph shows the increase in glucose uptake seen upon insulin 
administration when insulin was after TNF. A shows the addition o f insulin. This is shown 
both in the presence (n = 6) and absence (n = 6) o f TNF. Control data, n = 6. * P < 0.05, 
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I I Insulin, 10 U.l *1 , TNF, 20 ng.ml -1
Figure 3.11. End-point glycogen levels in hearts perfused under low glucose conditions 
where insulin was added after TNF. *** P < 0.001; insulin vs. control. ## P < 0.01; TN F 
and insulin vs. insulin alone, (n = 8 - 12 for each group)
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In the presence of insulin, C2 caused a concentration-dependant depression in developed 
tension, whereby 1 pM C2 did not adversely alter cardiac function, but both 5 pM and 10 
pM C2 had a marked negative inotropic effect (figure 3.12). As with TNF, none of the 
concentrations of C2 used was able to alter glucose uptake from the Krebs buffer (figure 
3.13). The actions of C2 on insulin-stimulated glycogen synthesis were very interesting 
(figure 3.14). C2, 1 pM, did not alter the end-point glycogen levels in the presence of 
insulin. However, both 5 pM and 10 pM of C2 completely and significantly blocked the 
insulin-stimulated glycogen synthesis (P < 0.001). From these results a concentration of 5 
pM C2 was chosen for use of C2 in subsequent experiments.
3.3.3 TNF, Ceramide and okadaic acid
To investigate the role of the ceramide-activated protein phosphatase (CAPP) in the
blockade of glycogen synthesis by both TNF and C2, the protein phosphatase inhibitor
okadaic acid was used. At 1 nM okadaic acid shows a high degree of specificity towards
the PP-2A subfamily of protein phosphatases, of which CAPP is one (Kolesnick, 1992).
The following protocol was used:
A B C  D E  F
111_ 11______ 1
0 5 10 25 30 105
min
i) A = initial perfusion, and addition of insulin, 10 U.l' 1 B = okadaic acid, O.lnM or InM, 
C = Low glucose, 2mM, D = ceramide, lpM, 5pM or lOpM, E = recirculation,
F = end of perfusion, freeze clamp hearts.











1—  Insulin + Ceramide, 1 g M
—a —  Insulin + Ceramide, 5g M 
—O—  Insulin + Ceramide, 10 |i M
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Time (min)
Figure 3.12. Effects o f C2-ceramide, 1 |liM (n = 6), 5 (iM (n = 6) and 10 (iM (n = 6) on 
developed tension in the isolated rat heart. C 2 -ceramide was added at A, recirculation 
commenced at B. * P < 0.05, 1 |iM  C 2 -ceramide with insulin vs. insulin alone. #  P < 0.05, 
5 pM  C2-ceramide with insulin vs. insulin. $ P < 0.05, $$ P < 0.01, $$$ P < 0.001, 10 |iM  





























Time after recirculation (min)
Figure 3.13. Effect o f C2-ceramide, 1 |iM  (n = 6), 5 |iM  (n = 6) and 10 |uM (n=6), on 
insulin stimulated glucose uptake for the recirculating Krebs buffer. For significance levels 
o f insulin effect, see figure 3.7.
Control
Insulin, 10 U .l'1 
Insulin and ceram ide, 1 g M 
Insulin and ceram ide, 5 g M 
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Insulin and ceramide, 1 \i M 
Insulin and ceramide, 5 g. M 
]  Insulin and ceramide, 10 g M
* * *
Figure 3.14. Effects o f ceramide, 1 jliM (n = 6), 5 jiM  (n = 6) and 10 |iM  (n = 6), on 
insulin stimulated glycogen synthesis in the isolated rat heart. *** P < 0.001, insulin vs. 
control. ## P < 0.01 ceramide and insulin vs. insulin.
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In the absence of either ceramide or TNF, but in the presence of insulin, 1 nM okadaic 
acid increased cardiac contractility, this action was significant at 50 min and 60 min (figure 
3.15). 0.1 nM okadaic acid did not alter cardiac contractility (figure 3.15). Figure 3.16 
shows the actions of both C2, 5 (iM, and okadaic acid, 0.1 and InM, both alone and in 
combination on CPP in the isolated heart in the presence of insulin. It can be seen that 5 
pM C2 did not alter CPP. Both concentrations of okadaic acid used, either with or without 
C2, showed a tendency to decrease CPP, but at none of these points was this action shown 
to be significant. Importantly, addition of okadaic acid at either concentration completely 
blocked the C2-mediated disruption in insulin-stimulated glycogen synthesis, without 
significantly altering end-point glycogen levels in the absence of C2 (figure 3.17).
However, when okadaic acid, 1 nM, was added prior to addition of TNF then it did not 
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Figure 3.15. Effects o f okadaic acid, 0.1 nM (a) and 1 nM (b), on changes in developed 
tension observed with C 2-ceramide, 5 pM , in the insulin treated low glucose perfusion 
model. Okadaic acid was added at A, C2-ceramide was added at B and recirculation began 
at C. * P < 0.05, insulin and ceramide, with respect to insulin alone; # P < 0.05, insulin, 
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Figure 3.17. Effects o f insulin and C2-ceramide alone and in combination on end-point 
glycogen levels after low glucose perfusion. Also shown the effects of okadaic acid both in 
the presence and absence o f C2-ceramide on insulin stimulated glycogen synthesis. *** P < 
0.001, insulin vs. control; ## P < 0.01, C2-ceramide with insulin vs. insulin alone. $ P < 
0.05, $$ P < 0.01, okadaic acid, ceramide and insulin vs. ceramide and insulin, (n = 4 - 8 
for ceramide and okadaic acid).
Control 
I I Insulin, 10 U.l ' 1 
□  Insulin + ceramide, 5  \i M
Insulin + ceramide +  okadaic acid, 1 nM 
Insulin + okadaic acid, 1 nM
  Insulin + ceram ide + okadaic acid, 0.1 nM
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Figure 3.18. Effects o f okadaic acid on the attenuation of insulin stimulated glycogen 
synthesis by TNF.*** P < 0.001, insulin vs. control; ## P < 0.01, TN F and insulin vs. 
insulin alone, (n = 8 - 12 for each group).
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3.3.4 Glycogen depletion studies
Due to the observed actions of TNF on glycogen metabolism (see above), it was decided 
to see if TNF could alter glycogen breakdown in the absence of insulin. Under zero 
glucose conditions one would expect glycogen synthesis to be minimal, and glycogen 
breakdown would predominate. Hearts were perfused under zero glucose conditions in 
order to study the degradation of glycogen with and without TNF as shown below:
AB CD  E
i l i l ________ 1
* * * *
0 5 10 15 60
min
A = initial perfusion, B = zero glucose, C = TNF, 20 ng.ml'1, D = recirculate,
E = end of perfusion.
* show the various points in the experiment where hearts were freeze clamped
Figure 3.19 shows glycogen depletion over the period of 60 min perfusion with no 
substrate. The remaining glycogen in control hearts was 73 %, 59 % and 20 % the initial 
content in hearts perfused with substrate-free medium for 15 min, 30 min and 60 min, 
respectively. The graph in figure 3.19 shows that TNF does not alter the rate of glycogen 
































Time after zero glucose (min)
Figure 3.19. Glycogen depletion in hearts perfused with zero glucose in the presence and 
absence TNF. (n = 4 for each time point measured).
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3.4 Low flow, low glucose ischaemic heart
The actions described above show that TNF can alter insulin action under conditions
where substrate supply would be limiting. For this reason it was decided to investigate the
actions of TNF under conditions of further substrate deprivation. Here global low flow
ischaemia (2 ml.min'1) under low glucose (2 mM) conditions was used according to the
following protocol:
A B CD  E F
I I  u I I
* *
0 10 25 30 50 105
min
A = initial perfusion, B = Low glucose, 2mM, C = TNF, 20 ng.ml'1, D = recirculation,
E = Low flow ischaemia, 2 ml.min'1, F = end of perfusion.
* show the two points in the experiment where hearts were freeze clamped.
As well as end-point glycogen levels, end-point ATP and PCr levels were also measured.
Another reason for using an ischaemic model to investigate the actions of TNF stems from 
studies suggesting that TNF can play a detrimental role during ischaemia (Colletti et al., 
1990; Meldrum et al., 1998).
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3.4.1 Actions of TNF during global low flow ischaemia under low glucose conditions
In hearts subjected to global low flow, 2 mintin'1, developed tension dropped as soon as 
ischaemia was initiated, and at no point did the developed tension recover (figure 3 .2 0 ). 
Inclusion of insulin, 10 U.f1, from the start of the experiment slightly slowed the decline in 
developed tension, however, this was only significant at the first time point after the start 
of ischaemia, 10 min). Addition of TNF 5 min before recirculation showed unexpected 
results. The rapid decrease in developed tension observed upon recirculation was not as 
great as in control hearts, and developed tension remained elevated throughout the 
ischaemic period. In hearts perfused with both TNF and insulin developed tension was 
again significantly elevated during low flow ischaemia, although the response was not 
significantly different from either TNF or insulin alone.
As expected, at the onset of global low flow ischaemia, there was a rapid fall in CPP, 
which was not significantly different between each group (decrease in CPP after initiation 
of ischamia for control hearts, insulin treated, TNF treated and insulin with TNF treated 
hearts: 43 ± 3 mmHg, 61 ± 14 mmHg, 49 ± 9 mmHg and 53 ± 12 mmHg respectively, P = 
NS between any groups, n = 6  for each group.
After the onset of ischaemia, a contracture developed, manifested as an increase in 
baseline tension (figure 3.21). Neither TNF nor insulin, alone or in combination, 
significantly altered the observed contracture, but several trends were apparent. Insulin 
appeared to slightly slow the development of contracture (figure 3.21). TNF, tended to
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Figure 3.20. Effects o f TN F and insulin, alone or in combination on developed tension in 
the isolated perfused rat heart under low glucose conditions, and subjected to global low 
flow ischaemia. Low  glucose perfusion began at A, TNF was added at B and recirculation 
comm enced at C. Low  flow ischaemia (2 ml.min'1) was initiated at D. Insulin was present 
from  the start o f  the perfusion protocol. * P < 0.05 TNF vs. control. # P < 0.05 insulin 
and TN F vs. control. $ P < 0.05 insulin vs. control n = 6 for each group.
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cause a small decrease in the severity of contracture, although this was not shown to be 
significant (figure 3.21).
3.4.2 Glucose uptake and metabolic changes
Glucose uptake followed a very similar pattern to that observed under low glucose 
conditions (section 3.3.1). Insulin significantly increased glucose uptake from the 
recirculating perfusate, an action which was not altered by inclusion of TNF. TNF alone 
did not alter glucose uptake (figure 3.22).
Very low lactate concentrations were observed in the recirculating perfusate prior to the 
onset of ischaemia. Lactate increased slightly in the control group and TNF treated 
groups. Insulin, however, both in the presence and absence of TNF caused a significant 
increase in the lactate accumulation (figure 3.23).
Neither ATP or PCr changed significantly during the ischaemic period in control hearts. 
However, with TNF and insulin, both alone and in combination, there was a significant 
decline in ATP and PCr over the ischaemic period (table 3.1). Both ATP and PCr end­
point levels were very low in hearts treated with both TNF and insulin, these values were 
significantly lower than either the control group or the TNF treated group.
Ischaemia caused a decline in glycogen content of the hearts, but there was no difference 
between any of the groups (table 3.1). Interestingly glycogen levels observed in these
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Time after ischaemia (mins)
Figure 3.21. Effects o f TN F and insulin, alone and in combination on the diastolic tension 








8 a  1.0-<Dco ^
8  a>^  £
^  0 .5 -
— ■—  Control 
— • —  Insulin, 10 U.l 
—A— TNF, 20 ng.ml 
—V— Insulin + TNF
0.0
60 800 20 40
Time after recirculation (min)
Figure 3.22. Glucose uptake from the recirculating Krebs buffer before and during global 
low flow ischaemia in the presence of TNF, insulin or both together. Low flow ischaemia 
was initiated at A. * P < 0.05 insulin vs. control. # P < 0.05 TN F and insulin vs. TNF 
alone (n = 6 for each group).
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Figure 3.23. Effects o f insulin and TN F alone and in combination on lactate accumulation 
in the recirculating perfusate. Recirculation began at time 0, low flow ischaemia (2 ml.min 
was initiated at A. * P < 0.05 insulin vs. control. # P < 0.05 TN F and insulin vs. TN F 
alone, n = 6 fro each group.
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ATP, pmoles per 
gram of tissue, dry 
weight.
PCr, pmoles per 
gram of tissue, dry 
weight.
Glycogen, pmoles of 
glucose equivalents 














Control 21 ±3 12 ±3 14 ±4 18 ± 2 93 ±19 41 ±10*
Insulin, 10U.11 35 ± 12 12 ± 2 * 21 ± 7 9 ± 1 * 123 ±21 38 ± 9  *
TNF, 20 ng.ml1 46 ± 6 16 ± 1 * 38 ±15 9 ± 1 * 105 ± 17 50 ± 9 *
Insulin + TNF 39 ±7 9 ± 1 *# 34 ±11 4 ± 1 
*$#
90 ±19 51 ± 7  *
Table 3.1. The above table shows a comparison between pre- and post- ischaemic ATP, 
PCr and glycogen levels in low glucose hearts in the presence of insulin, TNF or both 
together. * P < 0.05 post-ischaemic vs. pre-ischaemic. $ P < 0.05 insulin and TNF vs. 
TNF alone. # P < 0.05 insulin and TNF vs. control, (n = 4 for pre-ischaemic groups, n = 6 
for post ischaemic groups).
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studies were higher in control and TNF treated hearts which had undergone an ischaemic 
episode than in hearts which followed the low glucose perfusion (table 3.1 vs. figure 3.8). 
However in the presence of insulin, end-point glycogen levels were lower after global low 
flow ischaemia (P < 0.05).
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3.5 Actions of TNF in the isolated perfused heart, under 
constant flow conditions
As mentioned in the introduction, TNF has the ability to cause a depression in cardiac 
function, an action for which various mechanisms have been proposed (Finkel et a l., 1992, 
Shultz et al., 1995, Goldhaber et al., 1996, Oral et al., 1997). So the actions of TNF on 
cardiac function were investigated in hearts perfused with Krebs buffer containing 11.6 
mM glucose, where the energy substrate, glucose, is in plentiful supply. The protocol 
followed is shown below:
AB C D E
II u __________________________I
0 5 25 30 165
min
A = initial perfusion, B = antagonist or inhibitor, C = TNF, 20 ng.ml1,
D = recirculation, E = end of perfusion (however with all inhibitors except nitro-L- 
arginine, perfusion time was cut to 90 min)
* show where Starling curves were performed
3.5.1 Effects of TNF on cardiac contractility
Results from preliminary experiments, figure 3.2, indicated that in my hands, TNF (20 
ng.ml'1) caused an early and sustained depression in contractility, measured by developed 
tension via a hook in the apex of the heart. It was decided that left ventricular developed
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pressure (LVDP), measured using a fluid filled intraventricular balloon, was a superior 
indicator of cardiac contractility, than developed tension measured with a hook. Results 
presented in the following section have all been obtained using this model.
It can be seen from the experimental traces shown in figure 3.24, as well as the graph 
shown in figure 3.25, that as in preliminary experiments, cardiac contractility decreased in 
control hearts throughout the 160 min perfusion protocol. It should be noted that 
recirculation had no immediate significant effect on LVDP (LVDP before recirculation vs. 
after recirculation: 127 ± 3 mmHg vs. 120 ± 5 mmHg, P = NS). Importantly, as in 
preliminary experiments, addition of TNF 20 ng.ml'1 to the perfusate resulted in a 
depression in cardiac function, which persisted throughout the experimental protocol 
(figure 3.24 and 3.25). Rate of change of both systolic contraction and diastolic relaxation 
were also both depressed, shown in figure 3.26, although the depression in both 
differential parameters of LVDP took slightly longer to reach statistical significance (TNF 
treated vs. control) than the direct measure of LVDP.
TNF had no immediate or late, chronotropic effect (heart rate before TNF vs. after TNF: 
269 ±11 beats per minute (bpm) vs. 279 ± 8 bpm, P = NS, n = 10 for each. Heart rate 
after 160 min: control vs. TNF; 270 ± 20 bpm vs. 280 ±15 bpm. P = NS, n = 10 and n = 8 
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Figure 3.24. Typical experimental traces showing LVDP changes over a period of 90 min 
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Figure 3.25. Effects o f TN F on the decline in LVDP with time in the isolated rat heart 
under constant flow (10 ml.min'1) conditions. TNF was added at A, recirculation 
commenced at B. * P < 0.05, ** P < 0.01, *** P < 0.001; TN F vs. control, n = 13 for 
control hearts and n = 10 for TNF treated hearts.
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Figure 3.26. The above graphs show the rate o f change of systolic contraction, a) and the 
rate o f change o f diastolic relaxation, b) in control hearts (n = 7) and hearts treated with 
TN F (n = 9). TN F is given at A and recirculation began at B. * P < 0.05, ** P < 0.01; 
TN F vs. control.
3.5.2 Starling curves
As mentioned earlier, one o f the major advantages o f using a balloon to measure left 
ventricular contractility is that Starling curves can be performed in perfused hearts. A 
typical experimental trace of a Starling curve is shown in figure 3.27. A profile o f Starling 
curves, comparing TNF treated hearts with control hearts, is shown in figure 3.28. It can 
be seen that prior to TNF addition, the Starling curves performed at 15 min were very 
reproducible when comparing both groups o f hearts. Thereafter, however, TNF treatment 
lead to a progressive decline in the hearts ability to respond to an increase in left 
ventricular diastolic volume. This reached significance during the fifth and sixth Starling 
curves, performed at 135 min and 165 min. Again, as with the differential parameters of 
LVDP, this was at a later time point than the decline in contractile performance when 
measured directly using LVDP.
3.5.3 Perfusion with high glucose concentration
Under normal glucose conditions (11.6 mM), TNF caused an early depression in function, 
which was apparent after 25 min which was sustained throughout the experimental 
procedure. However, in previous studies with a low glucose (2 mM) perfusion model no 
such depression was observed (see above). Therefore, it was decided to investigate 
whether this depression in function was dependant on the glucose concentration and 
whether the depression in function could be potentiated with increased glucose 
concentrations. Indeed glucose has been shown to facilitate NO production (Sobrevia et
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* * *  *  *  *  *  *
Figure 3.27. The above experimental trace shows changes in balloon pressure during a 
typical Starling curve performed in an isolated perfused heart. * shows a volume increase 
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Figure 3.28. Profile o f Starling curves performed in the isolated perfused heart at 15 min 
(a), 45 min (b), 75 min (c), 105 min (d), 135 min (e) and 165 min (f), in the presence and 
absence o f TNF. * P < 0.05, ** P < 0.01; TNF vs. control (n = 8 - 13 for each point 
shown).
114
al., 1996; Costentino et al., 1997), and form relatively stable NO-donating compounds, 
which would prolong the short half-life of NO (Moro et al., 1995). The following protocol 
was used:
A B C D E
1 1  II_________________________ i
0 10 25 30 165
min
A = initial perfusion, B = high glucose perfusion, 25 mM, C = TNF, 20 ng.mT1,
D = recirculation, E = end of perfusion, hearts freeze clamped.
* show where Starling curves were performed
Perfusion of isolated hearts with Krebs buffer containing a high glucose concentration, 25 
mM, did not alter the tendency for a decline in cardiac function throughout the 160 min 
perfusion protocol (figure 3.29). The slow decline in cardiac function seen with 
recirculation was similar in all respects to that seen under a normal glucose conditions. 
The cardiac depression seen with TNF under normal glucose conditions was also apparent 
with a high glucose perfusion (figure 3.29), although this only reached significance (P < 
0.05) at one of the time points measured. This was probably due to a lower number of 
experiments conducted with high glucose. However, it can be seen from this figure, that 
the profile of depression followed a very similar magnitude and time course to that seen 
with normal glucose. From these experiments it is clear that high glucose did not 
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Figure 3.29. Effects o f TNF and time on LVDP in the presence o f normal glucose (11.6 
mM) and high glucose (25 mM). 25 mM glucose perfusion commenced at A, TN F was 
added at B and recirculation began at C. * P < 0.05; TN F with high glucose vs. high 
glucose control (n = 6 for each point with high glucose). Significant differences with the 
normal glucose hearts have been omitted for clarity, see figure 3.25 for these.
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3.5.4 End-point glycogen and products of the glycolytic pathway.
From the figure 3.30 it can be seen that addition of TNF did not alter end-point tissue 
levels of G-6-P, G-l-P, ATP, PCr, F-6-P or F-l,6-P under normal glucose, 11.6 mM 
conditions. Under high glucose conditions, TNF showed a tendency to reduce end point 
ATP levels. It can also be seen from this figure that none of the other products of the 
glycolytic pathway, mentioned above, were altered by TNF. When these values, are 
compared with the end-point ATP and PCr levels seen after global low flow ischaemia 
(table 3.1), then they are significantly lower in both normal glucose perfusion groups and 
high glucose perfusion groups both with and without TNF (P < 0.05). This is probably due 
to different protocols used with respect to the perfusion time. End point glycogen levels 
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Figure 3.30. The above two graphs show the effects o f TNF on end-point G-6-P, ATP, 
PCr, G -l-P , F 1-P and F -l,6 -P  for normal glucose, a (n = 6 - 9), and high glucose, b (n 
6 - 7), perfusion. * P < 0.05 TNF vs. control.
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Normal glucose perfusion High glucose perfusion




End-point glycogen levels 
(jimoles of glucose 
equivilents per gram of tissue, 
dry weight)
68.0 ±7.7 54.6 ± 8.8 47.08 ±7.0 53.1 ±7.4
Table 3.2. This table shows the end-point glycogen levels in both normal glucose perfused 
hearts, and high glucose perfused hearts, both in the presence and absence of TNF. (n = 6- 
10 for each group).
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3.5.5 Actions of sphingomyelinase on cardiac function
Recent reports by Oral et al., 1997 and Bozkurt et al., 1998 have implicated sphingosine, 
a metabolite of the sphingomyelin pathway, in the early depression in cardiac function 
observed by TNF. So it was decided to see if the depression in cardiac function observed 
with TNF could be mimicked by exogenous addition of the enzyme SMase. The following 
protocol was used to investigate the actions of SMase on cardiac function:
AB C D E
u  i i  i
* * *
0 5 25 30 90
min
A = initial perfusion B = antagonist or inhibitor C = TNF, 20 ng.ml'1 or SMase, 0.001 U.l'1, 
0.003 U.l'1 or 0.01 U.l'1 D = recirculation E = end of perfusion 
* show where Starling curves were performed.
Figure 3.31 shows the actions of different concentrations of SMase (0.001 U.l'1, 0.003 
U.l'1 and 0.01 U.l*1) on cardiac contractility. At all concentrations used SMase caused a 
marked negative inotropic effect. From this graph a concentration of 0.003 U.l'1 which 
gave a maximal depression in function was chosen for all subsequent experiments. This 
depression in LVDP was also reflected in the Starling curves, figure 3.35. It can be seen 
from this that in the presnce of SMase there is a marked decrease in the Starling response 
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Figure 3.31. Effects o f SM ase on LVDP in isolated perfused hearts. SM ase was added at 
A, and recirculation began at B. All concentrations used significantly reduced LVDP, but 
statistics have been omitted for clarity, figure 3.34 shows the statistical significance o f the 
depression in LV DP for 0.003 U .l1.
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CPP (increase in CPP 20 min after SMase: control, n = 7, vs. SMase, n = 8; 13 ± 5 mmHg 
vs. 75 ± 2 0  mmHg, P < 0.01). SMase did not alter heart rate (heart rate after 90 min: 
control vs. SMase; 285 ±11 bpm vs. 273 ± 25 bpm, P = NS).
3.5.6 Effects of antagonists and inhibitors on changes in contractility caused by TNF 
and SMase under constant flow conditions.
To further investigate the depression in cardiac function observed with both TNF and 
SMase various antagonists and inhibitors were utilised. The results generated from these 
are shown below.
3.5.6.1 Nitro-L-arginine
NO has been implicated in TNF induced cardiac depression (Finkel et al., 1992, Shultz et 
al., 1995) therefore nitro-L-arginine was used to block NO production from isoforms of 
NOS (Gross et al., 1990). Nitro-L-arginine, 100 pM, when included 20 min before 
addition of TNF, caused an intense coronary constriction (CPP before nitro-L-arginine vs. 
20 min after nitro-L-arginine: 56 ± 2 mmHg vs. 126 ± 9 mmHg, P<0.001), which was 
apparent throughout the protocol. However, from figure 3.32 it is clear that inhibition of 
NOS did not ameliorate the decrease in contractility seen with TNF. In fact it is possible 
that nitro-L-arginine actually caused a slight potentiation of the cardiac depressant action 
of TNF. Heart rate was not altered by nitro-L-arginine (heart rate before nitro-L-arginine 
vs. after nitro-L-arginine: 289 ± 12 bpm vs. 290 ± 12 bpm, P = NS).
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3.5.6.2. N-oleoylethanolamine (NOE)
N-oleoylethanolamine (NOE) blocks ceramidase, the enzyme responsible for the 
conversion of ceramide to sphingosine (Sugita et al., 1975, Oral et al., 1997). In hearts 
where NOE, 1 pM, was included into the perfusate 20 min before addition of TNF, the 
negative inotropic effect of TNF was blocked (figure 3.33). NOE did not alter basal 
contractility (LVDP before NOE vs. after NOE: 110 ± 4 mmHg vs. 109 ± 4 mmHg, P = 
NS) or heart rate (heart rate before NOE vs. after NOE: 267 ± 10 bpm vs. 263 ± 9 bpm, P 
= NS). NOE also caused a significant attenuation of the depression in function seen upon 
addition of SMase (figure 3.34). This protection from SMase-induced depression in 
function with NOE, was also observed in the Starling response (figure 3.35), where 
SMase caused a significant reduction in Starling curves performed at 75 min which was 
attenuated by prior inclusion of NOE.
3.5.6.3 Indomethacin
The cyclooxygenase inhibitor indomethacin was used to block any potential breakdown of 
arachidonic acid from TNF induced PLA2 activation. Indomethacin failed to alter the 
cardiac depression seen with TNF (LVDP after 90 min: TNF vs. indomethacin with TNF; 
82 ± 9 mmHg ± 6 mmHg vs. 66 ± 6 mmHg, P = NS). Indomethacin had no effect on basal 
parameters of LVDP (LVDP before indomethacin vs. after indomethacin: 101 ± 4 mmHg 
vs. 105 ± 4 mmHg, P = NS) or heart rate (heart rate before indomethacin vs. after 
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Figure 3.33. Effect o f NOE on the depression in LVDP induced by TN F (n = 9). NOE 
was added at A, TN F perfusion began at B and recirculation was started at C. * P < 0.05, 
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Figure 3.34. Effects o f NOE (n = 8) on the action of SMase on LVDP in the isolated rat 
heart. Control data, n = 13. NOE was added at A, SMase was given at B and recirculation 
began at C. * P < 0.05, ** P < 0.01, *** P < 0.001; SMase alone vs. control. # P < 0.05, 
## P < 0.01; SM ase and NOE vs. SMase alone.
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Figure 3.35. Effects o f NOE on the action o f SMase on the Starling response o f hearts, 
m easured at 75 min. SM ase (n = 6), NOE (n = 8) and control data, n = 13. * P < 0.05, ** 
P < 0.01, *** P < 0.001; SM ase alone vs. control. # P < 0.05, ## P < 0.01; SM ase and 
NO E vs. SM ase alone.
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3.5.6.4. Bosentan
Due to the fact that TNF has been shown affect the whole heart by the release of 
endothelin-1 (Klemm et al., 1995a; Hohfled et al., 1995), potential actions of endothelin-1 
were blocked by prior addition of the ETA-ETB-receptor antagonist bosentan (3 |iM) into 
the perfusate. This did not block the TNF-induced alterations in cardiac function (LVDP 
after 90 min: TNF vs. bosentan and TNF; 82 ± 9 mmHg vs. 73 ± 6 mmHg, P = NS). 
Bosentan also did not alter the basal LVDP (LVDP before bosentan vs. after bosentan: 
104 ± 2 mm Hg vs. 106 ± 2 mmHg, P = NS), or heart rate (heart rate before bosentan vs. 
after bosentan: 271 ± 9 bpm vs. 271 ± 6 bpm, P = NS).
3.5.7 Addition of recirculating perfusate from one heart to another
In order to see if the depression in LVDP seen upon administration of TNF was due to 
TNF-induced release, and subsequent build up, of a myocardial depressant substance into 
the recirculating perfusate, hearts were perfused with TNF as described above. After this 
the recirculating perfusate was taken from both a control heart and one perfused with TNF 
and passed through a separate heart for 10, 20 and 30 second periods. Upon application of 
the perfusate, from either TNF treated or control hearts, to a separate heart caused a 
decline in LVDP, however, there was no difference between the depression observed with 
the perfusate from control hearts, to that observed with the perfusate from TNF treated 
hearts. Change in LVDP with a 10 second perfusion was -15 ± 3 mmHg vs. —13 ± 3 
mmHg (P = NS, n = 3) for perfusate from control and TNF treated hearts respectively.
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Change in LVDP with a 20 second perfusion was -24 ± 5 mmHg vs. -17 ± 3 mmHg (P = 
NS, n = 3) for perfusate from control and TNF treated hearts respectively. Change in 
LVDP with a 30 second perfusion was -26 ± 6 mmHg vs. -15 ± 4 mmHg (P = NS, n = 3) 
for perfusate from control and TNF treated hearts respectively. See section 3.6.3 for the 
changes in CPP observed during this protocol.
3.5.8 Actions of recombinant rat TNF in the rat isolated perfused heart, under 
constant flow conditions
All of the experiments described above utilised recombinant human TNF to perfuse 
isolated rat hearts. Therefore, a series of experiments were completed in order to see if the 
cardiac depressant actions of recombinant human TNF could be reproduced with TNF 
derived from the relevant species of animal used in these studies. Experiments with rat 
TNF followed the same protocol as described with human TNF. As expected recombinant 
rat TNF, 20 ng.ml'1, caused a decrease in LVDP which appeared similar to that seen with 
human TNF, and appeared of no greater severity (figure 3.36). This decline in developed 
pressure did not reach the levels of statistical significance observed with human TNF, 
however, the number of hearts used was much lower (n = 4). Interestingly, out of six 
hearts treated with recombinant rat TNF, one went into ventricular fibrillation and one 
became extremely arrhythmic to the extent that the developed pressure could not be 
accurately determined. This is in contrast to hearts perfused with human TNF, none of 
which went into severe arrhythmias or fibrillations, and suggests that recombinant rat TNF 
has an additional toxic effect when compared to human TNF in this model.
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Figure 3.36. Action o f recombinant rat TN F on LVDP in the rat isolated perfused heart. 
Recombinant rat TN F was added at A, and recirculation commenced at B. * P < 0.05, ** 
P < 0.01 recombinant rat TN F vs. control (control, n = 6; TNF, n = 4).
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3.6 Effects of TNF in the coronary circulation
Whilst investigating the actions of TNF on cardiac contractility, using constant flow 
perfusion conditions, it was noted that TNF also caused an increase in coronary perfusion 
pressure (CPP), indicative of coronary constriction. A series of experiments were 
conducted to try to characterise this TNF-induced coronary constriction. See section 3.5 
for protocol.
When switching from an open circuit to a recirculating system, CPP rose slowly but 
steadily throughout the 90 min experiment (figure 3.37). TNF addition into the Krebs 
buffer resulted in a rapid and sustained rise in CPP, which was indicative of a coronary 
constriction (figures 3.37 and 3.38). The experimental trace shown in figure 3.38 indicates 
that the majority of the rise in CPP occurred within 10 min of TNF addition. After this 
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Figure 3.37. The above graphs show the rise in CPP, with time, and the effects o f TN F in 
the isolated perfused heart under recirculating conditions, a) shows the actual CPP, 
whereas b) shows the increase in CPP after the addition o f TNF. * P < 0.05, ** P < 0.01; 
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Figure 3.38. Typical experimental traces showing the coronary perfusion pressure changes 
in a control heart (a) and in a heart after TNF, 20 ng.m l'1, administration (b). These traces 
are representative o f 13 and 10 experiments respectively.
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3.6.1 Effects of antagonists and inhibitors on the coronary constriction seen with 
TNF
As when characterising the actions of TNF on cardiac contractility, various antagonists 
and inhibitors were used. The results of these studies are presented below.
3.6.1.1 Indomethacin
The cyclooxygenase inhibitor indomethacin, 10 |xM, which blocks the production of 
prostanoids from arachidonic acid (AA) breakdown, completely inhibited the TNF induced 
coronary constriction (figure 3.39). In the absence of TNF, indomethacin did not alter the 
increase in CPP observed over the 90 min perfusion period (figure 3.40). As mentioned 
before, indomethacin did not alter basal parameters of LVDP or HR.
3.6.1.2 NOE
As with the suppression in cardiac function, NOE, 1 |iM, completely blocked the TNF 
induced rise in CPP (figure 3.39), but did not alter the basal coronary tone in the absence 
of TNF (CPP after 90 min: control (n = 13) vs. TNF (n = 6): 129 ± 9 mmHg vs. 113 ± 16 
mmHg, P = NS). As mentioned before, NOE did not alter basal parameters of LVDP or 
HR.
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Figure 3 . 3 9 .  Effect of the antagonists indomethacin (n = 6 ) ,  NOE (n = 9 ) ,  Z D  1 5 4 2  (n = 
7 ) ,  GR 3 2 1 9 1  (n = 7 )  and bosentan (n = 7 )  on the TN F (n = 1 0)  induced coronary 
vasoconstriction, 1 0  min after addition of TNF. Control in the absence o f TN F n = 13. * P 
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Figure 3.40. Effects o f perfusion time (n = 12), indomethacin (n = 6), GR 32191 (n = 7) 
and ZD 1542 (n = 7) on CPP in the isolated perfused heart. Antagonists were added at A, 
recirculation began at B. * P < 0.05 GR 32191 vs. control. $ P < 0.05 ZD 1542 vs. 
control.
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3.6.1.3 Thromboxane A2 antagonists
Because indomethacin was shown to inhibit the TNF induced coronary constriction, it was 
decided to investigate the role of the vasoconstrictor prostanoid, thromboxane A2, as a 
possible mediator of this vasoconstriction. To do this two different drugs were utilised. 
GR 32191 a direct thromboxane receptor antagonist (Lumley et al., 1988) and ZD a 
combined thromboxane receptor antagonist and a thromboxane synthesis inhibitor 
(Brownlie et al., 1993). GR 32191, 10 |iM, and ZD 1542, 10 |iM, both completely 
inhibited the TNF induced increase in CPP (figure 3.39). These drugs also attenuated the 
slow rise in CPP seen upon recirculation in control hearts. This was in contrast to 
indomethacin, which did not alter basal CPP (figure 3.40).
An unexpected action of GR 32191 was to decrease HR (HR before GR 32191 vs. after 
GR32191: 265 ± 12 vs. 205 ± 16 bpm, P < 0.05), which could not be reversed by the 
muscarinic receptor antagonist, atropine (10 pM, data not shown). This was accompanied 
by a slight increase in basal LVDP (LVDP before GR 32191 vs. after GR 32191: 96 ± 2 
mmHg vs. 121 ± 8 mmHg, P < 0.05). This action was apparent in both the presence and 
absence of TNF. ZD 1542 did not alter either LVDP (LVDP before ZD 1542 vs. after ZD 
1542: 98 ± 7 mmHg vs. 99 ± 6 mmHg, P = NS) or HR (HR before ZD 1542 vs. after ZD 
1542: 272 ± 8 vs. 274 ± 9 bpm, P = NS).
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3.6.1.4 Bosentan
Addition of bosentan, 3 pM, to the perfusate failed to alter the rise in CPP seen with TNF 
(figure 3.39). This concentration of bosentan was, however, able to block the coronary 
constrictor actions ET-1, 100 pM, in the coronary circulation (increase in CPP after 5 min 
perfusion: ET-1 vs. ET-1 in the presence of bosentan; 97 ± 6 mmHg vs. 13 ± 1 mmHg, P
< 0.05). Bosentan did not alter CPP in the absence of TNF (CPP after 90 min: control vs. 
bosentan; 129 ± 9 mmHg vs. 114 ±11 mmHg, P = NS). As mentioned before, bosentan 
did not alter basal levels of either LVDP or HR.
3.6.2 Actions of U 46619 on CPP and contractility
From the above presented results it is not clear whether the TNF-induced depression in 
cardiac function was independent of the observed coronary constriction, or if the 
depression in cardiac function was in part dependant on the observed coronary 
constriction. To address this possibility it was decided to mimic the coronary constriction 
with the stable thromboxane A2 mimetic, U 46619, and to observe the effect of this 
vasoconstriction on contractile function.
Addition of U 46619, 30 nM, caused an immediate and significant increase in CPP (CPP 
increase 10 min after addition of U 46619 vs. control: 32 ± 8 mmHg vs. 15 ± 4 mmHg, P
< 0.05). This increase in CPP was similar in magnitude to that seen with TNF, 20 ng.ml'1
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(45 ± 1 2  mmHg). However, U 46619 did not alter cardiac contractility (LVDP before U 
46619 vs. LVDP after U 46619: 117 ± 3  vs. 121 ± 6 mmHg, P = NS).
3.6.3 Addition of recirculating perfusate from one heart to another
In order to see if the coronary constriction seen upon administration of TNF was due to 
TNF-induced release, and subsequent build up, of a coronary constrictor into the 
recirculating perfusate, hearts were perfused with TNF as described above. After this the 
recirculating perfusate was taken from both a control heart and one perfused with TNF 
and passed through a separate heart for 10, 20 and 30 second periods. There was no 
difference between the changes in coronary tone observed with the perfusate from control 
hearts, to that observed with the perfusate from TNF treated hearts. Change in CPP with a 
10 second perfusion was -7 ± 5 mmHg vs. 0 ± 7 mmHg (P = NS, n = 3) for perfusate from 
control and TNF treated hearts respectively. Change in CPP with a 20 second perfusion 
was -8 ± 5 mmHg vs. -4  ± 4 mmHg (P = NS, n = 3) for perfusate from control and TNF 
treated hearts respectively. Change in CPP with a 30 second perfusion was -15 ± 11 
mmHg vs. -5  ± 2 mmHg (P = NS, n = 3) for perfusate from control and TNF treated 
hearts respectively.
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3.6.4 Actions of recombinant rat TNF in the coronary circulation of the rat isolated 
perfused heart, under constant flow conditions
Experiments described in this section (section 3.6) have all utilised recombinant human 
TNF. Therefore a series of experiments were completed in order to see if the coronary 
constrictory actions of recombinant human TNF could be reproduced with recombinant 
rat TNF. Experiments with rat TNF followed the same protocol as described with human 
TNF (section 3.6).
Recombinant rat TNF did not significantly alter CPP when compared with control hearts, 
as shown in figure 3.41, however it can be seen from this graph that the standard errors 
for each group were large. This was probably the result of low n-numbers of each group, 
especially the TNF treated group (n = 4). However, it can be seen from this graph that 
recombinant rat TNF did have a tendency to increase coronary tone, and a greater number 
of experiments would probably make this effect a significant one. Therefore, the actions of 
human TNF appeared to be mimicked by rat TNF.
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Figure 3.41. Effects o f recombinant rat TN F on CPP in the rat isolated perfused heart 
under recirculating, constant flow conditions. TN F was added at A, and recirculation 
started at B (control hearts, n=6; TN F treated hearts, n=4).
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3.7 Actions of TNF in the isolated rat heart under a constant 
head of pressure
From  the experiments with U 46619 (section 3.6.2) it is clear that under constant flow 
conditions, coronary constriction of the magnitude seen with TNF does not adversely alter 
LVDP. However, under conditions where coronary flow can alter with coronary tone, 
such as with a constant pressure perfusion system, then such a constriction could alter 
substrate supply to the heart, and therefore contractile function. The diagram shown below 
describes the protocol followed:
A B  C D  E
ii ii i
* * *
0 5 25 30 90
min
A = perfusion under a constant head of pressure, B = NOE, lp,M, C = TNF 20 ng.mT1, 
D = recirculation, E  = end of perfusion.
* show where Starling curves were performed.
As expected, upon recirculation in control hearts there was a slight decrease in coronary 
flow, which continued throughout the experiment (figure 3.42). As predicted from  
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Figure 3.42. Effects o f TN F and NOE alone and in combination on coronary flow in hearts 
perfused at constant pressure (n = 6 - 7). ** P < 0.01 TN F vs. control, #  P < 0.05, ## P < 
0.01 N O E alone vs. TN F with NOE. Initial coronary flow at 0 min: 12.4 ± 0.6 ml.min*1; 
11 ± 1.2 m in tin '1; 8.9 ± 1 m in tin '1 and 10.3 ±  2.4 ml.min'1 for control hearts, TN F treated, 
NOE treated  and NOE with TN F treated hearts respectively.
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tone, manifested by a decrease in coronary flow (figure 3.42). The changes in LVDP 
observed under constant pressure conditions followed a similar pattern to the changes 
observed under constant flow conditions, and a marked depression in function was seen in 
the presence of TNF (figure 3.43). However it is clear from this figure that the depression 
in cardiac function seen with TNF was more severe under constant pressure conditions 
than constant flow. Prior addition of NOE, 1 jiM, blocked both the decrease in coronary 
flow (figure 3.42) as well as the depression in cardiac function observed with TNF (figure 
3.44).
The more severe depression in cardiac function with TNF, observed under these 
conditions, was also apparent when performing Starling curves. As mentioned above, 
under constant flow conditions with TNF, a significant depression in the Starling response 
was not observed until the fifth and sixth Starling curves performed at 135 min and 165 
min. Here, however, a marked depression in the Starling response was observed after 75 
min (figure 3.44). Prior addition of NOE was able to block this depression in function 
(figure 3.45).
3.7.1 Effects of decreased temperature on cardiac function
Whilst examining the action of TNF in isolated hearts perfused with TNF, under a 
constant head of pressure, TNF caused a vasoconstriction and the reduction in flow 
caused the temperature of the heart dropped to below 37 °C, as measured by a 
temperature probe inserted into the right ventricle. This drop in temperature was despite
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Figure 3.43. Effects o f TN F on LVDP in hearts perfused under constant pressure and 
constant flow conditions (n = 6 - 7). Change in LVDP is shown as a percentage o f before 
TN F addition to allow comparison between the two groups. * P < 0.05 TN F vs. control 
when perfused under constant flow conditions. $ P < 0.05, $$ P < 0.01, TN F under 
constant flow conditions vs. TN F under constant pressure conditions. W here initial LVDP 
at 0 min: 122 ±  4 mmHg; 126 ± 6 mmHg; 101 ±  6 mmHg and 106 ±  3 mmHg for constant 
flow control and TN F treated heart and constant pressure control and TN F treated hearts 
respectively.
C o n s t a n t  f lo w , C o n tr o l
— O —  C o n s t a n t  f lo w , T N F , 2 0  n g .m l  
— A —  C o n s t a n t  p r e s s u r e ,  C o n tr o l  
— O —  C o n s t a n t  p r e s s u r e ,  T N F , 2 0  n g .m l
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Figure 3.44. Effects o f NOE on the depression in cardiac function seen with TN F under 
constant pressure conditions. Shown as changes in LVDP after TN F administration (n = 6 
- 7). * P < 0.05, ** P < 0.01 TN F vs. control. #  P < 0.05 NOE vs. TN F with NOE. W here 
LVDP at 0 min for NOE treated controls and NOE with TNF treated animals: 107 ± 6 
mmHg and 100 ±  5 mmHg respectively.
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Figure 3.45. Starling curves in hearts perfused under a constant head o f pressure, 50 min 
after TN F addition. Control hearts (n = 7), TNF, alone (n = 7), NO E alone (n=6) and TN F 
with NOE. * P < 0.05, ** P < 0.01, TN F vs. control. # P < 0.05, ## P < 0.01, N O E alone 
vs. TN F with NOE.
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the fact that the hearts were surrounded by a heated water jacket. For this reason the 
effects of a drop in temperature on cardiac function was investigated.
A drop in temperature of the Krebs buffer from 37 °C to 33 °C caused a decrease in heart 
rate, from 286 ± 9 bpm to 201 ± 9 bpm (n = 4, P < 0.05) and a concomitant increase in 
LVDP, from 123 ± 2 mmHg to 133 ± 5 mmHg (n = 4, P < 0.05).
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3.8 Sphingosine in the isolated perfused rat heart
The experiments described above present evidence implicating the sphingoid base, 
sphingosine, as an essential mediator of the early depression in cardiac function and an 
important mediator of the coronary constriction seen upon TNF administration to isolated 
hearts. By this rational, some, if not all, of the actions of TNF described above, should be 
mimicked by exogenous addition of sphingosine. The following protocol was used to 
examine the actions of sphingosine in the isolated rat heart:
AB CD  E
ii ii i
* * *
0 5 25 30 90
min
A = initial perfusion, B = antagonists, C = sphingosine, 0.5 pM, 1 pM, 3pM 
or 10 pM, D = recirculation, E = end of perfusion.
* show where Starling curves were performed.
Addition of sphingosine (0.5 - 10 pM) to the isolated perfused hearts resulted in profound 
changes in the parameters of LVDP, left ventricular end diastolic pressure (LVEDP) and 
CPP. Figure 3.46 shows typical experimental traces from hearts perfused with lpM, 3 pM 
and 10 pM sphingosine. It can be seen from these traces that hearts perfused with 10 pM 
sphingosine showed a dramatic increase in LVEDP, which was accompanied by an equally 
dramatic fall in LVDP. The actions of 10 pM sphingosine were so severe that all 
















3 pM t t
5 min
R e c i r cu l a t e Sphingosine t t Recirculate 10 pM
Figure 3.46. Typical experimental traces showing changes in LVDP upon application of 
sphingosine, lp M  (a), 3 pM  (b) and '  'c ) .  These traces are representative of 6, 7 
and 2 experiments respectively.
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followed the same pattern, but to a lesser degree, figure 3.46. Figure 3.47 shows the 
response of hearts to sphingosine, 3 pM and 10 pM, when contractility was measured 
using both a hook in the apex of the heart and an intraventricular balloon to measure 
contractility. Interestingly, it is shown that although an increase in LVEDP is observed 
upon administration of sphingosine, this was not observed as in increase in the baseline 
hook tension. Upon perfusion with sphingosine, 3pM, there was an increase in CPP 
(figure 3.48), which followed slightly slower kinetics to the rise in CPP seen with TNF, 
plateauing after 15 min, as opposed to 10 min with TNF. Also, unlike with TNF, this 
coronary constriction was not altered by prior addition of indomethacin, 10 pM or ZD 
1542 pM (figure 3.48).
In studies undertaken by Candela et al,. 1991, TNF was shown to cause the release of 
prostaglandin E2 from fibroblasts, this was an action which showed remarkable synergy 
when in the presence of low concentrations of exogenous sphingosine (0.5 pM - 10 pM). 
Both prostaglandin E2 and thromboxane A2 are downstream metabolites of 
cyclooxygenase induced breakdown of arachidonic acid. For this reason the actions of 
TNF on cardiac contractility and coronary tone were observed in the presence of a low 
concentration of sphingosine, 0.5 p,M.
When both a low concentration of sphingosine, 0.5 pM, and TNF, 20 ng.ml'1, were 
perfused together through hearts, sphingosine did not potentiate any of the observed 










Figure 3.47. A typical experimental trace showing the effect o f sphingosine, 3 pM  and 10 
pM  in this isolated perfused rat heart. Contractility in this heart was simultaneously 
measured using a hook in the apex of the heart (a), and an intraventricular baloon (b).
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Figure 3.48. Effects of indomethacin (n = 4) and ZD 1542 (n = 4) on actions of 
sphingosine (n = 7) on CPP. Recirculation began at A. * P < 0.05, ** P < 0.01, *** P < 
0.001; sphingosine vs. control.
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± 10 mmHg vs. 75 ± 12 mmHg, P = NS. CPP after 90 min, TNF vs. TNF with 




During this study, various investigations have been carried out using the rat isolated 
perfused heart with the objective of describing the cardiac actions of TNF. It has been 
investigated whether TNF alters the recovery of hearts after a brief acidotic challenge. 
TNF has been shown to block insulin-stimulated glycogen synthesis without altering 
insulin-stimulated glucose uptake. Ceramide has been investigated as a potential 
mediator of this response. Contractile activity of hearts during low flow ischaemia 
under low glucose conditions was shown to be a increased by TNF. In hearts perfused 
under normal glucose conditions TNF acutely depressed contractile function, an effect 
which was investigated using pharmacological probes. In addition to this, TNF was 
shown to increase the tone of the coronary circulation and attempts to characterise 
these effects of TNF with pharmacological tools were made. It was also shown that 
under conditions where coronary flow could alter with coronary tone, the observed 
coronary constrictor action of TNF could indirectly depress cardiac contractility and 
synergise with the direct cardiac depressant actions of TNF. When characterising both 
the contractile and coronary effects of TNF, particular attention was paid to the 
sphingomyelin metabolite, sphingosine. As sphingosine was strongly implicated as a 
mediator of both the direct negative inotropic effects and the coronary effects of TNF, 
the actions of sphingosine in the isolated perfused heart were also investigated.




Preliminary experiments were conducted in order to define conditions under which to 
investigate the actions of TNF. It was decided to use a recirculating mode of perfusion 
as opposed to a non-recirculating mode, in order to reduce the amount TNF needed 
for each individual experiment. Therefore, it was necessary to describe a recirculating 
model with which to perfuse isolated hearts, and to assess the viability of these hearts 
under these conditions. 50 ml was used as the total recirculating volume. The results 
presented in the last section (section 3,1, figure 3.1) show that although the process of 
recirculation slightly reduced contractility, measured as developed tension using a 
hook in the apex of the heart, hearts perfused under recirculating conditions were still 
viable after at least 2 hours perfusion. This reduced contractility was probably a result 
of the build up of metabolites released from the heart during normal function.
It should be noted that upon addition of drugs to a recirculating system, any secondary 
release of substances could build up in the recirculating perfusate, and so any observed 
actions of these released substances could be confused with the direct actions of the 
drug. Another potential problem with a recirculating mode of perfusion is that after 
addition of a drug it is impossible to wash that drug out without switching back to a 
non-recirculating mode of perfusion. Thus the wash out of metabolites released from 
normal heart function, could effect measured parameters of heart function, and so any 
effects of wash out of drugs may not simply be due to the loss of the drug in question 
from the system.
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Despite these potential problems, a recirculating mode of perfusion, using a total 
volume of 50 ml was used to study the actions of TNF in the rat isolated perfused 
heart.
The second objective of these preliminary experiments was to find a concentration of 
TNF to use. A concentration of 20 ng.ml'1 was chosen for two reasons. Firstly similar 
concentrations of TNF have been observed in sera from animals during experimental 
sepsis (Tracey et al., 1987). Secondly, other investigators have used a concentration of 
20 ng.ml'1 during studies into the cardiac actions of TNF (Schulz et al., 1995). Indeed, 
upon administration of TNF, 20 ng.ml1, a negative inotropic effect was observed 
within 15 min of administration, which was evident for the remainder of the 
experimental procedure. A higher concentration of TNF, 100 ng.ml'1, failed to 
potentiate this depressed cardiac function. Therefore, it was decided that TNF at the 
concentration of 20 ng.ml1 would be used in subsequent experiments.
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4.2 TNF and cardiac acidosis
It has been shown that at low pH levels the trimeric structure of TNF is relaxed, and it 
has been suggested that in this state TNF can associate with hydrophobic regions of 
the plasma membrane, and form sodium (Na+) permeable channels (Kagan et al., 1992; 
Baldwin et al., 1996). During cardiac ischaemia a build up of protons occurs, both 
from ATP hydrolysis and release of lactate from the heart, resulting in a decrease in 
intracellular pH. Intracellular pH has been reported to reach values as low as 6.0 
during such ischaemic episodes (Kolacassides et al., 1996). Due to the associated 
increased circulating levels of TNF in ischaemic heart disease (Vaddi et al., 1994), as 
well as the realisation that TNF release can be observed with experimental 
ischaemia/reperfusion injury (Squadrito et al., 1993; Colletti et al., 1990), it was 
decided to investigate whether TNF could alter the recovery of hearts after an 
experimental acidotic challenge. Any increase in Na+ influx across the plasma 
membrane due to TNF would contribute to the increase in intracellular Na+ observed 
during ischaemia (Pike et al., 1990). This, via the action of the Na+/Ca2+ ion 
exchanger, in turn could contribute to the detrimental Ca2+ overload often associated 
with ischaemia (Tani & Neely, 1989). Indeed, studies have shown that the protective 
effects of adenosine during ischaemia/reperfusion injury are associated with a 
decreased release of TNF from the heart (Meldrum et al., 1998). In addition to this, 
neutralisation of TNF released during ischaemic injury can afford protection (Squadrito 
et al., 1993). This protection could be explained if, under the acidotic conditions 
expected during ischaemia, TNF formed these Na+ permeable ion channels.
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In this study, acidosis was achieved by omission of sodium bicarbonate from the Krebs 
buffer solution, and subsequent addition of small quantities of sodium bicarbonate until 
the desired pH was achieved. An acidotic challenge, pH either 5.5 or 6.2 for 5 min, 
resulted in very reproducible changes in parameters of developed tension and CPP, as 
well as very reproducible recovery of hearts after such challenges. Prior addition of 
TNF, 5 min before acidosis, did not significantly depress the recovery of hearts after 
acidosis. Under both acidotic pH values, prior inclusion of TNF may have slightly 
reduced the contractility during recovery period, however this was not statistically 
significant, and probably represented an aspect of the early direct negative inotropic 
effect of TNF discussed later (section 4.5).
Baldwin et al. (1996) showed that TNF associates with membranes at a very low pH 
of 4. Therefore, the lack of effect of TNF described above could have been because the 
acidotic challenge was not severe enough. This does not eliminate the formation of Na+ 
permeable ion channels by TNF as a potential deleterious action of TNF during 
ischaemia/reperfusion injury, however, it is unlikely to be a major factor in determining 
the outcome of an ischaemic episode. It should, however, be noted that although pH 
values of 6 have been reported during ischaemia (Kolacassides et al., 1996), it is likely 
that under such conditions pools of proton accumulate at local sites, potentially 
decreasing local pH to very low values not observed with current techniques.
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4.3 Insulin, TNF, ceramide and the low glucose 
recirculating heart
The aim of these investigations was to observe the actions of insulin in the isolated 
perfused heart under low glucose, 2 mM, conditions and to see if any of its actions 
could be altered by TNF. Under these substrate limiting, low glucose, conditions one 
would expect that the actions of insulin would be more important for cardiac function. 
The findings of this study can be summarised as follows: under low glucose conditions, 
developed tension declined at a faster rate when compared with perfusion under 
normal glucose, 11.6 mM, conditions. Under low glucose conditions, insulin slightly 
improved developed tension when added both at the start of the experiment or 15 min 
after recirculation. On neither occasion was this slight improvement in contractility 
observed in the presence of TNF. Insulin caused a marked stimulation of glucose 
uptake, as measured by a decrease in the glucose concentration within the recirculating 
Krebs buffer. Insulin also increased end point glycogen levels, suggesting stimulation 
of either glycogen synthesis, inhibition of glycogen breakdown or both of these. TNF, 
when added either before or after insulin did not alter insulin-stimulated glucose 
uptake, however in both circumstances TNF attenuated insulin-stimulation of end­
point glycogen levels. TNF did not alter the breakdown of glycogen under zero 
glucose conditions. C2.ceramide mimicked these actions of TNF, blocking the increase 
in end point glycogen levels without altering insulin-stimulated glucose uptake. 
Addition of the protein phosphatase inhibitor, okadaic acid, at a concentration where 
inhibition is selective for the PP-2A family of phosphatases including ceramide- 
activated protein phosphatase (CAPP) (Dobrowsky & Hannun, 1992), blocked the
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actions of ceramide on insulin-stimulated end point glycogen levels. Okadaic acid 
caused only a slight attenuation of the TNF-induced depression in insulin-stimulated 
glycogen synthesis, although this was not statistically significant.
As mentioned in the introduction there is a great deal of interest in the mechanisms 
behind TNF-induced insulin resistance since the realisation that TNF could mediate the 
insulin resistance observed during obesity-induced diabetes and NEDDM (Hotamisligil 
et al., 1993). Although there is much discrepancy between studies, much of the 
research in this area has focused on the theory that TNF alters the actions of insulin at 
a proximal site with respect to the insulin receptor signal (Feinstein et al., 1993; 
Hotamisligil et al., 1994a; Hotamisligil et al., 1994b; Kanety et al., 1995; Peraldi et al., 
1996; Hotamisligil et al., 1996; Wang et al, 1998). It has been shown that TNF can 
cause changes in the ability of the insulin receptor to undergo autophosphorylation 
accompanied by a decrease in the phosphorylation of IRS-1 (Feinstein et al., 1993; 
Hotamisligil et al., 1994a). It has also been suggested that an altered serine 
phosphorylation state of IRS-1 induced by TNF could turn it into an inhibitor of the 
insulin receptor (Kanety et al., 1995; Peraldi et a l ,  1996; Hotamisligil et al., 1996). 
Various different time courses have been reported to be required for TNF-induced 
insulin resistance to become apparent from one hour (Feinstein et al., 1993; Begum & 
Ragolia, 1996) to a few hours (Lang et al., 1992; Peraldi et al., 1996), or even a few 
days (Hotamisligil et al., 1996; Wang et a l,  1998) incubation time with TNF.
The results presented herein show differential effects of TNF on different aspects of 
insulin action in the isolated perfused heart under low glucose conditions, whereby 
TNF attenuated insulin-stimulated end point glycogen levels without altering insulin-
stimulated glucose uptake. These differential effects suggest that a direct or indirect, 
via IRS-1, inhibition of the insulin receptor is not the mechanism responsible for TNF- 
induced alterations in insulin action in this model. If inhibition of the insulin receptor 
was to occur, then both insulin-stimulated glucose uptake and insulin-stimulated 
glycogen synthesis would be affected, instead only end point glycogen levels were 
altered by TNF. The selective action of TNF on insulin-stimulated glycogen synthesis 
suggests a mechanism of action at a site down stream of the insulin receptor. In part 
these studies agree with a recent report by Begum & Ragolia (1996), who showed that 
TNF could have differential actions on insulin action in a skeletal muscle cell line. It 
was shown that over 60 min incubation with TNF, 10 ng.ml'1, was required to inhibit 
insulin-stimulated glucose uptake, however, the enzyme responsible for glycogen 
synthesis, GS, could be inhibited by only 10 min incubation with TNF. This effect on 
glycogen synthesis was accompanied by inhibition of insulin-stimulated activation of 
another glycogen regulatory enzyme, PP-1. These authors suggested that the effects of 
TNF on insulin-stimulated glycogen synthesis were more sensitive than the effects 
observed on insulin-stimulated glucose uptake (Begum & Ragolia, 1996). Maybe in 
my model, longer exposure to TNF would have decreased the ability of insulin to 
stimulate glucose uptake.
In my studies it was shown that the cell permeable analogue of ceramide, C2-ceramide, 
could mimic the effects of TNF on insulin-stimulated glycogen synthesis, without 
altering insulin-stimulated glucose uptake. Again these data are similar to those of 
Begum & Ragolia (1996) as well as those of Peraldi et al. (1996) who showed that the 
actions of TNF with respect to insulin sensitivity could be reproduced by cell 
permeable ceramide analogues or exogenous addition of SMase. Begum & Ragolia
163
(1996) actually showed that treatment of their skeletal muscle cell line with TNF 
caused an increase in cellular ceramide with a concomitant decrease in sphingomyelin. 
The only difference between these studies and mine was that both of these studies 
showed TNF-induced disruptions of insulin-stimulated glucose uptake. Peraldi et a l  
(1996) showed that both TNF and ceramide could act to inhibit the insulin receptor 
and subsequent phosphorylation of IRS-1. This does not appear to be the case in my 
studies for the reasons discussed above.
Inclusion of okadaic acid into my system completely blocked the inhibitory actions of 
ceramide on the insulin-induced glycogen synthesis, however although okadaic acid did 
show a tendency to block the inhibitory effects of TNF on insulin-induced glycogen 
synthesis, this did not achieve statistical significance. Therefore, although ceramide 
may play a role in this action of TNF, it is clear that other mechanisms for TNF- 
induced attenuation of insulin-stimulated glycogen synthesis must exist. From my 
studies it is unclear what these other mechanisms may be.
Okadaic acid, at the concentrations used, is a specific inhibitor of the PP-2A family of 
phosphatases (Cohen et al., 1989) of which CAPP is one (Dobrowsky & Hannun, 
1992). As mentioned above the effects of ceramide on insulin action were blocked by 
okadaic acid, therefore it appears that the observed actions of ceramide on insulin- 
stimulated end point glycogen levels involve activation of CAPP. PP-2A phosphatases, 
and so presumably CAPP, can dephosphorylate the glycogen associated form of PP-1 
(PP-lG)(Dent et al., 1990), thus interfering with insulin stimulation of PP-1G. PP-2A 
also has the ability to dephosphorylate GSK3 (Murai et al., 1996), thereby reversing 
the inactivation of GSK3 by insulin. Both of these are potential mechanisms which
164
would explain the inhibitory actions of ceramide on the observed changes in glycogen 
upon insulin administration, and could at least in part explain the inhibitory effect of 
TNF on the action of insulin.
A major limitation of the studies involving the actions of TNF on insulin-stimulated 
glycogen synthesis is that only one concentration of TNF was utilised. Although 
complete blockade of insulin-stimulated end point glycogen levels was not seen with 
TNF, it would be naive to assume that the response seen with this one concentration of 
TNF was submaximal or even maximal. Indeed, it is entirely possible that far lower 
concentrations of TNF could cause similar disruptions in insulin action. If the 
concentration of TNF used was grossly higher than that required to cause a maximal 
response, then one would expect that it would be harder to block this response than if 
a sub-maximal concentration of TNF were utilised. Therefore, any inhibitory actions of 
okadaic acid on the attenuation of the insulin response by TNF, could be masked by a 
high concentrations of TNF. Further investigations should continue focusing on the 
concentration dependency of this response with respect to TNF.
The results of this study are in contradiction to the observations of Kanety et al. 
(1995), who demonstrated that inclusion of okadaic acid, or inclusion of another 
phosphatase inhibitor, calyculin A, could increase the phosphorylation state of IRS-1 
and convert it into an inhibitor of the insulin receptor. Therefore, in this system 
okadaic acid mimicked the observed insulin inhibitory actions of TNF. In my model 
okadaic acid did not inhibit insulin action, instead it blocked the inhibition of insulin- 
stimulated end point glycogen levels caused by ceramide. The reason for this apparent 
discrepancy is unclear, however, Kanety et al. (1995) used a 100-fold greater
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concentration of okadaic acid than that used in my studies. At this concentration, 
okadaic acid is not selective for the PP-2A family of phosphatases, and may also inhibit 
PP-1 (Cohen et al., 1989). Non-selective inhibition of phosphatases could explain the 
obvious differences between my study and that of Kanety et al. (1995).
End point glycogen levels after low glucose perfusion, in the absence of insulin were 
not different when comparing control and TNF treated groups, however these end 
point glycogen levels were already very low. Therefore, it is impossible to tell from this 
whether TNF could affect glycogen homeostasis in the absence of insulin. For this 
reason a separate set of experiments were conducted to see if TNF could affect 
glycogen breakdown. Hearts were perfused with substrate free Kreb’s buffer and then 
freeze clamped at various time intervals and assayed for glycogen. One would expect 
no glycogen synthesis during these conditions due to lack of substrate, and glycogen 
breakdown would predominate. Glycogen depletion in control hearts under these 
conditions compared well with literature from other groups following similar protocols 
(Opie et al., 1962; Sultan & Kahn, 1997). The fact that TNF did not increase the rate 
of glycogen breakdown, suggests that the effects of TNF on insulin-stimulated end 
point glycogen levels are an actual inhibition of the insulin-mediated response, as 
opposed to a non-specific action of TNF on glycogen degradation. Unfortunately, 
glycogen synthesis in the absence of insulin could not be achieved (data not shown), 
therefore a non-specific action of TNF on glycogen synthesis cannot be ruled out.
It has been suggested that in the absence of insulin, TNF can actually cause an increase 
in basal glucose uptake in various tissues (Meszaros et al., 1987; Lang et al., 1992). 
Indeed, in the investigation by Lang et al. it was shown that TNF could stimulate
peripheral glucose uptake, an effect which was seen in various tissues, including the 
heart. The results presented herein are in contrast to the studies mentioned above, as in 
the heart, under the conditions used, TNF did not stimulate basal glucose uptake. The 
reason why TNF did not increase basal glucose uptake in my investigations probably 
involves the time course used in this study when compared to the other investigations. 
During my experiments, TNF was in contact with the heart for a total of 80 min as 
opposed to 3 hr (Meszaros et al., 1987) or 24 hr (Lang et al., 1992).
A recent observation by Guo & Donner (1996) showed that brief treatment of 3T3-L1 
adipocytes with TNF (15 min) could actually increase insulin-induced tyrosine 
phosphorylation of IRS-1, although chronic TNF treatment still caused insulin 
resistance. Guo & Donner did not actually investigate the functional consequences of 
this, but one would expect that this acute action of TNF would cause a potentiation of 
the insulin signal. I found no evidence that TNF could acutely potentiate insulin- 
stimulated glucose uptake in the isolated perfused heart.
With respect to contractility, TNF did not cause a negative inotropic effect in the low 
glucose perfusion model. This result is in contrast to other results presented herein, 
where acute negative inotropic responses to TNF were observed. The reason for this 
apparent discrepancy is not clear at present, however, as shown in figure 3.5 
developed tension in control hearts dropped significantly upon perfusion with Kreb’s 
buffer containing low glucose, when compared with normal glucose perfusion. This 
faster decline in cardiac viability, probably due to substrate deprivation, could have 
masked the expected negative inotropic action of TNF. Insulin initially showed a 
tendency to improve the developed tension, although this only reached statistical
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significance at one time point in hearts where insulin was added at the start of the 
experiment. When insulin was added 15 min after recirculation, developed tension was 
significantly improved at later time point, however, hearts from this insulin treated 
group already appeared to have slightly increased developed tension. The improvement 
in developed tension seen with insulin was probably due to increased substrate 
availability for the heart, evidenced by the increase in glucose uptake observed with 
insulin. Interestingly, addition of TNF in the presence of insulin did decrease 
contractility with respect to insulin alone, this was regardless of the time when insulin 
was added. Thus, the slight improvement in contractility seen with insulin may have 
allowed the negative inotropic action of TNF to become apparent.
The observed effects of ceramide on developed tension in this model were interesting. 
C2-ceramide, 1 (iM, did not adversely affect developed tension, and may have even 
improved contractility at later time points. C2-ceramide at higher concentrations, of 5 
|iM and 10 pM, caused a concentration-dependant negative inotropic response. A 
review of the literature suggests that three possible mechanisms could mediate this 
ceramide induced negative inotropic response. Firstly, ceramide is a direct metabolite 
of the SMase pathway, and upon activation of this pathway ceramide concentrations 
rise (Begum & Ragolia, 1996). Ceramide can then be subsequently metabolised to 
sphingosine by ceramidase (Kolesnick, 1991), another important enzyme in the SMase 
pathway. If, in cardiac myocytes, there is a basal activity of ceramidase, then a portion 
of the exogenously added ceramide could be converted to sphingosine. As discussed in 
more detail in the introduction (section 1.5.1) and later in this discussion (section 4.5), 
sphingosine can reduce the phenomenon of Ca2+-induced Ca2+ release (Dettbam et al., 
1994) as well as reducing L-type Ca2+ current (McDonough et al., 1994), and this
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would compromise cardiac contractility (Oral et al., 1997). In addition to this, 
ceramide itself may alter cardiac function directly, by inhibiting the L-type Ca2+ current 
(Schreur & Liu, 1997). A third potential mechanism which could mediate the 
ceramide-induced negative inotropic response stems from the ability of ceramide to 
cause apoptosis of cardiac myocytes (Bielawska et al., 1997). However, the time 
course required for ceramide-induced apoptosis is not consistent with the almost 
immediate negative inotropic actions of ceramide observed here. Commonly, several 
hours are required for ceramide to cause apoptosis (Obeid et al., 1993; Jarvis et al., 
1994).
The blockade of insulin-stimulated glycogen synthesis could have important 
consequences for the heart, especially under conditions of substrate deprivation, where 
endogenous energy stores within the heart become of crucial importance. Although 
controversy exists concerning beneficial and detrimental effects of high cardiac 
glycogen content prior to ischaemic episodes, under certain conditions glycogen can 
certainly protect (Goodwin et a l, 1994; Cross et al., 1996). However, contrary to this, 
preischaemic glycogen depletion in hearts has been shown to be protective during 
ischaemia (Neely et al., 1984; Kupriyanov et al., 1988). The distinction between these 
protective and detrimental consequences of cardiac glycogen levels appears to be a 
function of the severity of the ischaemic episode, whereby high glycogen levels are 
protective during relatively short ischaemic challenges and detrimental during 
prolonged ischaemia (Cross et al., 1996). The most important consequence of TNF 
blockade of insulin-stimulated glycogen synthesis, however, could concern the role for 
glycogen as a reserve of energy to support sudden increases in heart work. After such 
increases in heart work TNF could compromise the recovery of cardiac glycogen
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levels, and therefore subsequent increases in heart work may not be supported by 
cardiac glycogen as an energy source.
Inhibition of glycogen synthesis, by TNF, in the absence of an inhibition in glucose 
uptake, could have implications which are independent of those discussed above. 
Insulin stimulation of glucose uptake by the heart would lead to increased glycolysis, 
due to increased substrate delivery. Another action of insulin is to increase the activity 
of pyruvate dehydrogenase (Hughes et al., 1980), the enzyme which is responsible for 
the conversion of the end product of the glycolytic pathway, pyruvate, into acetyl 
CoA. Acetyl CoA can then be oxidised via the citric acid cycle. However, if glycogen 
synthesis is blocked then proportionately more glucose would undergo glycolysis. This 
could saturate the pyruvate dehydrogenase enzyme and lead to increased metabolism 
of glucose to lactic acid, via lactate dehydrogenase metabolism of excess pyruvate 
levels. Increased lactate could then lead to acidosis within the heart.
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4.4 TNF in the low glucose, low flow ischaemic heart
The above discussion concerns the effects of TNF on the perfused heart under 
substrate limiting conditions, and how the actions insulin were altered by TNF. To 
further these observations it was decided to investigate the actions of TNF under 
conditions of further substrate deprivation. Here a low flow, 2 ml.min'1, model of 
perfusion was utilised, still under low glucose, 2 mM, conditions. The findings of these 
investigations can be summarised as follows: upon a change in flow rate from 10 
ml.min'1 to 2 ml.min'1, there was a dramatic fall in parameters of developed tension and 
coronary perfusion pressure. Unexpectedly, TNF increased the contractility of hearts 
during this episode of low flow. Insulin also affected a slight protection from the 
decline in developed tension seen under low flow conditions, however this was only 
observed early after commencement of low flow. A marked contracture developed 
upon initiation of low flow. Insulin, in both the presence and absence of TNF, 
appeared to decrease the rate of formation of this contracture, but this effect was not 
proved to be significant. As in hearts perfused with low glucose insulin caused a 
significant increase in glucose uptake from the recirculating Kreb’s buffer. Again 
insulin-stimulated glucose uptake was not altered by TNF. Initiation of low flow 
caused the release of lactate into the recirculating perfusate. Insulin, both in the 
presence and absence of TNF, significantly increased the accumulation of lactate in the 
Kreb’s buffer. Release of lactate provides evidence that the low flow perfusion 
conditions were severe enough to constitute ischaemia, or at least hypoxia. Except for 
in control hearts, end point ATP and PCr levels were depressed after the low flow 
ischaemic episode in all groups, again indicating substrate deprivation. In control
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hearts, ATP levels did not significantly reduce, although a definite trend could be seen. 
However, end point PCr levels actually appeared to increase. The ischaemic episode 
decreased end point glycogen levels when compared to preischaemic levels, however, 
in contrast to earlier observations, no differences were observed between treated 
groups and control groups.
During the ischaemic episode, the improvement in contractility seen with TNF was a 
surprise, and suggests that TNF can protect from the loss of function observed under 
these conditions. A review of the literature shows that protection by TNF from 
ischaemia or hypoxia is not a novel observation. In a study by Eddy et al. (1992) it was 
shown that pre-treatment of animals for 24 hr with TNF, resulted in protection from an 
ex vivo ischaemic insult to the heart. This injury was assessed by release of lactate 
dehydrogenase from the heart. These authors showed that 24 hr pre-treatment with 
TNF resulted in increased expression of manganous superoxide dismutase, thus it was 
speculated that protection from ischaemia afforded by TNF was due to increased 
resistance of the heart to oxygen free radicals. A second, more recent study has 
demonstrated that 12 hr pre-treatment of isolated cardiac myocytes with TNF resulted 
in protection from a continuous hypoxic challenge (12 hr) (Nakano et al., 1998). In 
this study cell injury was assessed by lactate dehydrogenase release, 45Ca2+ uptake and 
3-[4,5-dimethylthiazol-s-yl]2,5-diphenyltetrazolium bromide (MTT) metabolism. It 
was concluded that an unknown mechanism was responsible for this protection, 
although TNF-induced expression of heat shock protein 72 may have played a role in 
the protection observed (Nakano et al., 1998). It would be tempting to speculate that 
the apparent protection seen with TNF in my model of ischaemia is analogous to the 
protection in one or both of the studies described above. But I do not believe that this
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is the case for the following reasons. In my studies, TNF was only present 25 min 
before the ischaemic insult, and was also present throughout the protocol. In both of 
the above studies several hours TNF pre-treatment was required for protection. Such 
long time periods as used in the studies discussed above would allow time for protein 
synthesis to increase the levels of manganous superoxide dismutase or heat shock 
proteins (Eddy et al., 1992; Nakano et al., 1998). Furthermore, it is unlikely that 
increased expression of manganous superoxide dismutase would even be protective in 
my model of low flow ischaemia. The reason for this is because hearts, even under 
these low flow conditions, were still being perfused, albeit at a lower than usual flow 
rate. This constant perfusion would be expected to wash any free radicals produced 
out of the system. I have no explanation for the observed increased contractility 
observed during low flow ischaemia with TNF. Insulin caused an early protection from 
the decline in developed tension seen upon initiation of ischaemia. This was probably 
due to the marked increase in glucose uptake, seen when insulin was present, which 
would have resulted in an increase in the substrate supply to the heart.
Almost at the onset of ischaemia a contracture developed, this was recorded as an 
increase in the baseline tension. The development of contracture was expected, and has 
been observed during other protocols of low flow ischaemia (Owen et al., 1990). TNF 
did not alter this contracture, however, inclusion of insulin appeared to slow its 
development. Indeed, if insulin had protected the hearts from the observed contracture, 
then it would fit with data showing that rate of glucose uptake can regulate the onset 
of contracture (Owen et al., 1990), where increasing glucose uptake in hearts 
subjected to global low flow ischaemia, protected from the development of 
contracture.
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The lactate released from the ischaemic heart shows that the conditions used were 
severe enough to constitute ischaemia, or at least hypoxia. This is because under 
aerobic conditions glucose is metabolised by glycolysis to pyruvate, decarboxylation of 
pyruvate by pyruvate dehydrogenase causes the formation of acetyl-CoA, which can 
then be oxidised in the citric acid cycle. Under anaerobic conditions, oxygen required 
for the citric acid cycle is simply not present, and pyruvate is reduced to lactate. 
Therefore, increased release of lactate indicates hypoxic conditions. Insulin both alone 
and in the presence of TNF caused a significant increase in the release of lactate from 
hearts in my studies. This is consistent with the increase in glucose uptake induced by 
insulin. Increased glucose uptake would increase the flux of glucose through glycolysis 
and, hence, increased pyruvate production, thus more pyruvate would be converted to 
lactate.
As expected, end point glycogen levels in hearts, regardless of treatment, were 
markedly depressed after ischaemia, when compared with preischaemic levels, and this 
reflects the utilisation of this endogenous energy store within the heart. Considering 
the clear stimulatory effects of insulin on end point glycogen levels under low glucose 
conditions (section 4.4), it was rather surprising that inclusion of insulin into the Krebs 
buffer did not alter end point glycogen levels with respect to control hearts under low 
glucose, low flow conditions. A clue to a possible explanation of this observation is 
evidenced by increased lactate release from insulin treated hearts. This indicates that a 
large proportion of glucose taken up by the heart under these conditions is utilised, via 
glycolysis, for energy production. Under such conditions low rates of glycogen 
synthesis would be expected, due to lower concentrations of the substrates (G-6-P
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and G-l-P) required for glycogen synthesis, despite the actions of insulin on the 
glycogen regulatory enzymes previously described. This theory makes sense when 
considering the survival benefits of increased energy production, versus that of 
increased energy storage, within substrate deprived hearts.
The changes in ATP and PCr were almost as expected. Ischaemia caused a decline in 
both ATP and PCr levels for all treatment groups, with the exception of ATP and PCr 
levels in control hearts. The decline in ATP and PCr is consistent with substrate 
deprivation was as expected (Van Binsbergen et al., 1996). However, in control hearts 
end point PCr levels were not different from preischaemic values. This is curious as 
ATP levels in control hearts did appear to decline during the ischaemic episode, and 
one would expect that this would have been preceeded by a decline in PCr, hence, if 
ATP levels were lower than preischaemic controls then one would expect that PCr 
levels should also have been lower than preischaemic values. I have no explanation for 
this at this point in time, however, the number of hearts used to determine pre­
ischaemic ATP and PCr levels was low, only four in each group. This may have lead to 
an artificially low estimation of preischaemic PCr levels from control hearts.
The increase in contractility observed with TNF suggests protection from the 
ischaemic insult, however, this increase in contractility was not accompanied by 
increased substrate supply to the heart, evidenced by the fact that TNF did not alter 
basal glucose uptake. If TNF, for some unknown reason, were to force the heart to do 
more work under conditions of limited substrate supply, as is suggested by the increase 
in developed tension seen, then it may be expected to have a deleterious action over a 
prolonged period of time, or during a reperfusion phase. Thus the actions of TNF
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under these conditions should not necessarily be viewed as protective. Further studies 
should continue with the inclusion of a reperfusion phase after an ischaemic insult to 
see if the presence of TNF under these conditions would be beneficial or harmful. 
Studies from other groups suggest that the release of TNF is directly detrimental to a 
tissue subjected to an ischaemic episode, and protection from ischaemia can be seen by 
blockade of TNF actions or inhibition of TNF release (Colletti et al., 1990; Squadrito 
et al., 1993; M eldrum ^a/., 1998).
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4.5 TNF and contractile function of isolated perfused hearts 
under constant flow conditions
The aim of this study was to examine the mechanisms underlying the early cardiac 
depressant actions of TNF in the isolated perfused rat heart. The findings of the study 
presented herein can be summarised as follows: isolated hearts perfused under constant 
flow conditions with TNF showed a depression in left ventricular contractility, as 
indicated by the decrease in LVDP which was evident within minutes of TNF 
treatment and was sustained for the remainder of the experiment. This negative 
inotropic action was also evidenced by a depressed rate of both systolic contraction 
and diastolic relaxation in TNF treated hearts. TNF also caused a depression in the 
Starling curves, although this depression only became significant during Starling curves 
performed 135 min and 165 min after initial perfusion of the hearts, or 110 min and 
140 min after addition of TNF. End point levels of glycogen, ATP, PCr, G-6-P, G-l-P, 
F-6-P and F-l,6-P were not altered in normal hearts after TNF addition. The observed 
depression in cardiac function was not potentiated by perfusion with Krebs buffer 
containing a high concentration of glucose, 25 mM. In hearts perfused with high 
glucose, TNF depressed end point ATP levels, but not glycogen, PCr, G-6-P, G-l-P, 
F-6-P or F-l,6-P levels.
The direct depression in LVDP seen with TNF in hearts perfused with Krebs buffer 
containing normal glucose, was not blocked by nitro-L-arginine, bosentan or 
indomethacin, which inhibit nitric oxide release, endothelin actions and cyclooxygenase 
mediated arachidonic acid metabolism respectively (Gross et al., 1990, Clozel et al.,
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1994, Vane, 1971). Thus NO, endothelins and arachidonic acid metabolites are 
unlikely to be involved in the TNF-induced decrease in LVDP. The negative inotropic 
actions of TNF were completely blocked by the ceramidase inhibitor NOE. This 
suggests that these actions of TNF are, at least in part, dependant on ceramidase 
converting ceramide to sphingosine, and is in agreement with the recent data of Oral et 
al., 1997 and Bozkurt et al., 1998. The fact that NOE also attenuated the negative 
inotropic actions of SMase provides indirect evidence that activation of the 
sphingomyelinase pathway can depress cardiac contractility in the whole heart, and 
that this effect can be blocked with an inhibitor of the enzyme responsible for the 
conversion of ceramide to sphingosine.
In the low glucose perfused heart TNF did not depress cardiac function, however, in 
hearts perfused with normal glucose TNF had a marked negative inotropic effect. 
Therefore the reason for investigating the effects of TNF in the isolated heart perfused 
with high glucose, 25 mM, containing Krebs buffer, was to investigate whether the 
TNF-induced negative inotropic effect was dependant on glucose. Perfusion of control 
hearts with high glucose did not affect the basal parameters of LVDP, and also did not 
alter the cardiac depression seen TNF. This adds further weight to the theory 
presented in section 4.3, where it was suggested that the faster decline in cardiac 
function seen in the low glucose heart could have masked the expected negative 
inotropic action of TNF. And suggests that the negative inotropic effects of TNF are 
independent of glucose.
As mentioned in section 3.6 and as will be mentioned later (section 4.6), administration 
of TNF to isolated hearts perfused under constant flow conditions caused an early and
sustained increase in coronary tone. By definition constant flow conditions ensure that 
coronary flow cannot change with coronary tone, and therefore one would not expect 
contractility to be altered by increased CPP caused by increased coronary tone. 
However, it is possible for the coronary circulation to alter cardiac function under 
constant flow condition via the “garden hose” effect (Katz, 1992b). With the “garden 
hose” effect increased CPP causes the coronary arteries to stretch the cardiac muscle. 
This in turn causes increased crossbridge cycling within cardiac myocytes, and, hence, 
can change cardiac contractility due to Starling’s laws of the heart. Thus, it is 
important that the direct cardiac actions of TNF can be distinguished from the 
coronary actions. Several lines of evidence show that the depression in cardiac function 
observed with TNF is a direct action, and independent of the TNF-induced coronary 
constriction. Firstly, the stretching of cardiac muscle seen during increased coronary 
perfusion pressures would be expected to increase the force of contraction due to 
increased crossbridge cycling, however a depression in LVDP was observed with TNF. 
Secondly, indomethacin did not attenuate the negative inotropic actions of TNF, but, 
as discussed in section 4.6, did block the coronary constrictor actions of TNF. Thirdly, 
the experiments conducted with the stable thromboxane mimetic, U46619 (section 
3.6.2), show that a similar coronary constriction to that seen with TNF, did not 
adversely affect contractile function under the constant flow conditions used in these 
experiments. Fourthly, administration of nitro-L-arginine also caused a 
vasoconstriction under constant flow conditions, however, this was of greater 
magnitude than that seen with either TNF or U46619, but again this was not 
accompanied by cardiac depression. These observations suggest a dissociation between 
the cardiac depression and the coronary constriction seen with TNF in this situation.
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The ceramidase inhibitor, NOE, which attenuated the depressant actions of TNF under
constant flow conditions, disrupts signalling through the SMase pathway by inhibiting
the conversion of ceramide to sphingosine (Sugita et al., 1975), an action which
appears to be specific for the SMase pathway (Coroneos et al., 1995). This suggests
that the depressant effects of TNF are due to increased sphingosine production.
2+Sphingosine has been shown to have the potential to disrupt cardiac myocyte Ca
handling, both by decreasing Ca2+ release from the sarcoplasmic reticulum (Sabbadini
\
et al., 1992, Dettbam et al., 1994, Webster et al., 1994), and also by a depressing the 
L-type Ca2+ currents (McDonough et al., 1994). I have shown that the addition of 
SMase also caused a decrease in cardiac function. However, it should be noted that the 
site of action of this exogenous SMase was not determined. The sphingomyelinase 
enzyme used in this study has a molecular size of 25 kDa (Matsuyama et al., 1992), so 
it is likely that it will have access to the cardiac myocytes from the coronary 
circulation. Cardiac depression seen with SMase was also attenuated by NOE, 
suggesting activation of the SMase pathway, and release of sphingosine is responsible 
for its cardiac depressant action. However, it should be noted that the source of the 
SMase used in this study was bacterial in origin, and, hence, it is possible that it 
contained trace amounts of endotoxin. Contamination with endotoxin, and hence 
subsequent activation of constitutive NOS by endotoxin, could explain why NOE did 
not completely block the SMase-induced depression in cardiac function.
Whilst activation of the sphingomyelinase pathway by TNF has been known for some 
time (Dressier et al., 1992, Schutze et al., 1992), it has only recently been shown in 
cardiac tissue (Oral et al., 1997). These authors demonstrated that TNF-induced
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sphingosine accumulation was responsible for an early negative inotropic action of 
TNF in isolated feline cardiac myocytes. These authors also showed that the depressed 
cardiac function observed upon TNF administration, or addition of sphingosine, was 
accompanied by a decrease in the intracellular Ca2+ transient seen during systole. This 
is consistent with previous work from the same laboratory showing that depressed 
Ca2+ transients are responsible for the early negative inotropic action of TNF 
(Yokoyama et al,. 1993), and is also consistent with the known effects of sphingosine 
on Ca2+-induced Ca2+ release (Webster et al., 1994). My data strongly supports this 
work and indicates that similar mechanisms for TNF-induced early cardiac depression, 
as exist in the feline myocardium, also exist in the rat heart.
The early depression in function was not dependent on NO because it was not altered 
by the NOS inhibitor nitro-L-arginine. This is in contrast to the observations of Finkel 
et al. (1992), but is in agreement with other reports showing that the early direct 
decrease in cardiac function produced by TNF was not prevented by NOS inhibition 
(Yokoyama et al., 1993; Oral et al., 1997, Bozkurt et al., 1998). Schulz et al. (1995) 
showed that TNF and IL-l(3-induced synthesis of iNOS was responsible for a late 
depression (> 2 hr) in function in the isolated perfused rat heart. To my knowledge, 
alterations in cardiac function involving iNOS take place over a long period of time 
due to the requirement of protein synthesis involved for iNOS expression (Schulz et 
al., 1992; Shindo et al., 1994; Balligand et al., 1994; Pinsky et al., 1995), this clearly 
is not the case in my system where a negative inotropic action was observed within 20 
min. In contrast to our experiments, Schulz et al. (1995) did not observe an early 
depression in cardiac contractility, in fact a small increase in cardiac work was seen. 
This is a discrepancy for which I have no explanation.
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My results show that the release of endothelin, which occurs after treatment of animals 
with lipopolysaccharide or TNF (Hohlfeld et al., 1995, Klemm et al., 1995a,b), does 
not play a role in the early negative inotropic action of TNF under constant flow 
conditions. This is evidenced by the fact that the E T a/b receptor antagonist, bosentan, 
did not alter the TNF-induced decrease in LVDP.
When the recirculating perfusate from one heart was passed through another, there 
was a decrease in contractility on the second heart. This adds further evidence to the 
idea the process of recirculation caused a faster decline in contractility due to the build 
up of metabolites in the recirculating perfusate (section 4.1). Also shown during these 
experiments was that the recirculating perfusate from a TNF treated heart did not 
cause a greater decline in contractility than the recirculating perfusate from a control 
heart. This shows that the depression in function seen with TNF was not the result of a 
build up of a substance released by TNF in the perfusate, but was probably the result 
of a direct action of TNF.
The results obtained during perfusion if recombinant rat TNF were very similar to 
those obtained with recombinant human TNF, an early depression in cardiac function 
seen within minutes of TNF perfusion. Thus I feel justified in using recombinant human 
TNF in the rat isolated perfused heart
In summary, I add further evidence in confirmation of the studies by Oral et al. (1997) 
and Bozkurt et al. (1998) showing that a direct and early negative inotropic action of 
TNF in the isolated perfused rat heart is likely to be mediated via activation of SMase.
4.6 Actions of TNF on the coronary circulation in hearts 
perfused under constant flow conditions
The aim of this study was to observe and characterise the acute actions of TNF on the 
coronary circulation of the isolated perfused rat heart under recirculating conditions. 
The major findings of these experiments can be summarised as follows: TNF caused an 
initial rise in CPP which was sustained throughout the experiment. This increase in 
coronary tone appeared to be mediated by the vasoconstrictor prostanoid, 
thromboxane A2, because it was completely abrogated by two different thromboxane 
antagonists, as well as by the cyclooxygenase inhibitor indomethacin. The inhibition of 
TNF-induced coronary constriction by indomethacin is especially interesting 
considering the lack of effect of indomethacin on the direct depression of left 
ventricular contractility. As with the TNF-induced depression in cardiac function, the 
increase in coronary tone observed with TNF was inhibited by the ceramidase inhibitor 
NOE, suggesting that sphingosine is also involved in the coronary constriction induced 
by TNF. The ETa/b receptor antagonist bosentan did not inhibit this action of TNF, 
indicating that the potent vasoconstrictor peptide, endothelin, is not involved in the 
immediate actions of TNF in the coronary circulation of the rat isolated perfused heart.
Other studies have shown that TNF can activate PLA2 (Clark et al., 1988; Hayakawa 
et al., 1993) and the SMase pathway (Kolesnick, 1991). However, I am unaware of 
any studies examining the effects of TNF on these pathways in the isolated perfused rat 
heart. Our studies show a role for these pathways in the responses of a whole organ to 
TNF. The fact that the ceramidase inhibitor NOE (Sugita et al., 1975) and two
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thromboxane antagonists, GR32191 and ZD1542, inhibited the coronary constrictor 
actions of TNF raises a number of possibilities. Three potential explanations could 
account for the observations that have been made: firstly, TNF activates SMase to 
release sphingosine, which in turn causes the release of thromboxane A2, to induce 
coronary vasoconstriction; secondly, TNF could activate the PLA2 pathway, resulting 
in thromboxane A2 synthesis, this may then release sphingosine to cause 
vasoconstriction; a third possibility is that two entirely different pathways are activated 
by TNF, which act in synergy to cause the constriction. It is not possible to tell from 
these studies which is the correct suggestion, although the third possibility is unlikely 
because the thromboxane antagonists and NOE both produced the same physiological 
response, complete inhibition of the TNF action, indicating that a sequential activation 
of the two pathways is more likely. When these data are compared with the data 
describing the actions of TNF on contractility of the isolated perfused heart, then 
indomethacin blocked the coronary constriction, but did not alter the TNF-induced 
depression in cardiac function. This is interesting as it suggests that in the myocardium, 
cyclooxygenase mediated breakdown of AA is not responsible for the activation of the 
SMase pathway. If this is also the case with respect to the coronary constrictory 
actions of TNF, then it indicates that sphingosine release is proximal to the release of 
thromboxane A2. In addition, Murohara et al. (1996) showed that exogenous addition 
sphingosine caused a coronary constriction in isolated porcine coronary arteries, which 
was completely inhibited by indomethacin, suggesting breakdown of AA, and 
subsequent production of a vasoconstrictory prostanoid. This taken together with the 
well known and characterised vasoconstrictory actions of thromboxane A2 (Moncada 
& Vane, 1978) imply that thromboxane A2 is the final mediator of the TNF-induced 
coronary constriction seen in my system.
184
Germane to this discussion, exogenous sphingosine has been shown to potentiate 
cytokine-induced prostaglandin production by increased activation of both PLA2 and 
cyclooxygenase enzymes in fibroblasts (Candela et al., 1991; Ballou et al., 1992). In 
the study by Candela et al. (1991), TNF stimulated the production of prostaglandin E2 
by human fibroblasts. Relatively low concentrations of sphingosine, 0.5 |xM, caused 
remarkable potentiation of the TNF response, and higher concentrations, 10 |XM, 
increased prostaglandin E2 production by 18-fold. (Candela et al., 1991). This was 
shown to be accompanied by synergistically increased activity of PLA2. Ballou et al. 
(1992) showed very rapid induction of cyclooxygenase protein synthesis (1-2 hrs) after 
sphingosine treatment. However, it is unlikely that induction of cyclooxygenase protein 
synthesis is involved in the actions of TNF observed herein due to the time required for 
protein synthesis. The vasoconstrictory action of TNF on the coronary circulation in 
the isolated perfused heart was observed within 5 min of TNF administration.
Interestingly, arachidonic acid has been shown to cause the stimulation of SMase and, 
hence, breakdown of sphingomyelin (Jayadev et al., 1994), and these authors 
postulated that TNF-induced activation of PLA2 was essential for TNF instigated 
activation of SMase. Taken together with the observations of Candela et al. (1991), 
these results lead to the intriguing possibility that a self potentiating mechanism exists 
in TNF signal transduction, whereby release of arachidonic acid, by TNF activation of 
PLA2, could cause release of sphingosine, via activation of SMase, which could, in 
turn, increase arachidonic acid breakdown as well as causing further activation of 
PLA2.
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Several recent reports from the same group have shown that following removal of 
hearts, 15 to 30 minutes, after administration of lipopolysaccharide or TNF to the 
whole animal, there is a marked increase in the coronary tone in the isolated rat heart 
(Hohlfeld et al., 1995; Klemm et al., 1995a, Klemm et al., 1995b). This coronary 
vasoconstriction was associated with increased circulating endothelin levels and was 
attenuated by the selective ETA receptor antagonist, FR139317 (Hohlfeld et al., 1995). 
The experiments described herein serve to extend the observations made by the above 
groups, as the ETA receptor antagonist used did not completely abolish the coronary 
constriction observed (Hohlfeld et al., 1995). Thus, a component of the coronary 
constriction observed may have been due to TNF-induced activation of the SMase 
pathway, and subsequent release of thromboxane A2. The fact that in my experiments 
the non-specific ET receptor antagonist, bosentan, at a concentration that attenuates 
the coronary constrictor response to 100 pM endothelin-1, did not affect the TNF- 
induced rise ip CPP, suggests that the release of endothelins are not involved early 
action of TNF seen in my studies. The reason for this apparent conflict is not at present 
clear, however, there are obvious differences between protocols followed. In the 
reports by the Vane group, the source of the proposed endothelins was not identified, 
and it is possible that overproduction of endothelins by organs other than the heart 
could have caused the large coronary vasoconstriction observed, clearly this would not 
apply to my studies, where TNF was added directly to the isolated heart perfused in 
vitro.
Metabolites of arachidonic acid have been proposed to play a role in the cardiovascular 
alterations observed during septic shock. Indeed, it has been postulated that the 
vasoconstrictor actions of released thromboxane A2 may in part compensate for the
profound peripheral vasodilation seen in shocked states (Cirino et a l, 1996). But 
conversely, inhibitors of arachidonic acid metabolism and thromboxane synthesis have 
been shown to be protective during shock (Fletcher & Ramwell 1977; Butler et al., 
1983; Bult et al., 1985; Boughton-Smith et al., 1989; Mozes et al., 1991). Subsequent 
experiments discussed in this report (section 4.7) demonstrate that, under certain 
conditions, these changes in coronary tone can act to alter cardiac function. Therefore, 
thromboxane A2-induced coronary vasoconstriction would at least in part explain the 
observed protection of inhibitors of thromboxane A2 action seen during shock.
A potential limitation of the work presented herein arises from a question over the 
specificity of the ceramidase inhibitor NOE, as it has been reported to inhibit cell 
swelling as well as Ca2+ release from isolated mitochondria, leading to inhibition of 
Ca2+-dependant activation of PLA2 (Epps et a l ,  1982, Broekemeier et al., 1985). 
Inhibition of Ca2+-dependant activation of PLA2 could account for the inhibitory 
actions of NOE on thromboxane A2 release, however, the concentrations of NOE 
required for the above effects were far higher (200 |iM) than those used in my 
experiments (1 |iM), and to my knowledge the concentration used in my experiments 
does not inhibit PLA2. NOE has also been shown to specifically inhibit the activity of 
growth factors such as platelet-derived growth factor which utilise the 
sphingomyelinase pathway but not for those which employ other pathways, e.g. ET-1 
(Coroneos et al., 1995), therefore, I feel justified in using this synthetic ceramide 
analogue as a specific inhibitor of ceramidase at the concentration used.
Due to the structure of the coronary circulation within the whole heart, where 
coronary arteries penetrate deep into the ventricular walls, coronary resistance can be
highly influenced by intramyocardial pressures (Katz, 1992c). Therefore, it is possible 
for changes in cardiac contractility to alter coronary tone, and so CPP. Except for 
GR32191, none of the inhibitors or antagonists used adversely effected cardiac 
contractility. GR32191 caused a marked bradycardia which was accompanied by a 
slight increase in cardiac contractility. In spite of this, GR32191 affected the same 
physiological antagonism, of the TNF-induced coronary vasoconstriction, as ZD 1542. 
To this end I believe that the observations made herein are a result of the actions of the 
drugs used on the coronary circulation, and are independent of changes in cardiac 
contractility. The bradycardia seen with GR32191, was probably due to non specific 
actions of this drug, because the other thromboxane antagonist ZD 1542 did not alter 
heart rate.
In the absence of TNF, and after recirculation, basal coronary tone slowly increased 
with time. This slow rise in CPP was significantly attenuated by both of the 
thromboxane A2 inhibitors, GR32191 and ZD 1542, suggesting that in the isolated 
perfused rat heart there is a constant, endogenous release of thromboxane A2. 
Pomposiello et al., (1997) have recently provided evidence to support this suggestion. 
However, in apparent contrast to this, indomethacin, which would be expected to 
inhibit thromboxane production, did not alter CPP in the absence of TNF. This could 
be explained if there is a basal turnover of both vasodilatory prostaglandins and 
constrictor thromboxane A2, inhibiting the production of both of these might have no 
net effect of CPP. Blockade of thromboxane receptors and thromboxane synthesis 
could lead to an imbalance in the opposing forces and, hence, coronary dilation due to 
the unopposed release of vasodilatory prostaglandins.
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In summary, TNFa caused an acute increase in coronary tone, evidence is presented to 
implicate sphingosine and thromboxane A2 in this response. If this were to occur in 
vivo, it would lead to a decrease in blood supply to the heart, and so could contribute 
to the serious cardiovascular consequences of septic shock, where cardiac output is an 
essential factor in vital organ perfusion.
189
4.7 Actions of TNF in isolated hearts perfused under a 
constant head of pressure
As discussed above, I have shown that in the rat isolated perfused heart, under 
conditions of constant flow, addition of TNF can result in an early and direct 
depression in cardiac function as well as an increase in CPP, indicative of coronary 
vasoconstriction. It was decided to perfuse hearts with a constant head of pressure in 
order to investigate whether the increase in coronary tone, observed under constant 
flow conditions, would also be observed under constant pressure perfusion. When 
hearts are perfused under a constant head of pressure, then coronary flow rate is 
allowed to vary with the tone of the coronary vessels. Therefore a coronary dilation 
results in an increase in coronary flow, and a coronary vasoconstriction results in a 
decrease in flow. A decrease in coronary flow would be expected to indirectly alter 
contractile function through decreased substrate supply to the heart, i.e. glucose and 
0 2. Evidence that decreased flow rate can adversely affect contractile function was 
presented in section 3.4, where it was shown that during a low flow ischaemic episode, 
under constant flow conditions, a marked decline in the force of contraction was 
observed. Therefore the ultimate aim of the studies utilising a constant pressure 
perfusion model was to see if the coronary constriction observed with TNF could 
impair contractile function, and hence synergise with the direct negative inotropic 
actions of TNF resulting in a more severe depression in cardiac contractility.
The results of this study can be summarised as follows: as expected, upon 
administration of TNF to hearts perfused under a constant head of pressure there was a
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decrease in the coronary flow rate, indicative of constriction of the coronary vessels. 
This coronary constriction was observed within 5 min, and appeared to be maximal 
after about 10 min. This time course was consistent with the increase in CPP observed 
in hearts perfused, with TNF, under constant flow conditions. TNF caused a 
depression in left ventricular contractility, which was evident within 10 min of TNF 
administration. The decline in cardiac function observed here paralleled the decrease in 
coronary flow. This differed from the depression in function observed under constant 
flow conditions where significant depression in left ventricular contractility was only 
seen after 20 min perfusion with TNF. The depression in contractility under constant 
pressure conditions was also more severe than seen with TNF under constant flow 
conditions. As with previous studies, NOE blocked both the decrease in coronary flow 
as well as the depression in cardiac function, again implicating sphingosine in these 
actions of TNF. Starling curves performed in the presence of TNF were markedly 
depressed when compared to control hearts. This depression in the Starling response 
was also inhibited by prior addition of NOE.
Thus, it was shown that the actions of TNF on the coronary vasculature could 
indirectly depress left ventricular contractility. The contractile dysfunction seen with 
TNF under these conditions was quicker in onset and of greater severity to the direct 
negative inotropic effects of TNF under constant flow conditions. This greater 
depression in cardiac function appeared to be a consequence of the coronary 
constriction. Other work from this laboratory has shown that, under constant flow 
conditions, the vasoconstrictory peptide ET-1 could depress cardiac contractility as a 
consequence of the coronary constrictory actions (Lai, personnal communication). 
This is in spite of the direct positive inotropic actions of ET-1 (Kramer etal., 1991).
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The implications for the results obtained here are important. If this depression in 
cardiac function were to occur during septic shock, then it would undoubtedly 
contribute to the severe hypotension observed in shocked states (Tracey et al., 1987). 
Thus if these actions of TNF could be blocked, then increased cardiac function would 
be expected to increase blood pressure and hence improve vital organ perfusion. 
However, clinical application of this work with respect to septic shock, may not be 
feasible. This is because TNF is one of the earliest mediators released during shock. 
During experimental shock induced by infusion of live bacteria, TNF appears in the 
blood stream after about 45 min, peaks after 90 min, and returns to baseline after 6 hr 
(Redl et al., 1991; Fischer et al., 1992). The rapid pharmacokinetics of released TNF 
makes the window of opportunity for treatment very small and it is unlikely that 
diagnosis would occur in time for blockade of TNF actions to be useful.
As mentioned earlier, raised serum levels of TNF can be seen in cardiac diseased states 
such as chronic heart failure (Levine et al., 1990; Ferrari et al., 1995) and ischaemic 
heart disease (Vaddi et al., 1994). Serum levels of TNF observed in these studies are 
unlikely to be high enough to cause the direct negative inotropic action of TNF 
observed in my studies, but the production of TNF by both cardiac myocytes (Kapadia 
et al,. 1995; Benigini et al., 1996; Meldrum et al,. 1998; Wagner et al., 1998) and 
resident cardiac mast cells (Frangogiannis et al., 1998), may cause local TNF levels 
within cardiac tissues to rise to disproportionately higher levels than observed in the 
sera of patients with cardiac disorders. Under these conditions, the direct negative 
inotropic actions of TNF, via the activation of the SMase pathway, could be 
physiologically relevant. Also as mentioned in the introduction, naturally occurring
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buffers to TNF do exist and high concentrations of “shed” TNF receptors can act to 
neutralise circulating levels of TNF (Tracey & Cerami., 1993). This statement is of 
particular interest when considering the production of TNF by the heart. By virtue of 
the size of the circulating “shed” TNF receptors (55 kDa and 75 kDa) they may not 
penetrate the interstices of some tissues and thus would not be expected to cross the 
coronary circulation (Kapadia et al., 1995). Therefore, TNF produced by the heart 
would not be susceptible to the potential buffering actions of “shed” TNF receptors. If 
this were the case then it would only apply to the direct cardiac depressant actions of 
TNF and not the coronary constrictor actions, because to cause a coronary 
constriction TNF would have to be present within the coronary circulation, and would 
thus be susceptible to buffering by these shed receptors.
The protection from the TNF-induced depression in cardiac function affected by NOE 
is interesting for two reasons. Firstly, as discussed above, the observed actions of NOE 
implicates activation of the SMase pathway, and subsequent sphingosine production, in 
the negative inotropic actions of TNF. The second reason stems from a series of early 
studies concerning NOE itself. It has shown that N-acylethanolamines, of which NOE 
is one, can accumulate in the infarcted canine myocardium (Epps et al., 1979; Epps et 
al., 1980). Subsequent studies from the same group investigating a potential role for 
these accumulated N-acylethanolamines showed that NOE could protect against a 
hypoxic challenge to both guinea-pig atrial and ventricular strip preparations (Epps et 
al., 1983). Thus, it was proposed that N-acylethanolamines produced by the ischaemic 
or infarcted heart, could act as endogenously produced protective agents. These 
observations are interesting when taken in the context of both the work presented 
herein, and publications showing the release of TNF during cardiac ischaemia
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(Squadrito et al, 1993; Meldrum et al., 1998). In the first of these studies it was 
shown in an anaesthetised rat model of coronary artery ligation that serum TNF levels 
were markedly increased upon release of the coronary artery ligature. Immunisation 
with a hyperimmune serum containing antibodies against TNF showed a significantly 
increased survival rate for experimental animals (Squadrito et al., 1993). Also 
Meldrum et al. (1998) showed that pre-treatment with adenosine protected the 
ischaemic hearts, an effect which was accompanied by reduced TNF release. Thus it 
appears that endogenous inhibitors (N-aceylethanolamines) of TNF-mediated 
sphingosine production, are produced during ischaemia or infarction, and could act to 
attenuate the potentially deleterious actions of TNF released under such conditions.
There has been much controversy concerning the cardiac actions of TNF, and indeed 
many authors have not been able to detect an early negative inotropic effect. Of these, 
the paper by Schulz et al. (1995), is probably the most important when considering the 
experiments presented herein. The investigations by Schulz et al. (1995), used an rat 
isolated working heart, under recirculating conditions, to examine the effects of TNF 
and IL-lp. No early negative inotropic effect of these cytokines was observed, even 
though the concentration of TNF used was exactly the same as in my studies, 20 
ng.ml'1. Thus my results are in contrast to those reported by Schultz et al. As 
discussed in section 4.5, this discrepancy is hard to resolve. However, one possible 
explanation could involve the concentrations of the phospholipid, sphingomyelin, 
present in the plasma membrane. Sphingomyelin is a dynamic phospholipid. In this 
regard, it has been shown that plasma membrane levels of sphingomyelin can change 
quite dramatically with both with the age (Yechiel et al., 1985; Yechiel & Barenholz, 
1986) and diet (Parrish et al., 1997). Generally, sphingomyelin levels in the heart rise
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with age, 18-month old rats have approximately 1.5-fold more membrane 
sphingomyelin that 3-month old rats (Yechiel & Barenholz, 1986). In cardiac 
myocytes, in vitro, this can also occur, whereby 15-day old cultures of neonatal 
cardiac myocytes contain more sphingomyelin than 5-day old cultures (Yechiel et al., 
1985). Similarly, a diet containing high cholesterol can lead to increased sphingomyelin 
levels in cells (Geelen et al., 1995; Keelan et al., 1997). Thus increased membrane 
sphingomyelin levels would lead to greater substrate for the SMase enzyme and 
presumably increased production of the second messengers of the SMase pathway, 
ceramide and sphingosine. Therefore different starting parameters with respect to 
membrane sphingomyelin levels, caused by either diet or age, could possibly explain 
the controversy surrounding the acute cardiac actions of TNF even in models which 
appear the same.
If this theory can be extrapolated into humans, then the consequences could be very 
important. Cardiac disease states are observed most often in the ageing population, 
where increased membrane sphingomyelin levels would be expected. Therefore, TNF 
released in cardiac disease states (Levine et al., 1990; Arbustini et al., 1991; Smith & 
Allen, 1992; Latini et al., 1994; Vaddi et al., 1994; Ferrari et al., 1995) may have a 
greater than expected deleterious cardiac action, due to the increased membrane 
sphingomyelin levels.
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4.8 Actions of sphingosine in the isolated perfused heart
In the studies described above it was shown that TNF could cause a direct depression 
in cardiac function, and a coronary constriction in the isolated perfused rat heart. The 
inhibition of these responses by the ceramidase inhibitor, NOE, implicated the 
ceramidase enzyme as an essential mediator of this response. Therefore, sphingosine 
was proposed as a mediator of the observed actions of TNF. In this regard, 
experiments were conducted to try to mimic the actions of TNF in the isolated 
perfused heart by exogenous addition of sphingosine. Concentration-dependent actions 
were observed, where sphingosine caused an increase in CPP, as well as a fall in 
LVDP. However, unlike TNF, application of sphingosine resulted in a dramatic 
increase in LVEDP.
Another discrepancy between the actions of sphingosine, and those of TNF, were in 
the observed coronary constriction seen. The coronary constriction with sphingosine 
followed slower kinetics than that with TNF. This was unexpected, as if sphingosine 
were the mediator of the TNF response, then one would expect that the response to 
sphingosine would be quicker in onset because there would be no need for TNF 
receptor binding, subsequent activation of SMase and breakdown of sphingomyelin to 
ceramide and then to sphingosine. A potential explanation for the differences in the 
coronary responses to TNF and sphingosine could lie with another discrepancy 
observed between TNF and sphingosine. Unlike TNF, the increase in CPP seen with 
sphingosine was not sensitive to inhibition by either indomethacin or ZD 1542, 
suggesting that cyclooxygenase metabolites of AA, especially thromboxane A2 , are not
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involved in the constriction. As mentioned in the introduction and discussed in section 
4.6, TNF causes the activation of PLA2, thus releasing AA. It seems likely that prior 
activation of PLA2 by TNF is required for the constrictory responses of sphingosine to 
become apparent. If this were the case, then the parallel activation of the PLA2 and 
SMase pathways are likely to essential for the TNF mediated coronary constriction. It 
appears that the slower increase in CPP seen with sphingosine alone is due to an action 
of sphingosine which is independent of the PLA2 pathway. The reason why there was 
not an indomethacin insensitive portion of the coronary constriction seen with TNF is 
probably because the concentration of sphingosine required to participate in the TNF 
response is lower than that required to cause a coronary constriction independent of 
TNF.
The fact that the coronary constriction seen with sphingosine was not blocked by 
indomethacin in my experiments is in contrast to the results of Murohara et al. (1996), 
who showed that in porcine coronary artery preparations, sphingosine caused a 
constriction, which could be inhibited by indomethacin. The reason for this difference 
is unclear, however a coronary artery ring preparation utilised by Murohara et al. is 
very different from the isolated perfused heart. In the isolated perfused heart, pressor 
responses observed are likely to be a result of changes in the deep resistance beds of 
the coronary circulation. A coronary artery ring preparation is derived from larger 
conductance vessels within the coronary circulation, as opposed to the deep resistance 
vessels. Thus, differential responses between different anatomical regions of the 
coronary circulation could explain the discrepancy between the results of Murohara et 
al. (1996) and those presented herein.
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Application of sphingosine, > 3 |iM, to perfused hearts caused a large increase in 
LVEDP, or contracture. This made any measurements of LVDP hard to interpret due 
to the close relationship between LVEDP and LVDP, therefore although LVDP did 
decrease, it was uncertain if this was a consequence of this large increase in LVEDP. 
Thus, it is hard to ascertain whether sphingosine mimicked the negative inotropic 
actions of TNF. A very interesting observation concerning the contracture seen with 
sphingosine was that in hearts where the contractility was measured using both a hook 
and an intraventricular balloon, the contracture was not seen as an increase in baseline 
hook tension, only as an increase in LVEDP. This suggests that the contracture was 
not of the same type as observed in the low flow ischaemic heart, as in the low flow 
ischaemic heart, an increase in baseline tension was seen. Due to the disruptions in 
Ca2+ handling often seen with sphingosine (Sabbadini et al., 1992; Dettbam et al., 
1994; McDonough et al., 1994; Webster et al., 1994; Oral et al., 1997), then it is 
plausible that exogenous sphingosine could cause this contracture by causing a Ca2+ 
overload, resulting in high diastolic intracellular Ca2+ and reduced relaxation of the 
myofillaments. But as mentioned before, sphingosine would be expected to decrease 
Ca2+ release from the sarcoplasmic reticulum, and not increase resting Ca2+ 
concentrations. Also, after perfusion with sphingosine, hearts did not have a so called 
“stone heart” appearance, which is a characteristic of a Ca2+ overload. Therefore it 
seems reasonable to assume that the developed contracture was not due to a massive 
elevation in resting Ca2+ levels. The mechanism responsible for the contracture seen 
with sphingosine deserves further investigation.
The developed contracture seen with sphingosine was not observed with TNF. The 
reason for this is also unclear, but suggest that either the final mediator of the TNF-
induced disruptions in ventricular contractility is not sphingosine, or that the 
contracture was the result of an non specific action of exogenous sphingosine. I believe 
that it is due to a non specific of sphingosine, maybe even on non muscle cells within 
the heart. It has been shown that TNF activates the SMase pathway in a cell free 
system (Dressier et al., 1992), suggesting very tight coupling of the TNF receptors to 
the enzymes responsible for the SMase pathway. Thus one would expect the signal 
generated from the TNF receptors to be fairly localised, and so to target specific 
effectors of the SMase response, in this case the sarcoplasmic reticulum. However, 
application of exogenous sphingosine to the whole heart would be expected to swamp 
all parts of the heart, thus explaining any non specific effects. Further work should 
continue with the aim of clarifying the precise mechanisms behind the dramatic effects 
of sphingosine in isolated perfused hearts.
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4.9 Summary
This project was designed to investigate the actions of TNF in the rat isolated perfused 
heart. During this study many interesting results have been achieved, some of which 
were expected, some which were not.
I have demonstrated that TNF did not alter the recovery of hearts after brief acidotic 
challenges.
I have shown that, under certain conditions TNF has the ability to differentially alter 
the actions of insulin in the isolated perfused heart. Namely, TNF attenuated insulin- 
stimulated glycogen synthesis, without disrupting insulin-stimulated glucose uptake. 
This was an action which was mimicked by ceramide. Okadaic acid blocked the actions 
of ceramide in insulin-stimulated glycogen synthesis, but only partially attenuated those 
actions of TNF.
TNF was shown to cause an increase in the contractility of heart perfused under low 
flow, low glucose conditions.
I have also shown that in the isolated perfused heart TNF caused both an early and 
direct negative inotropic action and I have presented evidence to suggest a role for 
sphingosine and activation of the SMase pathway in this action. In addition to this, 
TNF caused a very quick coronary constrictor response which, after pharmacological 
investigation, was shown to be probably due to concurrent activation and interaction
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between the PLA2 and SMase pathways. When perfused under conditions of constant 
pressure, this increase in coronary tone could add to and potentiate the direct cardiac 
depressant actions of TNF.
Exogenous addition of sphingosine caused profound alterations in cardiac function. A 
large increase in coronary tone was observed, which was insensitive to inhibition by 
indomethacin and ZD 1542. In addition to this, higher concentrations of sphingosine 
caused a severe cardiac contracture to develop, which was accompanied by a large 
depression in LVDP. However, due to the contracture, it was impossible to interpret 
this decline in cardiac function.
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4.10 Future work
Further investigation into the actions of TNF on insulin sensitivity should be carried 
out. Different concentrations of TNF should be utilised to determine a precise 
concentration-response. If the concentration used in these studies were supermaximal 
then experiments with okadaic acid should be repeated.
Further studies concerning the actions of TNF during ischaemic conditions should be 
examined. A recovery phase should be included into the experiments utilising low flow 
conditions to see if the apparent protective actions of TNF in this model are truly 
protective.
Many questions were raised by the perfusion of whole hearts with sphingosine, and 
work is currently continuing in this laboratory, to investigate these actions. The current 
work involves investigations into the actions of sphingosine in isolated muscle 
preparations such as papillary muscles and atria in order to see if the actions of 
sphingosine in the whole heart can be reproduced in isolated muscles. If so then this 
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